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ABSTRACT 
 
 
 
 
Iron overload cardiomyopathy (IOC) has been recently described as a dilated 
cardiomyopathy, characterized by left ventricular (LV) remodelling with chamber 
dilatation and reduced LV ejection fraction (LVEF). However, primary 
haemochromatosis, a genetically determined condition leading to iron overload, 
is classically categorized as an infiltrative cause of cardiomyopathy.  Moreover, 
secondary haemochromatosis may lead to severe diastolic LV dysfunction in 
the early stages of the disease, before LVEF is affected. In this study, it 
described the forms, pathophysiology, and genotypic expressions of HFE and 
hepcidin (HAMP) gene mutations focusing on the possibility of digenic 
occurrence  that could lead to potential development of  iron overload 
cardiomyopathy among Irish patients and their direct family members. 
 
The prevalence of iron overload cardiomyopathy (IOC) in Irish population is 
increasing. The spectrum of symptoms of IOC varied. Early in the disease 
process, patients may be asymptomatic, whereas severely overloaded patients 
can have terminal heart failure complaints that are refractory to treatment. It has 
been shown that early recognition and intervention may alter outcomes. In this 
study the combination of cardiac biomarkers (troponin I and creatine kinase), 
iron studies (serum ferritin, serum hepcidin, and transferin saturation) level 
determinations and genotyping of the HFE (C282Y/H63D) and hepcidin HAMP 
(C70R) gene mutations were carried out and allele frequencies were correlated 
within the Irish population. 
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The first finding of this study was a trend towards significant elevation of iron 
studies: serum ferritin level, percent transferin saturation and decreasing serum 
hepcidin observed in dilated cardiomyopathy patients and direct family 
members identified with HFE C282Y/H63D and HAMP C70R heterozygotes 
who were asymptomatic. This was not associated with age and suggested that 
there was a threshold level of iron studies above which symptoms occur. This 
discordance between the symptomatic and asymptomatic HFE C282Y/H63D 
and HAMP C70R heterozygous formed the basis of subsequent analyses. 
 
The second finding of this study was a trend towards significant elevation of the 
selected cardiac biochemical markers from the median level of serum troponin-I 
and creatine kinase observed in patients and direct family members with HFE 
C282Y/H63D and HAMP C70R heterozygous who were again asymptomatic. 
This was not associated with age and cardiac complaints or history and 
suggests that there was a threshold level of cardiac biochemical marker 
activities that triggered the condition and as predisposing factors to a potential 
development of iron overload cardiomyopathy. 
 
The genotypic expressions of HFE and HAMP were identified and showed that 
among the Irish patients diagnosed with dilated cardiomyopathy and their family 
members, a significant trend of digenic occurrence of both mutations.  The 
heterozygous C282Y/H63D and C70R revealed in this study that it was a 
predisposing factors developed at certain age of life.  
 
 
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CHAPTER   1   Introduction 
 
 
 
 
 
1.0 Overview and concept of dilated cardiomyopathy (DCM) 
Dilated cardiomyopathy (DCM), a heart muscle disorder defined by the 
presence of a dilated and poorly functioning left ventricle (Elliott 2000).  It is 
characterized further by absence of abnormal loading conditions as in 
hypertension, valve disease or ischaemic heart disease sufficient to cause total 
systolic impairment. There are numerous instances of cardiac and systemic 
diseases causing systolic impairment and left ventricular dilatation, but in the 
majority of patients, there are no identifiable cause, hence given the term 
―idiopathic‖ dilated cardiomyopathy (IDC). There were experimental and clinical 
data in animals and humans suggested that genetic, viral, and immune factors 
contributed to the pathophysiology of IDC (Guija et.al. 2010). 
 
Dilated cardiomyopathy (DCM) is a primary disease of the myocardium 
(cardiomyopathies), second only to coronary heart disease as a cause of heart 
failure, accounting for approximately 20% of cases in the western world (Maron 
2009).  Cardiomyopathy represents a various group of heart-muscle disorders, 
which were further subdivided according to their anatomic and haemodynamic 
findings. The reduced systolic contractile function is the critical haemodynamic 
feature of congestive cardiomyopathy or DCM.  (Guija et.al. 2010).  Idiopathic 
DCM often presents after many years of asymptomatic, progressive left 
ventricular dysfunction and adverse remodelling. Only 50% of patients with 
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DCM survive more than 5 years after diagnosis.   Premature death results from 
unmitigated  pump failure, arrhythmia, and from co-morbidities such as stroke or 
thromboembolism. Despite contemporary strategies of heart failure 
management, idiopathic DCM remained a common cause of end-stage heart 
failure and accounted for about 50% of referrals for cardiac transplantation 
(Muchir 2000). 
 
 
1.1 Incidence of  dilated cardiomyopathy 
The difficulties of studying the disease including its relatively low prevalence, its 
potentially pluricausal nature or cause by two or more factors, and the fact that 
it is often a diagnosis of exclusion. It presented until now a significant 
challenges to the cardiovascular scientific community, since the mechanism of 
myocardial damage and related etiologic and prognostic factors are virtually 
unknown (Mestroni 1999).  
 
The development of more reliable measures of immune-mediated damage and 
non-invasive measures of impaired cardiac function presented new research 
opportunities in this disorder. Standardized diagnostic criteria for use in 
observational and interventional trials were developed, and priorities for future 
research were proposed. Population-based registries and nested case-control 
studies, where feasible, were appropriate study designs for tracking incidence 
and prevalence, and for identifying risk factors (Jung 1999). Interventional 
studies should focus on secondary prevention, through modifying immune-
mediated damage in clinically evident DCM, and through prevention of sudden 
death in patients with the disorder. Primary prevention trials must await the 
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identification of modifiable risk factors and of appropriate and effective 
interventions (Schmitt et al 2003). 
 
1.2 Differential diagnosis of dilated cardiomyopathy 
DCM is a progressive, usually irreversible disease causing heart failure, left 
ventricular contractile dysfunction, ventricular and supraventricular arrhythmias, 
conduction system abnormalities, thromboembolism, and sudden death 
(Crispell 1999). DCM may manifest clinically at a wide range of ages, but most 
commonly occurs in the third or fourth decade of life. It is usually identified 
when limiting symptoms are severe, but arrhythmias or sudden death were 
uncommonly early manifestations (Shizukuda 2009). In family screening studies 
with echocardiography, asymptomatic or mildly symptomatic relatives may be 
identified.  In contrast to arrhythmogenic and hypertrophic cardiomyopathy, 
arrhythmias were typically prominent only after the onset of significant heart 
failure (Wood 2005). 
 
DCM is a heart muscle disorder defined by the presence of a dilated and poorly 
functioning left ventricle (Figure 1.0) in the absence of abnormal loading 
conditions (hypertension, valve disease) or ischaemic heart disease sufficient to 
cause global systolic impairment. A large number of cardiac and systemic 
diseases can cause systolic impairment and left ventricular dilatation, but in the 
majority of patients no identifiable cause is found—hence the term ―idiopathic‖ 
dilated cardiomyopathy (Elliott 2000). 
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Figure 1.0 Anatomical difference between a normal and DCM hearts.  
“Images adapted with permission from the publisher. [Jameson JN, Kasper DL, Harrison TR, 
Braunwald E, Fauci AS, Hauser SL, Longo DL. (2005). Harrison's principles of internal medicine (16th ed.). 
New York: McGraw-Hill Medical Publishing Division].” 
Comparison between normal and DCM heart, where the  DCM heart showed a large, 
dilated left ventricle typical of a dilated, or congestive, cardiomyopathy. Many of these 
have no known etiology  or "idiopathic dilated cardiomyopathy" (Jameson et.al. 2005).  
 
The clinical and pathologic differential diagnosis of dilated cardiomyopathy was 
to exclude secondary causes of heart failure. The distinction between coronary 
artery disease resulting in cardiomyopathy (ischemic cardiomyopathy) and 
primary DCM can be problematic.  The diagnosis of ischemic cardiomyopathy 
can only be confirmed if coronary artery disease and associated global left 
ventricular dysfunction was out of proportion to the coronary obstruction exists.  
For example, if an ejection fraction of less than 40% with less than or equal to 
50% narrowing of a proximal or more than 50% narrowing of a distal artery is 
found (Morgensen 2004). This definition of ischemic cardiomyopathy has been 
shown ineffective.  The term ischemic cardiomyopathy is now generally 
reserved for patients with severe coronary disease and global left ventricular 
dysfunction, typically with healed transmural infarct (Lamke 2003).  
Dilated 
ventricle
e 
Normal Heart   DCM  Heart 
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Pathologically, the histologic features are nonspecific. Grossly enlarged, dilated 
hearts can be seen in long-standing hypertensive heart disease, and valve 
disease and severe coronary disease should be excluded.  The endomyocardial 
biopsy, amyloid, iron deposition, and significant inflammation should be 
excluded by routine staining supplemented by special stains.  In addition, the 
clinical history that excluded other causes of heart failure should be elicited 
before a specific diagnosis of DCM is made (Anderson 2004). 
 
 
 
1.3 Clinical importance of the biochemical marker analysis 
Many biomarkers have been shown to be released in association with the acute 
and chronic phases of heart failure but cause and effect relationships were 
often yet to be established. These biomarkers have been shown to have 
diagnostic, prognostic, and risk stratification significance.  One or more of these 
biomarkers may provide improved identification of those patients in whom more 
intensive therapeutic intervention is warranted.  More importantly, if 
deterioration occurs slowly, as appears to be the case in chronic heart failure, 
elevations or changes of these biomarkers could potentially be used to provide 
an early indication of progression of disease and allow for preventative 
interventions (Bezzina 2008).  Therefore, the monitoring of serial changes in 
these biomarkers may well be the means, in any individual cardiomyopathy 
patient, to identify risk prospectively and to help determined which therapeutic 
modality would be most effective in that specific patient. 
 
 
  
 
Jereza, Noel                                                                                                         23                                                                                                                
 
1.3.1 Pathophysiology of serum ferritin 
Serum ferritin is a high-molecular weight iron-containing protein that functions in 
the body as an iron storage compound.  Each ferritin molecule is thought to 
consist of a spherical protein shell of molecular weight about 460,000 daltons 
made up of 24 subunits with a variable amount of iron as a core of ferrocoxide-
phosphate.  When fully saturated, may consist of over 20% iron by weight 
(Abbott Architect 2008). Approximately 25% of the iron in a normal adult is 
present in various storage forms.  About two-thirds of the iron stores in the 
human body exist in the form of ferritin.  The remaining iron stores were 
contained in insoluble haemosiderin, which most likely represents a form of 
denatured ferritin (Abbott Architect 2008). 
 
Increasingly changes in cellular iron and ferritin were emerging as an important 
element in the pathogenesis of disease. These changes in ferritin were 
important not only in the classic diseases of iron acquisition, transport, and 
storage, such as primary haemochromatosis, but also in diseases characterized 
by inflammation, infection, injury, and repair. Among these were some of the 
most common diseases that badly affect individuals, neurodegenerative 
diseases such as Parkinson disease (Linert et. al. 2000) and Alzheimer disease 
(Kondo et.al.1996) vascular diseases such as cardiac and neuronal ischemia-
reperfusion injury (Cheepsunthen et al 2001, Chi et.al. 2000) atherosclerosis 
itself (Pang et.al. 1996) pulmonary inflammatory states (Ryan et.a.l 1996)  
rheumatoid arthritis (Biemond et.al. 1986, Ahmadzadeh et.a.l 1990) and a 
variety of premalignant conditions and frank cancers (Wu et.al. 1997). 
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Iron is stored mainly in the liver within the complex protein, ferritin; each 
molecule of ferritin can bind as many as 4500 atoms of iron. Only a tiny fraction 
of the body's ferritin circulates in plasma, but circulating ferritin levels have an 
approximate relation to total iron stores. The adult human body contains about 4 
grams of iron, of which 3 grams are bound in haemoglobin, myoglobin, and 
enzyme systems; for example, each 500 mL of blood contains about 200 mg of 
iron. The additional 1 gram of iron is stored in reserve. When excess amounts 
of iron are absorbed (as in haemochromatosis) or infused (as in repeated 
transfusion therapy for chronic haemolytic disorders), the excess iron ultimately 
deposited in various organs, where the iron induces an inflammatory reaction 
that induced fibrotic damage to the organ. The basis for selective variability in 
organ deposition is unknown; however, a hereditary mechanism is possible, 
given that identical twins have identical patterns of iron deposition in organs 
(Crosby 1996). Although not frequent, the classic triad of darkened skin, 
cirrhosis, and diabetes developed; and the lungs, kidneys, and eyes are never 
damaged by the disease. Both the conduction and the pumping systems of the 
heart can be damaged by iron overload. Cardiomegaly, bradycardia, 
arrhythmia, and congestive heart failure result. Cardiomyopathy of 
haemochromatosis may be either dilated or restrictive and usually alleviated 
greatly by phlebotomy. Iron overload is therefore an important diagnosis to 
consider for all patients who have cardiomyopathy, congestive heart failure 
(Cutler et.al. 1980), atrial fibrillation, or nonathletic bradycardia.  
 
When haemochromatosis manifests in adolescence, as it occasionally does, the 
heart is the organ most affected and cardiac death from arrhythmia or 
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congestive heart failure is the typical outcome. What portion of cases of 
"idiopathic cardiomyopathy" actually represents undiagnosed 
haemochromatosis is yet to be determined. Cardiomyopathy and arrhythmia 
were well documented outcomes of iron overload (Cutler et.al.1980) but a 
currently contested hypothesis proposed that elevated iron stores were related 
to coronary artery disease in heterozygotes (Sullivan 1990). 
 
1.3.2 Pathophysiology of  transferrin saturation  
The two tests (serum iron and total iron binding capacity) were used to calculate 
the transferrin saturation, a more useful indicator of iron status than just iron or 
total iron binding capacity (TIBC) alone. In healthy people, about 20-40% of 
available sites in transferrin were used to transport iron.  In iron deficiency, the 
iron level is low, but the TIBC is increased, thus transferrin saturation becomes 
very low. In iron overload states, such as haemochromatosis, the high serum 
iron level and low or normal TIBC, caused high transferrin saturation. The 
Unsaturated Iron Binding Capacity (UIBC) may be ordered as an alternative to 
TIBC (Datz et.al. 1998).   
 
The excess levels of body iron include: serum ferritin, fasting serum iron and 
total iron binding capacity (TIBC). Serum iron divided by TIBC X 100% provides 
the transferring saturation (TS) percentage.  In classic hereditary 
haemochromatosis, both TS and serum ferritin are above normal. TS values 
greater than 45% warn of potential iron overload and should be investigated. A 
test that is less commonly used, but also helpful, is the UIBC (Cox et.al. 2002).  
If a person with haemochromatosis diagnosed with serum ferritin less than 
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1,000 ng/mL, the chances of finding undetected cirrhosis, the most common 
life-threatening disease caused by iron overload, are minimal, as low as 1%. If 
however serum ferritin is allowed to rise above 1,000 ng/mL, the risk of cirrhosis 
or liver cancer increase 20-200 fold (Claeys et.al. 2002). 
 
Ideally, and for high testing accuracy, serum iron should be tested when fasting; 
patients should take nothing by mouth past midnight or prior to blood work and 
should avoid vitamin C supplements three days prior to tests and reduce 
consumption of Vitamin C rich juices during this same period. In general, the 
best time for blood work is in the morning. Haemoglobin or haematocrit are 
performed to assure levels are sufficient enough to perform blood removal with 
therapeutic phlebotomy (Datz et.al. 1998). 
 
Serum transferrin saturation measures the proportion of transferrin bound to 
iron, and  derived by dividing the serum iron by the total iron binding capacity 
and therefore expected to correlate with iron burden. However, the test has 
been found to be lacking in sensitivity, as linearity becomes questionable once 
saturation levels >80% are reached, and the test has not yet proven to be 
useful in iron estimation for patients with transfusional iron overload. For 
patients with hereditary iron overload, the test may be more useful (Abbott 
Architect 2008). Although it may not be a reliable test for iron overload, elevated 
serum transferrin saturation is a sensitive and specific disease marker for 
hereditary haemochromatosis. Fasting serum transferrin saturation >50% in 
women and >60% in men, has a sensitivity of 0.92, a specificity of 0.93, and a 
positive predictive value of 86% for the diagnosis of hereditary 
haemochromatosis (Abbott Architect 2008). 
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Excess iron and iron overload can facilitate the occurrence of a variety of 
diseases, including cirrhosis, congestive heart failure, diabetes, and cancer. 
Pathologic iron accumulation affects many organs, such as the liver, pancreas, 
and heart, among others (Burke 1998). Hereditary iron overload is 
characterized by excessive intestinal absorption and cellular deposition of iron 
and is found in several conditions, including haemochromatosis which is among 
the most common inherited metabolic abnormalities, particularly among those of 
Northern European origin. Serum transferrin saturation is a commonly used 
indicator for a predisposition of iron overload, and its measurement is a frequent 
first step in screening protocols for hereditary haemochromatosis (McCullen 
2002). 
1.3.3 Pathophysiology of serum Troponin-I  
Cardiac troponins are part of the troponin–tropomyosin complex in the thin actin 
filaments of heart-muscle myofibrils. This complex consists of troponin C 
(cTnC), cardiac troponin I (cTnI), cardiac troponin T (cTnT) and tropomyosin  
(Figure 1.1). Although troponins are found in both skeletal and cardiac muscle, 
there are specific cTnI and cTnT isoforms in the heart (Sasse et.al. 1993). The 
troponin–tropomyosin complex is responsible for the Ca2+-induced contraction–
relaxation cardiac cycle occurring between actin and myosin filaments. 
 
Troponin mutations promote cardiac hypertrophy, disarray, enlargement and 
interstitial fibrosis by impairing Ca2+ sensitivity, cellular metabolism and 
contractility or by promoting myocyte stress with subsequent activation of stress 
responses (Gomes et.al. 2004, Towbin et.al. 2004, Willott et.al. 2010).  
Mutations in cardiac troponins have been proved to cause familial hypertrophic, 
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dilated, or restrictive cardiomyopathy.  Moreover, a single mutation in a codon 
of cTnI has been demonstrated to induce multiple cardiomyopathic phenotypes 
(restrictive or hypertrophic). 
 
Figure 1.1  The troponin complex.  
“Images adapted with permission from publisher. [Sasse S, Brand NJ, Kyprianou P, et al., 1993. 
Troponin I gene expression during human cardiac development and in endstage heart failure, Circ Res, 
72, pp. 932–8].”  
Cardiac troponins bind to tropomyosin in thin actin filaments. Besides cardiomyocyte 
disruption, cardiac troponins can be released in plasma following either cytoplasmic 
cleavage in low-molecular-weight peptides (right) or reversible increase in membrane 
permeability without cellular necrosis (left). MMP = matrix metalloproteinase (Sasse 
et.al. 1993). 
 
Troponins are intracellular proteins; therefore, their presence in blood is a 
sensitive and peculiar indicator of heart cell damage. cTnI and cTnT are 
currently considered the most sensitive and specific biochemical markers of 
myocardial damage (Alpert et.al. 2000, Apple et.al. 2007).  However, cardiac 
troponins are heart-specific but are not disease-specific biomarkers. Following 
cardiomyocyte necrosis and proteolysis of contractile proteins, both single 
peptides (free troponin subunits, fragments of troponin subunits) and peptidic 
complexes (such as TnT–TnI–TnC [TIC] complex and TnI–TnC [IC] complex) 
are released. The total concentration of cTnI is five to 12 times greater than the 
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concentration of free cTnI and TIC complex quickly disintegrates to cTnT and IC 
complex. Therefore, following myocyte death, free cTnT, IC complex and a 
certain amount of free cTnI appear in the blood (Chang et.al. 2008).  
Nevertheless, some studies have demonstrated cardiac troponin release even 
in the absence of lethal sarcolemma disruption, either through proteolysis and 
subsequent release of cellular cardiac troponin or through reversible damage to 
cardiomyocyte membranes without cellular necrosis 
 
Cardiomyopathies present by definition a non-ischaemic aetiology: genetic, 
inflammatory, toxic, immune, or neuroendocrine (Elliott et.al. 2008).  
Nevertheless, myocardial necrosis and apoptosis play a major role in the 
pathophysiology of primitive cardiomyopathies, promoting further ventricular 
remodelling and impairment of systolic and diastolic function. The first 
description of troponin release in patients with heart failure (both ischaemic and 
non-ischaemic in origin) was reported in 1995 by Missov (Missov et.al. 1995). 
 
The mechanisms believed to be responsible for ongoing myocyte injury and/or 
cell death in heart failure include activation of adrenergic, renin–angiotensin–
aldosterone, or endothelin signalling pathways, calcium-handling abnormalities, 
inflammatory cytokines, nitric oxide, oxidative stress, and mechanical stress. 
Each of these factors, alone or in combination, can promote either myocyte 
necrosis or myocyte apoptosis through activation of specific genetic pathways. 
Even repetitive bouts of ischaemia have been advocated in the pathophysiology 
of DCM, although not representing the primary cause of disease, they may 
promote myocyte death, replacement fibrosis and further remodelling (Parodi 
et.al. 1993, Maron et.al. 2009). 
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Several in vitro studies have identified a relationship between myocardial wall 
stretch and myocyte injury (Cheng et.al. 1995), with increased troponin 
proteolysis in volume-overloaded rat hearts (Feng et.al. 2001), while other 
studies support the relationship between myocardial wall stress and 
subendocardial ischaemia, even in the absence of coronary artery disease. 
Several works have also demonstrated a correlation between myocyte injury 
and biochemical markers associated with neurohormonal and flogistic activation 
in patients with heart failure (Nishio et.al. 2007).   
 
Adrenergic activation is a hallmark of heart failure, promoting irreversible 
contraction band lesions in myocardial cells with coagulative myocytolysis or 
Zenker necrosis (Todd et.al. 1985).  Adrenergic effects seem to derive from 
cyclic adenosine monophosphate (cAMP)-mediated calcium overload, as well 
as from microcirculatory dysfunction (Mann et.al. 1992).  Also, angiotensin II 
can induce cardiomyocyte necrosis (Tan et.al. 1991) and apoptosis of neonatal 
and adult ventricular myocytes (Kajstura et.al. 1997) independently of 
adrenergic activation and haemodynamic overload. 
 
Dilated cardiomyopathy patients present elevated levels of inflammatory 
biomarkers, which are associated with troponin increase. Cytokines have been 
demonstrated to reduce cardiac contractility in a concentration-dependent 
manner (Kumar et.al. 1996), promote cardiomyocyte death via the Fas/FasL 
(type II transmembrane protein) system (Larrick et.al. 1990), and predict worse 
prognosis. Septic shock, a condition of extreme cytokine over-expression, is 
always accompanied by troponin release: cardiac ischaemia and cardiac 
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metabolic disorders have both been excluded in its pathogenesis, while 
microvascular thrombosis seems to play a role (Bernard et.al. 2001).   
 
All of these mechanisms, in particular adrenergic activation and haemodynamic 
overload, have been demonstrated to increase during effort- and stress-related 
situations in everyday life, determining phasic bouts of troponin release and 
disease progression. Moreover, it has been hypothesised that the more the 
myocardium is remodelled, the more it is susceptible to cardiac damage; in 
other words, troponin increases following cardiac damage (adrenergic 
activation, haemodynamic overload, and inflammation), in particular in the 
advanced stages of cardiac disease when the heart is weaker and more 
susceptible to mechanical and neurohormonal stress. Several studies have 
investigated the role of autoimmunity response to troponin. Administration of 
monoclonal antibodies to cTnI induces heart dysfunction and dilation by chronic 
stimulation of Ca2+ influx in cardiomyocytes (Okazaki et.al. 2003). 
 
Troponin I (TnI) is a regulatory subunit of the troponin complex associated with 
the actin thin filament within muscle cells.  Troponin-I, in conjunction with 
troponin-C and troponin-T, plays an integral role in the regulation of muscle 
contraction.  Three distinct tissue specific isoforms of troponin-I have been 
indentified from skeletal and cardiac muscles.  The cardiac isoform exhibits only 
60% similarity with the skeletal muscle isoform and contains additional amino 
acids at the N-terminus; cardiac troponin-I has a molecular weight of 
approximately 24,000 daltons (Abbott Architect 2008).  
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1.3.4 Pathophysiology of serum creatine kinase  
Creatine Kinase is an enzyme that catalyzes the phosphorylation of creatine by 
ATP to form phosphocreatine. It occurs as three isozymes (specific to brain, 
cardiac muscle, and skeletal muscle, respectively), each having two 
components composed of M (muscle) and/or B (brain) subunits. Differential 
determination of isozymes is used in clinical diagnosis (Abbott Architect 2008).  
The functional implications of creatine kinase (CK) alterations is a critical 
question whether the abnormalities of the CK system have the potential to 
contribute to contractile dysfunction in the failing heart.  
 
The CK system is thought to optimize myocardial energy metabolism by 
maintaining ADP levels high at the mitochondria where ATP is generated and 
low at sites of ATP utilization, thereby contributing to maintenance of a high free 
energy for ATP hydrolysis to enhance the efficiency of contraction (Wyss et.al. 
1992).  Acutely inhibiting CK activity with iodacetamide or replacing myocardial 
creatine by feeding with poorly hydrolyzable creatine analog impair the maximal 
cardiac workloads that can be achieved in response to catecholamine 
stimulation or increased perfusate calcium (Tian et.al. 1996, Mekhfi et.al. 1990).  
Studies of hearts from mice lacking genes for either CK-M or both CK-M and 
CK-Mt perform normally during basal conditions but may have impairment of 
maximal contractile performance, and require increased cytosolic free ADP 
levels to achieve any given level of contractile work (Saupe et.al. 2000, Saupe 
et.al. 1998).  Nevertheless, even during severe reductions of CK activity, 
contractile performance appears to be impaired only at very high cardiac 
workloads.  
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The systolic and diastolic unloading provided by the left ventricular assist device 
 (LVAD) resulted in increased of CK-M and CK-Mt protein expression that were 
associated with increased of total CK activity. These changes would be 
expected to facilitate intracellular phosphoryl transfer from sites of energy 
production to sites of energy utilization, and to allow maintenance of lower 
cytosolic free ADP levels at any level of oxygen utilization. Whether these 
changes in response to mechanical unloading have the potential to improve 
contractile performance in the failing myocardium will require further study 
(Bessman et.al. 1985).  
 
CK-MB is an 84,000 molecular weight enzyme that represents a significant 
fraction of the creatine kinase present in myocardial tissue. CK-MB values are 
used to assist in the diagnosis of myocardial infarction (MI).  CK-MB is also 
present in a variety of other tissues, although at much lower levels. The 
appearance of CK-MB in serum, in the absence of major muscle trauma, may 
be indicative of cardiac damage and thus, myocardial infarction (MI). MI is 
defined as myocardial cell death due to prolonged ischemia. The magnitude 
and temporal course of CK-MB elevation and declined may clarify the timing of 
the myocardial insult, allowibg an estimate of infarct size, and contributed to the 
non-invasive assessment of reperfusion. 
 
1.3.5 Pathophysiology of serum hepcidin 
Hepcidin is the primary regulator of iron homeostasis where hepcidin modulates 
iron availability by promoting the internalization and degradation of ferroportin, a 
key iron transporter and so far the only identified mammalian iron exporter, 
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which is essential for both iron absorption in the duodenum and recycling of 
iron/iron efflux by macrophages. Hepcidin is a negative regulator of iron 
absorption and mobilization (Figure 1.2); high hepcidin levels turn off both 
duodenal iron absorption and release of iron from macrophages while low 
hepcidin levels promote iron absorption and heme iron recycling/iron 
mobilization from macrophages (Kemna 2005). Thus, hepcidin levels are 
expected to be high in iron overload states and diminished in iron deficient 
states.  
 
 
Figure 1.2 Hepcidin as regulator of iron absorption and mobilization.  
“Images adapted with permission from the author. [Kemna E, Pickkers P, Nemeth E, van der Hoeven 
H, Swinkels D., 2005. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans 
injected with LPS. Blood, 106, pp.1864-1866.]”  
The consequent increase in hepcidin blocks macrophage iron release as well as the 
intestinal absorption of iron, resulting in hypoferremia. Abbreviations: TF, transferrin; 
Fe, iron; DMT1, divalent metal transporter1(Kemna 2005). 
 
 
Hepcidin production can be induced by inflammation, which explains the 
reduced availability of iron in the anaemia of chronic disease, whereas anaemia 
and hypoxia have been shown to increase iron absorption and mobilization by 
decreasing hepcidin production (Murphy 2007, Kemna 2005). Measurements of 
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prohepcidin, the precursors of the biologically active 25- hepcidin, have been 
generally disappointing because they seem to be poorly correlated with 
hepcidin and unresponsive to known hepcidin regulators (Kemna 2005). 
 
The work by Ganz et.al. validates an immunoassay for human hepcidin levels in 
serum, which has a lower limit of detection of 5 ng/ml and yields a normal range 
for serum hepcidin of 29 to 254 ng/ml in men and 16 to 288 ng/ml in women. 
The assay has enough sensitivity to detect changes in serum hepcidin due to 
diurnal variation and in response to oral iron (Ganz 2005).   The next challenge 
will be to demonstrate what is the additional value of these measurements 
compared with the traditional diagnostic repertoire for iron metabolism 
disorders. In particular, what will this assay add to the information presently 
conveyed by serum ferritin, since both ferritin and hepcidin are similarly affected 
by changes in iron availability and inflammation, careful studies will be required 
to demonstrate the unique additional value of measuring serum hepcidin (Park 
2001). 
 
Cardiac hepcidin expression may have predominantly a local effect in the heart. 
By a local effect, the observed up-regulation of cardiac hepcidin expression in 
response to hypoxia may explain the previously reported ischemia-related 
enhanced cardiac ferritin content. Ferritin is a major intracellular iron 
sequestering and storage protein that is assumed to play an important 
cytoprotective role against free radical formation by controlling the free cytosolic 
iron concentration (Balla et.al. 1992). Because elevated serum hepcidin can 
result in an increased intracellular ferritin content, that the up-regulation of 
hepcidin in response to hypoxia provide a coordinated mechanism for protecting 
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cardiac cells against the hypoxia-related free radical formation by controlling the 
free cytosolic iron concentration (Andriopoulos  et.al. 2006). 
 
1.4  Other laboratory tests implicated in DCM 
Echocardiography of a patient with DCM includes anatomical and functional 
assessment with the use of all available techniques.  In most cases, the left 
ventricle is spherical in shape and global hypokinesis or slow movement of its 
walls can be observed.  Global function of the left ventricle depends on the joint 
assessment of left ventricular filling volume (diastolic function) as well as on left 
ventricular ejection fraction (systolic function) (Beers 1999). 
 
Natriuretic peptides: BNP and NT-proBNP in diagnosing dilated 
cardiomyopathy.  Early diagnosis of DCM in its initial phase enables the start of 
effective treatment with the purpose of stopping the progress of the disease and 
delaying the development of symptomatic heart failure. Regarding this fact, 
scientists are searching for routine and widely accessible diagnostic methods 
which could be used in assessing the state of advancement of the disease and 
in controlling the results of treatment and the prognosis. Such a role may be 
played by natriuretic peptides, especially brain natriuretic peptide (BNP) and N-
terminal prohormone brain natriuretic peptide (NT-proBNP) (Murphy 2004). 
 
Concentrations of BNP and NT-proBNP in blood serum are similar in healthy 
people, but in people with heart failure the concentration of NT-proBNP is 2–10 
times higher than that of BNP.  BNP is secreted into blood as a biologically 
active and shorter peptide, and NT-proBNP is secreted as a biologically inactive 
NH2 — the final part (Crispell 1999). They are secreted in equal amounts but 
BNP has a shorter half-life in blood serum and, as a consequence, its 
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concentration is lower.  A factor stimulating the secretion of BNP is the 
stretching of myocytes rather than the pressure load itself. BNP causes a dose 
dependent decrease of arterial pressure resulting in direct vasodilatation and 
movement of intravascular volume into extravascular space which is a result of 
vascular endothelium increased permeability and of increased hydrostatic 
pressure in the capillary bed (Grogan 1995).  
 
Other mechanisms decreasing initial load are diuresis and natriuresis, which 
also inhibit the activity of the renin–angiotensin–aldosterone system. Natriuretic 
peptides inhibit adrenergic stimulation through central suppression of 
sympathetic discharge and through suppressing secretion of catecholamines 
from nerve endings in a synapses (Scicluna 2008). Through enlargement of 
afferent arterioles and contraction of efferent arterioles, they increase 
intraglomerular pressure and glomerular filtration; relaxation of mesangial cells 
increases the filtering surface.  Moreover, natriuretic peptides inhibit the 
transport of sodium and water in proximal tubules dependent on angiotensin II 
and, being antagonists of vasopressin, they inhibit the transport of water in 
collecting tubules and block reabsorption of sodium (Medeiros-Domingo 2007). 
 
1.5 Treatment and management of DCM 
In most cases, treatment for DCM is done to relieve symptoms, improve heart 
function, and help affected individual live longer. The majority of people will 
need to take a number of medicines along with making healthy lifestyle 
changes. Surgical procedures may also be considered, especially when 
medicines do not improve the condition (Mestroni 1999). In some cases, the 
cause of the condition can be successfully addressed, such as when DCM is 
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caused by excessive alcohol consumption. Limiting how much the individual 
drink may help prevent the disease from progressing.  But in viral myocarditis 
(inflammation of the heart muscle caused by a virus), there are no medicines to 
attack the viruses that cause dilated cardiomyopathy (Michels 1992). 
 
Angiotensin-converting enzyme (ACE) inhibitors. Angiotensin II receptor 
blockers (ARBs), and vasodilators, which widen blood vessels to improve blood 
flow and reduce the heart's workload. ACE inhibitors are considered the basis of 
therapy for DCM. They specifically have been shown to improve symptoms and 
prolong life in people who have heart failure.(Beggs 1997)  ARBs may be used 
when a person cannot tolerate ACE inhibitors or the medicine is not controlling 
symptoms ( Beggs 1997, Murphy 2004). 
Diuretics, to help remove excess fluid from the body. Spironolactone is a 
diuretic that prevents potassium loss and has been shown to prolong life in 
people with severe forms of heart failure (Murphy 2004). Digoxin, which can 
help increase the strength of the heart muscle contraction, improve blood flow, 
and reduce symptoms of heart failure (Murphy 2004). 
Anticoagulants such as warfarin, for example Coumadin and heparin, to prevent 
blood clots that can develop when blood is not being pumped efficiently through 
the heart and out to the rest of the body. Blood clots may lead to strokes or 
heart attack. People with both DCM and atrial fibrillation are at higher risk for 
developing blood clots (Messina 1997). Antiarrhythmics, such as amiodarone, 
which control the heart rate when abnormal, rapid heartbeats (arrhythmias) are 
present (McNair 2004).  
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1.6 Outcome and prognostic factors in DCM 
The prognosis of DCM usually refers to the likely outcome of dilated 
cardiomyopathy. The prognosis may include the duration, chances of 
complications, probable outcomes, prospects for recovery, recovery period for 
DCM, survival rates, death rates, and other outcome possibilities in the overall 
prognosis (Mestroni 1999). In this study the prognosis of DCM among the Irish 
patients, showed poorly because usually diagnosed late. 5-year survival  50%. 
10-year survival  25%. Unfortunately, by the time it is diagnosed, the disease 
often has reached an advanced stage and heart failure has occurred. 
Consequently, about 50 percent of patients with dilated cardiomyopathy live 5 
years once heart failure is diagnosed; about 25 percent live 10 years after such 
a diagnosis (Michels 1992, Ganz 2005). 
 
1.7 The iron metabolism of patients affected with DCM 
Most of the iron within the body is found in haemoglobin within erythrocytes 
(about 1800 mg of iron).  Iron is stored in macrophages (and to a lesser extent 
in hepatocytes), which represents the storage pool of iron (about 1600 mg of 
iron) (Andrews 1999).  Small amounts of iron are found in myoglobin and in 
plasma (bound to transferrin).  Iron is conserved within the body. The typical 
adult human body contains about 3000-4000 mg of iron.  Only about 1 mg of 
iron is lost from the body per day (through blood loss or sloughed mucosal 
epithelial cells) and must be replaced through the diet. The majority of iron 
required by the body is acquired by recycling iron from senescent (or old) red 
cells (Hentze 2004). 
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Dietary iron is obtained either from inorganic sources or animal sources (in 
heme from breakdown of haemoglobin or myoglobin). Dietary iron enters 
intestinal cells via specific transporters. The iron is then used by the cell 
(incorporated into enzymes), stored as ferritin (excreted in the faeces when the 
intestinal epithelial cell sloughs) or is transferred to the plasma (Weatherall 
2001). Plasma transfer of iron from enterocytes to the transport protein, 
apotransferrin, occurs through specific iron channels, called ferroportins, (Figure 
1.3) and is facilitated by a protein (with ferroxidase activity) called hephaestin 
(Templeton 2003). When apotransferrin binds iron, it is called transferrin. 
Hephaestin contains copper, so copper deficiency will decrease iron absorption 
as the iron absorbed from the diet cannot be transferred to plasma). Hepcidin, a 
main iron regulating protein, decreases ferroportin and thus decreases iron 
absorption (Niederau 1996).  
 
Figure 1.3 Mechanisms of the cells regulating body-iron homeostasis. 
“Images adapted with permission from the publisher. [Kemna E, Pickkers P, Nemeth E, van der 
Hoeven H, Swinkels D., 2005. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in 
humans injected with LPS. Blood, 106, pp.1864-1866.]”  
Enterocytes, macrophages and hepatocyte acquire iron from different sources and 
deliver it to the rest of the body through the iron exporter ferroportin, which needs 
copper-ferroxidases to release iron to plasma transferrin.  Ferroportin acts under the 
control of hepcidin and this interaction can explain the system regulation of iron 
metabolism (Kemna 2005).  
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Iron is not free in the circulation but exists as transferrin (bound to 
apotransferrin). Most of the iron used for red blood cell haemoglobin production 
is obtained from haemoglobin breakdown of old RBCs (called recycling). When 
red blood cells reach the end of their lifespan (senescent), they are 
phagocytized by macrophages (in the spleen, liver, bone marrow). Hydrolytic 
enzymes in macrophages degrade the ingested RBCs and release 
haemoglobin (Pietrangelo 2004). Proteolytic digestion of haemoglobin liberates 
heme and globins. Globins are broken down to amino acids, which can be used 
for protein production. The iron is released from heme, leaving a porphyrin ring 
which is converted to bilirubin. Once iron is released from the heme, it is utilized 
by the cell (iron is an essential component of many enzymes), exported (via 
ferroportin), or stored as ferritin like enterocytes (Weatherall 2001, Pietrangelo 
2004). In macrophages, caeruloplasmin (which like hephaestin in intestinal cells 
also requires copper) is a ferroxidase and facilitates the transfer of macrophage 
iron to transferrin. So copper deficiency decreases iron release from 
macrophages and affects iron absorption. Like enterocytes, hepcidin 
downregulates ferroportin causing iron sequestration in macrophages (Esposito 
2003). 
Deposition of iron in the heart is a gradual process and depends on the 
increasing levels of serum iron. Under normal iron homeostasis, cardiac iron is 
regulated through transferrin-mediated uptake mechanisms. During iron 
overload, transferrin is saturated, and nontransferrin-bound iron is released into 
the circulation and enters cardiac myocytes in the ferrous form through L-type 
calcium channels (LTCC) as has been described (Tsushima et al 1999).  
Endosome-mediated uptake might also play a role, but is poorly understood 
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(Wood 2008).  Iron is then bound to ferritin and transported to lysosomes for 
degradation and long-term storage in the cardiac myocyte (Wood 2008).  
 
Pathologic iron deposition begins initially within the epicardium and extends to 
the myocardium and then the endocardium, which helps explain the 
preservation of systolic function until very late in the disease (Liu et al 1999). 
Once the antioxidant capacity of the cell is exceeded, iron is catalyzed by the 
rapid Fenton reaction producing hydroxyl ions, which is an extremely reactive 
free radical species that causes lipid peroxidation producing membrane 
permeability alterations. These modifications create a leak of hydrolytic 
enzymes that initiate cell damage and subsequent cardiac myocyte death. In 
cases with concomitant myocardial ischemia, iron overload can accelerate 
ischemia-induced reperfusion injury, and may lead to an autocatalytic process 
that results in a cardiomyopathic process. 
 
1.8 Structure and location of HFE (High Iron) gene 
Researchers have identified more than 20 mutations in the HFE gene that 
cause type 1 haemochromatosis. Two particular mutations are responsible for 
most cases of this disorder. Each of these mutations changes one of the protein 
building blocks (amino acids) used to make the HFE protein. One mutation 
replaces the amino acid cysteine with the amino acid tyrosine at position 282 in 
the protein's chain of amino acids (written as Cys282Tyr or C282Y) (Bacon 
1999). The other mutation replaces the amino acid histidine with the amino acid 
aspartic acid at position 63, written as His63Asp or H63D (Figure1.4). The 
Cys282Tyr mutation prevents the altered HFE gene from reaching the cell 
surface, so it cannot interact with hepcidin and transferrin receptors. As a result, 
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iron regulation is disrupted and too much iron is absorbed from the diet. This 
increase in the absorption of dietary iron leads to the iron overload 
characteristic of haemochromatosis (Liang 2002).  
 
 
Figure 1.4 Diagram of the HFE gene 
“Images adapted with permission from the publisher. [Swinkels, D.W., Janssen, M.C., Bergmans, J., 
Marx, J.J. (2006). Hereditary hemochromatosis: genetic complexity and new diagnostic approaches. 
Clinical Chemistry, 52(6): 950-68.]” 
The Cys282 -> Tyr282 substitution is the cause of the C282Y mutation and 
His63 -> Asp63 substitution causing H63D mutation (Swinkels et.al. 2006)  
 
 
1.9 Prevalence of C282Y and H63D gene mutations 
Hereditary haemochromatosis is the most common disease with an autosomal 
recessive inheritance pattern in Caucasians with the prevalence of the C282Y 
mutation approximately ten times that of cystic fibrosis causing alleles 
(Pietrangelo 2004). Within Irish populations, the frequency of the C282Y allele 
has been calculated as 0.099 and H63D allele is 0.141 (Murphy, Curran et.al. 
1998). These values are consistent with the worldwide average C282Y 
  
 
Jereza, Noel                                                                                                         44                                                                                                                
 
homozygosity in people of northern European descent that has been calculated 
to be approximately 0.5% (Papanikolaou, Politou et.al. 2000; Jackson, Carter 
et.al. 2001; Powell, Dixon et.al. 2005). The prevalence of these mutations in 
non-white populations is much lower with a large population study in the US 
providing estimates for C282Y homozygosity in Native Americans, Hispanics, 
African Americans, Pacific Islanders and Asians that were at least one quarter 
of the frequency in the non-Hispanic whites (Adams, Reboussin et.al. 2005). 
The allele frequencies for the H63D mutation are similar in haemochromatosis 
patients and the general population, but when extremely rare occurrence of the 
C282Y/H63D haplotype are taken into account, H63D is actually more prevalent 
in haemochromatosis than in the general population (Beutler 1997; Beutler, 
Felitti et.al. 2001). The presence of either C282Y or H63D alleles even in the 
heterozygous state is able to influence iron overload (Whitfield, Cullen et.al. 
2000). Population studies have shown that compound heterozygosity for C282Y 
and H63D presents a higher risk for the development of HH than either mutation 
alone, and the extent of iron loading generally follows the trend C282Y 
homozygotes > C282Y/H63D compound heterozygotes > H63D homozygotes > 
C282Y heterozygotes > H63D heterozygotes > wildtype (Cardoso, Porto et.al. 
2001; Beutler, Felitti et.al. 2002). 
 
1.10 Genetic basis of hepcidin   
For a whole host of reasons, gene expression is invariably random. Thus, a 
random population-sampling would reveal wide variations in gene expression 
profiles and in hepcidin levels. Variation in hepcidin expression may be sexually 
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dimorphic or it may depend on age, iron levels, and infection/inflammation or 
simply on time of day (Robertson et.al. 2009).  For example, estradiol has been 
shown to repress hepcidin transcription in fish suggesting that differences in the 
complement of sex hormones could induce some variation in hepcidin 
expression within and between the sexes; this may underlie variation in 
hepcidin expression and liver iron loading between males and females (Kroot 
et.al. 2009). 
Regulatory variation in hepcidin expression may be determined by polymorphic 
cis-acting, non-coding regions of the gene. Thus these regions are just as 
crucial to quantitative differences in its expression as point mutations within its 
open-reading frame (ORF) because some of these regions contain transcription 
factor-binding sites. Trans-acting factors also determine hepcidin expression 
variation; these include transcription factors and iron regulatory or modifier 
proteins (Lee et.al. 2009). Structural variation in the hepcidin gene i.e. gene 
dosage or copy number polymorphism, inversions and insertions, may also 
determine variability in its expression. It is assumed that where certain 
individuals inherit different copy numbers or structural variants of the hepcidin 
gene, there may be consequential variation in hepcidin expression and iron 
absorption. Although conceptually possible, this type of variation has not yet 
been identified (Feuk et.al. 2006). 
The most important epigenetic modifiers of hepcidin expression are the 
environment and diet because of their potential to influence chromatin structure 
e.g. through DNA methylation. For example, individuals that are exposed to 
infectious diseases may express more hepcidin than those in relatively sterile 
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environments. Similarly, diets that are rich in iron may increase hepcidin 
synthesis. On the other hand, individuals living in chronically hypoxic 
environments (e.g. high altitude) may express reduced levels of hepcidin 
compared with those at sea-level. Unfortunately,  these assumptions are based 
on working knowledge of hepcidin expression dynamics as no epidemiological 
data are available to support them (Choi et.al. 2008).  Nevertheless, it is highly 
likely that gene-environment and gene-nutrient interactions may critically modify 
hepcidin expression levels between individuals or populations, and their 
predisposition to iron-overload or anaemia (Choi et.al. 2008).  
The product encoded by this gene is involved in the maintenance of iron 
homeostasis, and it is necessary for the regulation of iron storage in 
macrophages, and for intestinal iron absorption. The pre-protein is post-
translationally cleaved into mature peptides of 20, 22 and 25 amino acids, and 
these active peptides are rich in cysteines, which form intramolecular bonds that 
stabilize their beta-sheet structures. These peptides exhibit antimicrobial 
activity. Mutations in this gene cause haemochromatosis type 2B, also known 
as juvenile haemochromatosis, a disease caused by severe iron overload that 
results in cardiomyopathy, cirrhosis, and endocrine failure. (Ganz 2005).  
 
1.11 Discovery and structure of hepcidin 
Hepcidin was first discovered in human urine and serum.  Most data on 
hepcidin expression, regulation, structure and function were obtained by in vitro 
approaches and studies in mice.  Hepcidin was initially isolated from plasma 
ultrafiltrate and named liver-expressed antimicrobial peptide (LEAP). Almost 
simultaneously, it was isolated from human urine and named hepcidin after its 
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hepatic origin and bacterial effect in vitro (Hunter 2002, Nemeth 2006).  The 
development of severe iron overload by knocking out the gene in mice 
suggested hepcidin to be involved in iron metabolism, whereas this key role in 
regulation was stressed by the discovery of hepcidin mutations in patients.  The 
newly discovered peptide was found to be regulated by inflammation, iron 
stores, hypoxia and anaemia (Park 2001). 
 
Hepcidin, a peptide hormone produced by the liver, is the principal regulator of 
iron homeostasis. Hepcidin production increases with iron loading and 
inflammation and decreases with anemia and hypoxia.  Hepcidin acts by binding 
to ferroportin, the sole cellular iron exporter, and inducing its internalization and 
degradation. Because ferroportin is expressed in the duodenum, spleen, liver, 
and placenta, hepcidin increase, and the subsequent decrease of ferroportin, 
results in inhibition of duodenal iron absorption, release of recycled iron from 
macrophages, mobilization of iron stores from the liver, and iron transfer across 
placenta (Nicolas 2002). Excessive hepcidin production resulting from 
increased expression in liver tumuors or transgene expression, or acute 
administration of synthetic hepcidin, leads to either acute or chronic 
hypoferremia (Nemeth 2003).  
 
Alternatively, hepcidin deficiency resulting from mutations in the hepcidin gene 
itself, or the genes encoding HFE, transferrin receptor 2, or haemojuvelin, 
appears to be the cause of most types of hereditary haemochromatosis (Nicolas 
2003). The hepcidin gene encodes an 84–amino acid prepropeptide with a 
typical signal sequence and a consensus cleavage site for a prohormone 
convertase that generates the mature bioactive 25–amino acid form found in 
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plasma and urine.  The 25–amino acid peptide hep 25 forms a hairpin loop 
stabilized by 4 disulfide bonds, one of which is an unusual vicinal bond between 
adjacent cysteines at the hairpin turn (Kemna 2005). Three-dimensional nuclear 
magnetic resonance (3D-NMR) structure studies also showed that hepcidin is 
an amphipathic peptide similar to most antimicrobial peptides. However, unlike 
antimicrobial peptides that display great species-to-species variation, hepcidin 
sequence is conserved across species, ranging from fish to mammals, with 
human sequence showing 60% similarity to the zebra fish hepcidin-1 (Huang 
2005). 
 
1.12 Mechanism of hepcidin in maintaining iron homeostasis 
The understanding of iron homeostasis regulation increased with the 
identification of the purported master regulator of iron absorption, hepcidin 
(encoded by the HAMP gene). Hepcidin was originally recognised as an anti-
microbial peptide in human urine (Krause, Neitz et.al. 2000) and blood (Park, 
Valore et.al. 2001) studies. In the iron pathway (Figure 1.5), hepcidin binds to 
FPN1 (on the baso-lateral membrane of enterocytes and on macrophages) 
causing it to become internalised and resulting in iron retention within the cell 
and prevention of iron from entering the plasma (Nemeth et al. 2004). Hepcidin 
is produced predominantly by the liver, the main storage site for excess iron and 
thus the hepatocytes are believed to be the major site of iron homeostasis 
(Gehrke, Herrmann et al. 2005). 
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Figure 1.5  Hepcidin internalization and degradation 
“Images adapted with permission from the publisher. [Nemeth E, Preza GC, Jung CL, Kaplan J, 
Waring AJ, Ganz T., 2006. The N-terminus of hepcidin is essential for its interaction with ferroportin: 
structure-function study. Blood, 107, pp.328-333.]” 
Hepcidin binds to ferroportin and induces its internalization and degradation. By this 
mechanism, the interaction of hepcidin with ferroportin regulates the flow of iron into 
plasma, and thereby regulates the distribution of iron in the body (Nemeth 2006).  
 
 
 
The regulation of hepcidin is complex with a number of transmembrane proteins 
associated with the initiation of HAMP transcription via a number of different 
pathways. In an inflammation mediated response, interleukin-6 (IL6) induces 
the expression of HAMP through the JAK-STAT pathway (Wrighting and 
Andrews 2006). Recently members of the bone-morphogenetic protein (BMP) 
pathway have been implicated as key regulatory molecules in modulating 
HAMP expression (Corradini, Schmidt et.al. 2010). Signalling through the BMP 
receptor (BMPR), by BMP6 in particular, induces the expression of HAMP 
through the SMAD signalling pathway (Babitt, Huang et.al. 2006).  
 
Hemojuvelin (HJV) is present on the hepatocyte membrane. In conditions of low 
iron, HJV may be cleaved to its soluble form (sHJV) by another membrane 
protein, serine protease matriptase-2 (TMPRSS6). The sHJV inhibits HAMP 
induction by binding BMPs and preventing them from binding the BMPR 
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(Silvestri, Pagani et.al. 2008). The pathways involved in HAMP regulation are 
outlined below. 
 
Whilst hepcidin controls the efflux of iron from cells, the uptake of iron is also 
regulated, although the two pathways are not mutually exclusive. The 
mechanisms of iron regulation are not fully understood and the precise 
functions of some of the proteins involved in this pathway remain unknown. 
TFRC is the main receptor for iron uptake on the cell membrane. HFE and holo-
TF compete for binding sites on TFRC (Giannetti and Bjorkman 2004), and as 
the holo-TF has a greater affinity (Figure 1.6), it causes the dissociation of HFE 
and iron is absorbed into the cell. Transferrin receptor 2 (TFR2) is thought to 
play a role in the regulation of iron absorption by sensing iron saturation levels 
of transferrin (Wallace, Summerville et al. 2005). 
 
Figure 1.6 Regulation of HAMP expression in the hepatocyte.  
“Images adapted with permission from the author. [Barton JC et.al. 2009. HFE, SLC40A1, HAMP, 
HJV, TFR2, and FTL mutations detected by denaturing high-performance liquid chromatography after iron 
phenotyping and HFE C282Y and H63D genotyping in 785 HEIRS Study participants. Am. J. Hematol. 
84:710–714.]”  
The schematic flow within the hepatocyte on the regulation of HAMP(Hepcidin gene) 
when IL6(interkeukin-6) binds to the IL6R(interleukin-6 receptor), activating the 
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JAK/STAT(Janus Kinase2/Signal Transducers and Activators of Transcription) pathway 
to enhance HAMP expression. When iron is abundant, TFR2(Transferrin Receptor2) is 
thought to detect iron levels but the mechanism is unknown.  BMPs(Bone Morphogenic 
Protein) bind to the BMPR(Bone Morphogenic Protein Receptor) and HAMP expression 
is activated through the SMAD(or Similar to Mothers Against Decapentaplegic) 
pathway. When iron is low, TMPRSS6 (Transmembrane Proteinase Serine6) cleaves 
HJV (Haemojuvelin) which then binds to the BMPs so they cannot bind BMPR and 
HAMP expression is not up-regulated (Barton et.al. 2009).  
 
 
1.13 The HAMP gene and hepcidin 
The HAMP C70R mutation (Figure 1.7) provides instructions for the production 
of a protein called hepcidin. Hepcidin was originally identified as having 
antimicrobial properties, which refers to the ability of this protein to fight 
bacterial infections. Researchers have discovered that hepcidin plays a major 
role in maintaining iron balance in the body. It is believed that hepcidin 
circulates in the blood and inhibits iron absorption by the small intestine when 
the body's supply of iron is too high (Pigeon 2001). 
 
Researchers have proposed that hepcidin production in the liver increases 
when iron enters liver cells from the blood. Hepcidin is then released into the 
bloodstream and travels throughout the body. This protein interacts primarily 
with other proteins in the intestines, liver, and certain white blood cells to adjust 
iron absorption and storage. In this way, iron supplies are monitored and iron 
absorption is adjusted to reflect the needs of an individual's body (Pigeon 2001, 
Nicolas 2001). 
 
 
At least eight mutations in the HAMP gene have been identified that result in 
haemochromatosis. People who have mutations in the HAMP gene are affected 
by a severe type of juvenile hemochromatosis, sometimes called type 2 
haemochromatosis, that begins between the ages of 10 years and 30 years. 
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People with mutations in the HAMP gene are unable to make normal hepcidin 
and cannot inhibit iron absorption, even when the body has sufficient supplies of 
iron. The organs of affected people become overloaded with iron, especially the 
liver and the heart, leading to the organ damage characteristic of this disorder 
(Gehrke 2005, Lebron 1998).  
 
Figure 1.7 Molecular diagram of C70R mutation 
“Images adapted with permission from the author. [Roetto A, Daraio F, Porporato P, Caruso R, et al., 
2004.  Screening hepcidin for mutations in juvenile hemochromatosis: identification of a new mutation 
C70R. Blood, 103, pp.2407-2409.]”  
The upper lane is the electrophoretograms of the HEPC genomic sequence spanning 
the C70R mutation. The sequence is shown for DNA of a wild-type subject (WT), 
proband (P), and the heterozygous parent (M) and the (*) indicates the mutation. The 
lower lane is the three-dimensional structure of HEPC 25 and 20 amino acid peptides. 
The mutated cysteine is indicated in yellow; a white bracket marks the S-S bond 
disrupted by the mutation (Roetto et.al 2004) 
                                        
1.14 The role of hepcidin  in DCM 
The hepatic hepcidin expression is regulated by hypoxia and inflammation, 
factors influencing iron homeostasis. Pigeon et al  analyzed whether cardiac 
hepcidin expression is regulated in response to these stimuli, too. In their study, 
they demonstrate clearly that cardiac hepcidin expression is regulated in 
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response to hypoxia and inflammation. Their data show that, in contrast to the 
liver, in which hypoxia results in down-regulation of hepcidin expression, cardiac 
hepcidin expression is significantly up-regulated in response to hypoxia (Pigeon 
2001).  
 
Hepcidin produced in the liver and released into the blood is supposed to have 
a systemic effect by negatively regulating iron absorption in the duodenum. The 
downregulation of hepatic hepcidin expression in response to hypoxia and 
anaemia results in increased intestinal iron absorption. Cardiac hepcidin 
expression may have predominantly a local effect in the heart (Pietrangelo 
2006). By a proposed local effect, the observed up-regulation of cardiac 
hepcidin expression in response to hypoxia may explain the previously reported 
ischemia-related enhanced cardiac ferritin content.  
 
Ferritin is a major intracellular iron sequestering and storage protein that is 
assumed to play an important cytoprotective role against free radical formation 
by controlling the free cytosolic iron concentration (Pigeon 2001). Because 
elevated hepcidin can result in an increased intracellular ferritin content, 
speculation  that the up-regulation of hepcidin in response to hypoxia may 
provide a coordinated mechanism for protecting cardiac cells against the 
hypoxia-related free radical formation by controlling the free cytosolic iron 
concentration (Kemna 2005). 
1.15 The relationship of hepcidin and iron overload 
Iron overload has traditionally been evaluated by measuring serum ferritin levels 
or liver iron concentration (LIC). Serum ferritin levels up to about 4,000 μg/L 
reflect the amount of iron in macrophages, while higher levels increasingly 
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reflect ferritin leakage from hepatocytes (Rothenberg 1996).  LIC measurement 
has traditionally required liver biopsy, but the recent development of 
standardized magnetic resonance imaging (MRI) techniques has allowed non-
invasive sequential measurements of LIC. MRI has also allowed the 
assessment of myocardial iron deposits, which have been directly linked to the 
risk of cardiomyopathy in iron-overload disorders (Lebron 2999).  
 
Understanding of the molecular mechanisms that determine iron absorption and 
distribution is rapidly developing and will help explain some of the 
pathophysiological consequences of iron overload, as well as differences 
between various disease states. Hepcidin deficiency is a feature common to 
various forms of genetic haemochromatosis (Feder 1998). Moderate hepcidin 
deficiency is seen in classic haemochromatosis (C282Y) and results in iron 
deposition mainly in the liver; in juvenile haemochromatosis, which is 
characterized by a much more severe hepcidin deficiency, iron loading is more 
rapid and iron deposition in the heart tends to be more prominent (Papanikolaou 
2004). 
 
1.16 Mechanism of iron overload in DCM 
Iron-overload cardiomyopathy (IOC) manifests itself as systolic or diastolic 
dysfunction secondary to increased deposition of iron in the heart and occurs 
with common genetic disorders such as primary haemochromatosis and beta-
thalassemia major. Although the exact mechanism of iron-induced heart failure 
remains to be elucidated, the toxicity of iron in biological systems is believed to 
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be attributed to its ability to catalyze the generation of oxygen-free radicals 
(Buja 1971).  
 
In the current investigation, the dose-dependent effects of chronic iron-loading 
on heart tissue concentrations of iron, glutathione peroxidase (GPx) activity, 
free-radical production, and cardiac dysfunction were investigated in a murine 
model of iron-overload cardiomyopathy (Laurita 2003).  It was shown that 
chronic iron-overload results in dose-dependent (a) increases in myocardial iron 
burden, (b) decreases in the protective antioxidant enzyme GPx activity, (c) 
increased free-radical production, and (d) increased mortality. These findings 
show that the mechanism of iron-induced heart dysfunction involves in part free 
radical–mediated processes (Oudit 2003). 
 
Iron overload cardiomyopathy is an old disease that has evolved from a rare 
undiagnosable and untreatable condition to a now much more common, 
diagnosable, and potentially treatable condition.  Pathologically it is due to a 
direct free iron effect on the myocytes, and not due to interstitial infiltration. This 
also implies that the disease process is reversible if the tissue iron 
concentration can be controlled (Kuryshev 1999). The advent of magnetic 
resonance imaging and future genetic identification can identify the population 
at risk.  Chelation therapy, including newer forms of oral chelators, likely will be 
more commonly available to benefit an ever increasing number and spectrum of 
the population. Further active research will be needed to improve our 
pathophysiological understanding and clinical treatment of this increasingly 
common condition (Laurita 2003). 
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Iron overload cardiomyopathy has been recently described as a dilated 
cardiomyopathy, characterized by left ventricular (LV) remodeling with chamber 
dilatation and reduced LV ejection fraction (LVEF). However, primary 
haemochromatosis, a genetically determined condition leading to iron overload, 
is classically categorized as an infiltrative cause of restrictive cardiomyopathy.  
Moreover, secondary haemochromatosis may lead to severe diastolic LV 
dysfunction in the early stages of the disease, before LVEF is affected. In the 
present review, pathophysiology, and phenotypic expression of IOC has been 
emphasized, focusing on ventricular geometry and function and describing the 
early diastolic abnormalities that lead ultimately to heart muscle dysfunction 
(Rivers et.al. 1987). 
 
1.17 Clinical manifestations of iron overload in DCM 
Heart failure due to myocardial iron overload remains the leading cause of 
death in patients with transfusion-dependent anaemias. Iron overload-induced 
cardiomyopathy is reversible if intensive chelation therapy is instituted on time. 
Thus, early detection of myocardial iron deposition is imperative to prevent overt 
heart failure (Liu 1994). Conventional cardiac monitoring, including physical 
examination, electrocardiography, echocardiography or serum ferritin levels fail 
to predict manifest or subclinical myocardial involvement resulting from iron 
overload. Cardiovascular magnetic resonance imaging T2* (cMRI-T2*, 
pronounced T2 star) times correlate well with myocardial iron levels (Sachdev 
2007).  This timely review focuses on the utility of cMRI-T2*, for the preclinical 
detection of myocardial iron overload and monitoring of myocardial iron content 
during chelation therapy (Liu 1994). 
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The heart is almost always affected in idiopathic (primary) haemochromatosis. 
In addition cardiac iron deposits occur in secondary haemochromatosis, which 
occurs, for example, in patients who have received multiple blood transfusions 
for treatment of anaemia. The degree of involvement may be slight and without 
evidence of gross changes, but often it is sufficient to produce a brownish 
discoloration of the myocardium (Valenti 2004). 
 
The deposits are more prominent in the subendothelial than in the subepicardial 
zone. Microscopically, haemosiderin granules are identified within myocardial 
fibers and occasionally in the connective tissue cells. In the myocytes, the iron 
is deposited in sarcoplasmic siderin granules, which are distinct from lipofuscin 
granules. Varying degrees of degeneration, edema, and fibrosis of the 
myocardium can be seen. Electrocardiographic changes and even cardiac 
failure may occur. Arrhythmias may occur as a result of iron deposits in the 
fibers of the conduction system (Rosenqvist 1989). 
 
1.18 Rates of iron loading in patients with DCM 
Iron overload may be assessed by serum markers, such as ferritin, transferrin 
saturation, labile plasma iron, non-transferrin-bound iron (NTBI), or by 
estimation of liver iron concentration (Liu 1994).  Ferritin is the most widely 
validated and widely available serum metric, but can have large disparities with 
respect to the hepatic and cardiac iron burdens. Liver biopsy offers accurate 
estimates of total body iron balance, but it is invasive, expensive, and subject to 
sampling variation. Both magnetic susceptometers and magnetic resonance 
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imaging (MRI) machines can be used to estimate liver iron non-invasively 
(Cooper 2003). 
  
MRI-based techniques have many advantages, including wider availability, 
lower cost, the ability to measure iron accurately in many organs, as well as the 
ability to assess cardiac functional parameters. The multimodal capability of 
MRI is important because iron cardiomyopathy is the leading cause of death in 
thalassaemia major. While liver iron correlates well with total iron balance, it has 
little predictive value for the risk of cardiac iron uptake (Laurita 2003). 
 
This disparity arises from different iron transport kinetics in the liver and the 
heart. The heart primarily loads iron through NTBI, unlike the liver, which also 
recycles transferrin-bound iron. Heart iron uptake is significantly delayed 
compared with increases in liver iron concentration, but can ultimately load quite 
quickly (Pietrangelo 2004). In contrast, iron clearance from the heart is often 
fairly slow, with rate constants 5 to 6 fold slower than for the liver. Thus, kinetic 
differences create a hysteresis between cardiac and liver iron concentration, 
weakening their statistical association. As a result, the ability of MRI to detect 
and quantitate otherwise clinically silent cardiac iron deposition and functional 
decompensation has completely changed the practice of iron chelation therapy 
(Cecchetti 1991). 
 
 
1.19 Digenic inheritance of HAMP and HFE gene mutations in DCM 
Hereditary Haemochromatosis (HH) is a clinically and genetically 
heterogeneous disease caused by inappropriate iron absorption. Most HH 
patients are homozygous for the C282Y mutation in the HFE gene. However, 
penetrance of the C282Y mutation is incomplete, and other genetic factors may 
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well affect the HH phenotype. Ferroportin and TFR2 mutations also cause HH, 
and the two new HAMP mutations in two different families, in which there is 
concordance between severity of iron overload and heterozygosity for HAMP 
mutations when present with the HFE C282Y mutation (Wallace 2007). 
 
Mutations in the transferrin receptor 2 gene TFR2 (chromosome 7, band q22) 
and in ferroportin I (SLC11A3, chromosome 2, band q32)  have been reported 
to cause HH, and juvenile haemochromatosis (JH) patients have been 
described who are homozygous for mutations in the hepcidin gene HAMP  on 
chromosome 19, band q13. Hepcidin is a recently identified antimicrobial 
peptide synthesized by hepatocytes in response to bacterial infection and 
inflammation (Roetto 2004). Recent studies have implicated HFE in regulation 
of HAMP expression.  With the aim of identifying other mutations or 
polymorphisms that might contribute to the variable penetrance seen in HH, 
Merryweather-Clarke et al identified two new HAMP mutations in two different 
families who have combinations of mutations in both HFE and HAMP (Wallace 
2007).  
 
Taken together, the combination of a genetic alteration at both the HFE and 
HAMP loci could lead to an adult-onset phenotype of hereditary 
haemochromatosis that is not apparent when an individual carries only one of 
these gene alterations. A similar situation has very recently been reported by 
Merryweather-Clarke et al who have partially described the pedigree of a 
proband heterozygous for the C282Y HFE mutation and for a HAMP deletion 
that removes the last 3 nucleotides of exon 2 and the first one of intron 2.  Thus, 
on the basis of the example of several other genetic disorders, it is interestingly 
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to propose that, at least in some cases, a digenic model of inheritance might be 
responsible for an adult-onset iron overload phenotype. 
 
1.20 Significance of investigating the potential coexistence of HFE and 
HAMP haemochromatosis gene mutations among family members of 
Irish patients with DCM. 
The term ‗haemochromatosis‘ (also genetic or hereditary haemochromatosis) is 
generally used to describe a primary inherited disorder of iron metabolism 
leading to progressive iron loading of parenchymal cells of the liver and other 
organs with cirrhosis, diabetes and arthritis being the major manifestations. 
Recent advances in the molecular genetics of iron metabolism have confirmed 
that HAMP and HFE-associated haemochromatosis is the most common form 
of the disease, being responsible for over 90% of cases in Caucasian subjects; 
one in ten Caucasians is a heterozygous carrier, and one in 200 is homozygous 
and thus at risk (Biasotto 2003). Within Irish populations, the frequency of the 
C282Y allele has been calculated as 0.099 and H63D allele is 0.141 (Murphy, 
Curran et.al. 1998), but no report on frequency in HAMP C70R mutations. 
 
Clinical expression is variable, the majority (approximately 75%) of homozygous 
demonstrate biochemical expression (elevated serum ferritin and transferrin 
saturation levels), but a much lower proportion (varying from 1 to 10%) have 
advanced disease such as cirrhosis, diabetes, and cardiomyopathy (Roetto 
2004).   Approximately 20% show hepatic fibrosis on liver biopsy. Case 
detection of homozygous subjects is important because significant clinical 
disease can be present in those detected coincidentally and especially in first-
degree relatives. The most effectual method of early detection is by family 
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(cascade) screening or by primary care physicians with a high index of clinical 
suspicion (Merryweather-Clarke 2002, Roetto 2004). 
 
In accordance with the demonstration by Nicolas et.al. of an increased hepatic 
iron loading in Hfe-mice with an additional HAMP deficient allele, they are also 
in accordance with several studies that, during the past 2 years, have 
concluded that the HAMP gene product, called hepcidin, might act through the 
same regulatory pathways as HFE to control the amount of iron in the body 
(Nicholas et.al. 2001). In the case of an excess of iron in the body, the control 
process should include a form of action on the reticulo-endothelial 
macrophages, by promoting inhibition of iron release from senescent or old red 
blood cells and an action on duodenal cells, by promoting inhibition of 
alimentary iron absorption (Dupic et.al. 2002).  Even if the relationship between 
HFE and HAMP has still to be clearly defined, it is interesting to note that the 
first demonstration of a relation between the 2 proteins has very recently been 
forthcoming from  studies that have highlighted that HFE plays an important role 
in the regulation of hepatic HAMP gene expression (Muckenthaler et.al. 2003).  
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1.21 Aims of study 
 
1.21.1 Over-all aim of the study 
The over-all aim of this study is to investigate the association of 
haemochromatosis gene mutations C282Y/H63D (HFE gene), C70R (HAMP 
gene), iron and cardiac biomarkers in Irish patients diagnosed dilated 
cardiomyopathy and their family members. 
1.21.2 Specific aims of the study 
Specific aim 1: To document the coexistent HFE and HAMP gene mutations as 
contributing factors in the development of dilated cardiomyopathy among family 
members. 
 
Specific aim 2: To determine the mechanisms of serum ferritin, transferrin 
saturation, serum hepcidin, troponin-I and creatine kinase as predictor iron and 
cardiac biomarkers in the development of dilated cardiomyopathy. 
 
 
 
 
 
 
 
 
 
 
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CHAPTER   2   Materials and  
                         Methods 
 
 
 
 
2.1 Materials  
2.1.1 Ethical statements 
The research protocol was approved by the Medical Ethics Committee of the 
UPMC Beacon Hospital, MedLab Pathology Ltd. and Hermitage Medical Clinic, 
where both strives to ensure that the four basic principles of ethical research 
are central to this work in which it is involved – whether undertaken by its own 
researchers in isolation or in collaboration with other institutions and/or 
individual researchers or research networks.  
 
These principles are - Beneficence - as a researcher I strive to ensure that my 
work should make a positive contribution to the welfare of those affected by it. 
Non-maleficence - I endeavour to ensure that the research work undertaken by 
the UPMC Beacon Hospital, MedLab Pathology Ltd. and Hermitage Medical 
Clinic  does not cause harm to any sectors of society and, in particular, to 
participants (where applicable). Justice - the benefits and risks associated with 
my work should be well assessed in advance and both should be equitably 
distributed throughout population group. Autonomy of subjects - where 
applicable, the research respects and protects the rights and dignity of 
participants. Participants‘ blood sample and related data collection exercises 
are given sufficient details on the research in question as to allow them to make 
an informed decision to participate or otherwise in a research study. 
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2.1.2 Reagents and chemicals 
Reagents and chemicals used in this study have been prepared and supplied 
by various vendor approved by the Materials and Management, UPMC Beacon 
Hospital, MedLab Pathology Ltd and Hermitage Medical Clinic.  The reagents 
and solutions used  in HFE and HAMP genotyping by PCR-RFLP analysis were 
sterile water-50 mL bottle, nuclease-free sterile water-50 mL bottle (Cruinn, 
Ireland);  1x TBE buffer (containing 108 g of tris-hydroxymethyl-aminomethane 
[TBE], 55 g of boric acid, 7.5 g of EDTA, disodium salt and deionized water, 
2.5% Hi-sieve agarose Lo-melt gel cast with ethidium bromide, 100bp DNA 
ladder (Helena BioSciences, Ireland); 10x RE buffer, BbrpI endonulcease 
(Roche Diagnostics, UK).  
 
The primers, ladder and digest enzyme used in amplifications of the HAMP 
mutations were AmpliTaq DNA polymerase, SacII enzyme, bromphenol blue 
dye 0.05%, C70R Primers Ex1 F/R 206bp, C70R Primers Ex2 F/R 192bp, C70R 
Primers Ex3 F/R 352bp (Applied Biosystems, UK). The kit used for DNA 
extraction-QIAmp DNA blood kit 50 which include proteinase K, phosphate 
buffered saline, buffer AL, buffer AE, buffer AW1, buffer AW2  and QIAmp spin 
column,  96% ethanol (Qiagen, Ireland). The primers, ladder and digest enzyme 
used in amplifications of HFE mutations were MgCl2, platinum taq DNA 
polymerase, 100mM dNTP, Primers 282 rev/mut, Primers 63 fwd/mut, 5% 
DMSO (Sigma-Aldrich/Invitrogen, Ireland).  
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2.2 Methods used in the study 
 
2.2.1 Patient and control samples 
Patient blood samples were collected in two 3.5 mL tubes of K3EDTA (purple lid 
tube) which have been pooled and used in DNA extraction for the HFE and 
HAMP genotyping and blood sample collected in gold lid top 4.5 mL tube with 
gel separator (SST tube, no added anticoagulant), allowed to clot after-which 
the tube has been centrifuged for 10 minutes at 4500 rpm (or 2268 rcf) to obtain 
the serum for biochemical marker analysis. The patient blood samples were 
obtained from both male and female patients newly and previously diagnosed 
with dilated cardiomyopathy with an age range between 40 to 65 years old. 
Additional blood samples were collected from the first and second generation 
among family members age between 19 to 50 years old at the UPMC Beacon 
Hospital. Informed consent has been explained and signed by all subjects. 
 
The same set of blood collection tubes used for the control group samples and 
also been centrifuged for 10 minutes at 4500 rpm (or 2268 rcf) to obtain the 
serum for biochemical marker analysis. The control group blood samples were 
collected from 58 healthy volunteers attending the outpatient clinic at UPMC 
Beacon Hospital, with no known severe or acute medical conditions or any 
known history of chest pain and cardiac related illnesses or complaints, 
matched for age and sex. Informed consent has been explained and signed by 
all subjects. 
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2.2.2 Mechanism of immunoassay (Ferritin and Troponin-I) determination 
using Abbott ARCHITECT C8200i 
The clotted whole blood sample was centrifuged at 4500 rpm (or 2268 rcf) for 
10 minutes and the serum was assayed for ferritin, and Troponin-I. It is an 
automated two-step immunoassay to determine the presence of the  analyte 
concentration in human serum using Chemiluminescent Microparticle 
Immunoassay (CMIA) technology with flexible assay protocols, referred to as 
Chemiflex (Abbott Architect 2008). The automated analysis employed various 
steps to determine the concentration includes resuspension of micropartciles, 
aspiration of 200 μL serum sample and assay reagents, incubation and washing 
(Figure 2.0) 
 
Figure 2.0 The principles of Chemiflex reaction 
“Images adapted with permission from Abott Diagnostics. [Architect System SR200., 2008. STAT 
Troponin-I Reagent Information Kit Ref 2K41. Abbott Laboratories-Diagnostics Division., pp. 1-8.]” 
The chemiluminescent label conjugated to the antibody or antigen and it produces light 
when combined with its substrate. The chemiluminescent reaction offers high 
sensitivity and ease of measurement.  A noncompetitive sandwich format yields results 
that directly proportional to the amount of analyte present (Abbott Architect 2008).  
 
The calibrators, controls and samples loaded to initiate analysis. Pressing the 
RUN button, the ARCHITECT i System performs the following functions. Moves 
the sample to the aspiration point then loads a reaction vessel (RV) into the 
process path.  It will then aspirates and transfers 200 μL serum sample into the 
reaction vessels (RV). Advances the RV one position and transfers 
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microparticles into the RV and then it mixes, incubates and washes the reaction 
mixture after which adds 180 μL conjugate to the RV and then it mixes, 
incubates and washes the reaction mixture. Adds 200 μL Pre-Trigger and 200 
μL Trigger Solutions and then measures chemiluminescent emission to 
determine the quantity of analyte in the sample (Figure 2.1),  then generate and 
calculates the result expressed in relative light units (RLU). 
                                                
                        1                                       2                                         3 
                                                     
                        4                                        5                                         6 
Figure 2.1 The sequence of reactions after adding pre-trigger/trigger 
“ Images adapted with permission from Abott Diagnostics. [Architect System SR200., 2008. STAT 
Troponin-I Reagent Information Kit Ref 2K41. Abbott Laboratories-Diagnostics Division., pp. 1-8.]”  
1) The pre-trigger added to designed to release the patented acridinium away from the solid 
phase and into solution; 2) A magnet pulls the paramagnetic microparticles to the side of the 
reaction vessel (RV) wall, preventing the microparticles from interfering in the light 
release/capture process; 3) Trigger is added to the solution to provide an alkaline medium for 
light generation; 4) The acridinium label is released into the solution; 5) The light generated is 
measured as, 6) Relative Light Unit (RLU) (Abbott Architect 2008). 
 
2.2.3 Reagent component configuration in CMIA analysis 
The Architect immunoassay is a two-step immunoassay to determine the 
presence of anlayte in human serum and plasma using CMIA technology with 
flexible assay protocols, referred to as Chemiflex. The configurations of the 
 
RLU 
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various reagents use comprised of – Microparticles, conjugate, diluents, trigger, 
pre-trigger and wash buffer. 
The microparticle bottle has 6.6 mL of antbody (mouse, monoclonal) coated 
microparticles in TRIS buffer with protein (bovine and goat) stabilizers and 
antimicrobial agents as preservative. The conjugate bottle has 5.9 mL of 
antibody (mouse, monoclonal) acridinium-labeled conjugate in MES buffer with 
protein (bovine) stabilizer and ProClin 300 as preservative. The 10.0 mL assay 
diluent bottle containing protein (bovine and goat) stabilizers in phosphate 
buffer and a ProClin 300 preservative. 
The other reagents, Pre-Trigger Solution contained 1.32% (w/v) hydrogen 
peroxide, the trigger solution contained 0.35 N sodium hydroxide and a wash 
buffer contained  phosphate buffered saline solution with antimicrobial agents 
as preservative. 
2.2.4 Determination and analysis of serum ferritin 
The serum sample and anti-ferritin coated paramagnetic microparticles are 
combined.  Ferritin present in the sample binds to the anti-ferritin coated 
microparticles.  After washing, anti-ferritin acridinium labeled conjugate is added 
in the second step.  Pre-trigger and trigger solutions are then added to the 
reaction mixture; the resulting chemiluminescent reaction is measured as 
relative light units (RLUs).  A direct relationship between the amount of ferritin in 
the sample and the RLUs detected by the Architect optical system.  Result 
values expressed as ng/mL.  Reference range of 20-150 ng/mL for males and 
17-150 ng/mL for females (Abbott Architect 2008). 
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2.2.5 Determination and analysis of Troponin-I  
The serum sample, assay diluent and anti-troponin-I antibody coated 
paramagnetic microparticles are combined.  Troponin-I present in the sample 
binds to the anti-troponin-I coated microparticles.  After incubation and wash, 
anti-troponin-I acridinium-labeled conjugate is added in the second step.  
Following another incubation and wash, pre-trigger and trigger solutions are 
then added to the reaction mixture; the resulting chemiluminescent reaction is 
measured as relative light units (RLUs).  A direct relationship between the 
amount of troponin-I in the sample and the RLUs detected by the Architect 
optical system.  The concentration of troponin-I is read relative to a standard 
curve established with calibrators of known troponin-I concentrations.  Result 
values expressed as ng/mL with reference range of 0 – 0.3 ng/mL for male and 
female (Abbott Architect 2008). 
2.2.6 Calculation of transferrin saturation 
Calculations to derive percent(%) Transferrin Saturation: % Transferrin 
Saturation = Serum Iron (umol/L) divided by Total Iron Binding-Capacity 
(umol/L) then multiplied by 100.  Reference range for men, 20-50% and women 
at 15-50% (Passing 1983). 
Serum Iron and Total Iron Binding-Capacity (TIBC) are measured by full 
automation procedure using 200 μL serum sample from collected whole blood 
and tested for biochemical assay for total iron binding capacity and serum iron 
to obtain the % transferrin saturation using Abbott Architect SR2000 Immuno-
chemistry analyzer. 
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The iron in serum is dissociated from its Fe (III) - transferrin complex by the 
addition of an acidic buffer containing hydroxylamine. This addition reduces the 
Fe(III) to Fe(II). The chromogenic agent, Ferene, forms a highly coloured Fe (II) 
- complex that is measured photometrically at 560nm (Abbott Architect 2008). 
 
The unsaturated iron binding capacity (UIBC) is determined by adding 50 μL 
Fe(II) iron to serum so that they bind to the unsaturated iron binding sites on 
transferrin. The excess Fe(II) ions are reacted with Ferrozine to form the colour 
complex, which measured photometrically at 560 nm. The difference between 
the amount of Fe(II) added and the amount of Fe (II) measured represents the 
unsaturated iron binding. The total iron binding capacity (TIBC) is determined by 
adding the serum iron value to the UIBC value (Abbott Architect 2008). 
 
To calculate TIBC (Total Iron-Binding Capacity): Iron Level + UIBC = TIBC 
(μg/dL), SI Unit Conversion: μg/dL x 0.179 = μmol/L.  Serum Iron reference 
range for men, 5.5 – 25.78 μmol/L and for women, 4.48 – 27.92 μmol/L 
(Passing 1983). 
 
2.2.7 Determination and analysis of creatine kinase (CK) 
The Abbott ARCHITECT C8000 Chemistry analyser which employs the 
automated methodology NAC (N-acetyl-L-cysteine) of measuring Creatine 
Kinase (CK).  CK present in the sample, catalyzes the transfer of high energy 
phosphate group from creatine phosphate to ADP.  The adenosine diphosphate 
(ADP).  The adenosine triphosphate (ATP) produced in this reaction is 
subsequently used to phosphorylate glucose to produce glucose-6-phosphate 
(G-6-P) in the presence of hexikinase.  G-6-P is then oxidized by glucose-6-
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phosphate dehydrogenase (G-6-PDH) with the concomitant reduction of 
nicotinamide adenine dinucleotide phosphate (NADP) to nicotimamide adenine 
dinucleotide phosphate reduced (NADPH).  The rate of formation of NADPH is 
monitored at 340nm and is proportional to the activity of CK in the sample.  
These reactions occur in the presence of N-acetyl-L-cysteine (NAC) which is 
present as an enzyme reactivator (Abbott Architect 2008).  Result values 
expressed in units/L with reference range of 30-200 units/L for males and 29-
168 units/L for females. 
2.2.8 Determination and analysis of serum hepcidin using DRG Hepcidin 
ELISA kit 
Serum hepcidin sample processed using the DRG Hepcidin ELISA kit which is a 
solid phase-enzyme-linked immunoabsorbent assay (ELISA), based on the 
principle of competitive binding.  The microlitre wells coated with a monoclonal 
antibody directed towards the antigenic site of the bioactive Hepcidin 25 
molecule.  Endogenous Hepcidin of a patient sample competes with the added 
Hepcidin-biotin conjugate for binding to the coated antibody.  After incubation 
the unbound conjugate is washed off. An incubation with a streptavidin-
peroxidase enzyme complex and a second wash step follows.  The addition of 
substrate solution results in a colour development to the concentration of 
Hepcidin in the patient sample (DRG Manual 2008). The optical absorbance of 
the mixture is read using spectrophotometry at 460nm and converted into ng/ml. 
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2.2.9 DNA extraction from whole blood using Qiagen AMP50 kit 
Genomic DNA from blood was extracted for a large proportion of samples prior 
to the commencement of this work, however there were new samples, 
recollections and also some samples that required re-extraction due to the 
sample depletion. DNA template was extracted from buffy coat collected using 
whole blood tube with an anticoagulant called ethylenediaminetetraacetic acid 
(EDTA), a polyamino carboxylic acid and a colourless, water-soluble solid. 
 
The buffy coat (Figure 2.2) is the fraction of an anticoagulated blood sample 
after density gradient centrifugation that contains most of the white blood cells 
and platelets.  The layer of buffy coat were collected after centrifugation at 2500 
rcf (or 4725 rpm), for 10 minutes, centrifugation controlled at 22°C. All buffy coat 
samples, were separated from the EDTA sample tube between 7 to 28 hours 
after collection left at room temperature. DNA extractions were performed from 
the buffy coat aliquot and were stored at -20°C until processing commenced 
(Qiagen 2007). 
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Figure 2.2 Buffy coat preparation  
“Images adapted with permission from the publisher. [Qiagen., 2007.  QIAmp DNA Mini and Blood 
Mini Handbook, 11, pp.20-27.]” 
After centrifugation, one can distinguish a layer of clear fluid (the plasma), a layer of 
red fluid containing most of the red blood cells, and a thin layer in between, making up 
less than 1% of the total volume of the blood sample, the buffy coat (so-called because 
it is usually buff in hue), with most of the white blood cells and platelets (Qiagen 2007).  
 
2.2.10 Procedure for DNA Extraction using QiagenTM  Spin Protocol 
DNA extraction were performed using the kit QiagenTM according to the 
manufacturer instructions (Qiagen 2007).  Pipetted 20 μL QIAGEN Protease (or 
Proteinase K) into the bottom of a 1.5 mL microcentrifuge tube. Added 200 μL 
whole blood/buffy coat sample. Added 200 μL Buffer AL to the sample, then 
vortexed for 15 seconds. Incubated at 56°C for 10 minutes then briefly 
centrifuged for 2 seconds. Added 200 μL ethanol (96–100%) to the mixture, and 
vortexed for 15 seconds then briefly centrifuged for 2 seconds. Pipetted the 
mixture to the QIAamp 2 mL Spin Column collection tube, and centrifuged at 
6000 x g (8000 rpm) for 1 min.  Placed the QIAamp Spin Column in a clean 2 
mL collection tube, and discarded the tube containing the filtrate. Added 500 μl 
Buffer AW1 into the QIAamp Spin Column, closed the cap and centrifuged at 
6000 x g (8000 rpm) for 1 min. Repeated this same step but added 500 μl 
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Buffer AW2, closed the cap and centrifuged at full speed (20,000 x g; 14,000 
rpm) for 3 min.  Finally added 200 μL Buffer AE, then incubated at room 
temperature (15–25°C) for 1 min, and then centrifuged at 6000 x g (8000 rpm) 
for 1 min and stored at -20°C until analysed. 
 
2.2.11 Amplification of PCR using ABI Applied Biosystems Veriti thermal 
cycler 
The PCR amplification were carried out using ABI Applied Biosystems Veriti 
Thermal Cycler, a Veriti 96-Well Thermal Cycler (PN 4375786), with 0.2ml 
sample wells distributed by Applied Biosystems, UK. The Veriti Thermal Cycler 
has a run recovery feature if a power failure occurs during a run - the instrument 
will attempt to continue the run when the power returns. In addition, the Veriti 
96-Well Thermal Cycler has VeriFlex™ Blocks. These are six independently 
regulated thermal blocks to aid in designing a primer set and run method for 
optimal PCR conditions.  The MicroAmp® Reaction Tube (0.2mL) with 
MicroAmp™ 8-Cap Strips were used in holding the DNA templates. The 
complete steps and procedures were followed as outlined in Chapter 3 of the  
Veriti™ Thermal Cycler User Guide pages 3-2 to 3-25. 
 
 
2.2.12 Imaging and printing of the gel electrophoresis Biorad Molecular 
Imager® 
The gel electrophoresis were captured and printed using the Biorad Molecular 
Imager® Gel Doc™ XR+ System with Image Lab™ Software (170-8195) 
distributed by Biorad/Fannin, Ireland.  It is a gel imaging system, connected to 
the computer in a darkroom, with UV transilluminator, epi-white illumination and 
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camera.  It is a very comprehensive and automated imaging which focused 
images at all times, regardless of zoom level or sample position. It has an 
appropriate, automatic, and consistent flat fielding correction of image data for 
every application and automatic correction of imaging artifacts. Gel 
electrophoresis band images have been stored in the laboratory computer file 
folder and printed in A4 size glossy photographic paper properly identified with 
complete traceability numbers for easy retrieval of images. 
 
2.2.13 Genotyping the DNA samples 
Genotyping is the process of determining the genetic constitution – the 
genotype of an individual by examining their DNA sequence. DNA is isolated 
from a blood sample; it is then copied several times through a process called 
PCR, or polymerase chain reaction. DNA extracted from patient/disease group 
and control samples were genotyped using methods including polymerase 
chain reaction (PCR) and restriction fragment length polymorphism (RFLP) 
analysis. Once a large quantity of DNA has been made, it is cut up into millions 
of short pieces. The millions of short DNA pieces were then labeled and loaded 
into a gel electrophoresis for genotyping analysis.  
2.2.14 Preparation of buffers, dNTPs and primers 
The Table 2.0 outlined the preparation and mixture of the working 
concentrations of the dNTPs and buffers. The various dilutions were 
meticulously prepared to ensure correct reactions and volumes. The Table 2.1 
and Table 2.2 showed the product size and primer sequence used in the 
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genotyping of the DNA templates to isolate the various mutations in HFE and 
HAMP genes. 
Table 2.0 Preparation of working concentrations for dNTP and Buffer 
 
  10 mM dNTPs PREPARATION 
STOCK = 100mM each dNTP 
0.5ul gives 0.2mM per simplex reaction 
 
Stored at: -20OC 
dNTPs 
100 
Reactions 
500 
Reaction
s 
Conc. 
No. of aliquot = 2 tubes in 
250 ml 
A 10 50 -- 
C 10 50 -- 
G 10 50 -- 
T 10 50 -- 
Sterile H2O 60 300 -- 
Total 
volume 
100 500 10mM 
5X PCR BUFFER PREPARATION 
Prep# 
Final 
conc 
10X Buffer 
supplied 
50mM MgCl2 
supplied 
Water 
Total 
Volume 
1 1.0mM 250 (500)* 50 (100)* 200 (400)* 500(1000)* 
2** 1.5mM 250 (500)* 75 (150)* 175 (350)* 500(1000)* 
3 2.0mM 250 (500)* 100 (200)* 150 (300)* 500(1000)* 
4 2.5mM 250  125 125 500 
5 3.0mM 250 (500)* 150 (300)* 100 (200)* 500(1000)* 
6 3.5mM 250 175 75 500 
7 4.0mM 250 (500)* 200 (400)* 50 (100)* 500(1000)* 
8 4.5mM 250 225 25 500 
9 5.0mM 250 250 0 500 
dNTP  50 ul/vial (Stock)      
**Prep/Conc in use                   
*5X Buffer  for 1.5mM, If final volume of 1000 = 200ul/vial 
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Table 2.1 Primer sequence and product size (HFE: C282Y and H63D) 
 
 
 
HFE 
 
 
Primer Sequence 
 
Product 
size 
 
C282Y 
 
 
 
282 Mut 
 
5’-GTA CCC CCT GGG GAA GAG CAG AGA TAC A-3 
 
 
188  
282 Rev 
 
5’-CCA TCC CCT AAC AAA GAG CAG ATC CAC-3’ 
 
H63D 
 
 
 
63 Fwd 
 
  5’-CAC ACT CTC TGC ACT ACC TCT T –3’ 
 
 
130  
63 Mut 
 
  5’ –GGC TCC ACA CGG CGA CTC ACG T- 3’ 
 
 
 
 
 
 
 
Table 2.2 Primer sequence and product size (HAMP – C70R) 
 
 
 
HAMP 
 
 
Primer Sequence 
 
Product 
size 
 
Exon1 
 
 
 
Fwd 
 
5’-GTA CCC CCT GGG GAA GAG CAG AGA TAC A-3 
 
 
206  
Rev 
 
5’-CCA TCC CCT AAC AAA GAG CAG ATC CAC-3’ 
 
Exon2 Fwd 5’-GTA CCC CCT GGG GAA GAG CAG AGA TAC A-3 192 
Rev 5’-GTA CCC CCT GGG GAA GAG CAG AGA TAC A-3 
 
Exon3 
 
 
 
Fwd 
 
  5’-CAC ACT CTC TGC ACT ACC TCT T –3’ 
 
 
352  
Rev 
 
  5’ –GGC TCC ACA CGG CGA CTC ACG T- 3’ 
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2.2.15 Performing the polymerase chain reaction (PCR) 
The PCR amplification was carried out using ABI Applied System Veriti Thermal 
Cycler, a Veriti 96-Well Thermal Cycler (PN 4375786), with 0.2–mL sample 
wells. The standard three-step cycle included denaturing at 94˚C, annealing at 
various temperatures and extension at 72˚C for various times depending on 
size of the amplified segment (Smith et al. 1995).  
 
For the HFE genotyping, PCR was carried out in a 24 μl PCR reaction, 0.2 μl of 
5 U/ul Platinum Taq DNA polymerase (Invitrogen), 5.0 μl of 5x PCR buffer, 5.0 
μl of 10mM dNTP mix (Invitrogen), 1.0 μl of 100 ng/μl both primers (C282Y and 
H63D)  and 5.0 μl of 5x PCR buffer containing 1.5mM MgCl2 (Invitrogen) and 
17.3 μl of sterile distilled water (Cruinn). In this reaction 1.0 μl of DNA was 
added as the template in the PCR experiments.  
 
For the HAMP genotyping, PCR is carried out in a 49 μl PCR reaction, 0.2 ul of  
1U/ul AmpliTaq polymerase (Invitrogen), 5.0μl of 10x PCR buffer containing 
2.5mM MgCl2 (Invitrogen), 0.5μl of 10mM dNTP mix (Invitrogen), 1.0μl of 
25pmoles C70R primers/exons 1,2,3 (Applied Biosystems), 16.3μl sterile 
distilled water (Cruinn) and 24.0μl of 5% DMSO (Sigma-Aldrich).  In this 
reaction 2.0 μl of DNA was added as the template in the PCR experiments.  
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2.2.16 PCR-Restriction Fragment Length Polymorphism (PCR-RFLP) 
analysis 
PCR-RFLP analysis utilizes an elimination or creation of a recognition sequence 
of a restriction enzyme as a result of a single nucleotide polymorphism (SNP). 
Differentiation of the alleles is achieved by performing PCR and digesting the 
resulting fragment with the appropriate enzyme. Inclusion of a control restriction 
site within the PCR fragment is important as a control site for digestion; 
however, this is not always possible because additional sites may not be 
available in the surrounding sequence.  
 
HFE restriction digestions were carried out overnight at 37°C, using 15 μL  of 
the PCR product, 0.5 μL of 10 U/ μL BbrP1 enzyme (Roche Diagnostics, UK) 
and 0.5 μl 10x RE buffer (pre-diluted 20-fold with 4.0 μL nuclease-free sterile 
water) added directly to the PCR product. The restriction fragments were 
separated by gel electrophoresis using 2.5% Hi-Sieve Agarose gels stained in 1 
mg/L ethidium bromide (Helena Biosciences, Ireland) for 60-70 minutes at 97 
volts.   
 
HAMP restriction endonuclease digestions were carried out  overnight at 37°C, 
using 44.5 μL  of the PCR product, 1.0 μL of 10 U/ μL SacII enzyme (Sigma-
Aldrich/Invitrogen, Ireland), 0.5 μL of 10x RE buffer (pre-diluted 20-fold with 4.0 
μL nuclease-free sterile water) added directly to the PCR product with a total 
volume of 50 μL. The restriction fragments were separated by gel 
electrophoresis using 2.5% Hi-Sieve Agarose gels stained in 1 mg/L ethidium 
bromide (Helena Biosciences, Ireland) for 50-60 minutes at 80-90volts.   
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2.2.17 C282Y and H63D HFE simultaneous genotyping 
The simultaneous detection of C282Y and H63D gene mutations were 
determined using polymerase chain reaction (PCR) method by Stott et.al. with 
minor modifications.  The PCR-mediated site directed mutagenesis was used to 
create unique BbrP1 restriction sites in each product of a duplex PCR that 
amplifies two fragments spanning the C282Y and H63D loci. The primers 
(Sigma-Aldrich/Invitrogen) 282mutation (5’-GTA CCC CCT GGG GAA GAG 
CAG AGA TAC A-3’), 282reverse (5’-CCA TCC CCT AAC AAA GAG CAG ATC 
CAC-3’), 63forward (5’-CAC ACT CTC TGC ACT ACC TCT T-3’), 63mutation 
(5’-GGC TCC ACA CGG CGA CTC ACG T-3’) allow simultaneous amplification 
of the C282Y locus (188bp) and the H63D locus (130bp).  These primers are 
equally mismatched to both alleles but uniquely introduce BbrP1 sites into the 
products from both the wild-type alleles.  Digestion using restriction 
endonuclease BbrP1 (Roche Diagnostics) yields complete digestion of both 
wild-type products, generating bands of 162bp and 110bp for C282Y and H63D 
respectively.  The presence of either mutation destroys the corresponding 
restriction site, allowing complete determination of the patient‘s genotype in a 
single reaction (Stott 1999). 
 
 
The PCR reactions were carried out using ABI Applied Biosystems Veriti 
Thermal Cycler, a Veriti 96-Well Thermal Cycler in 25 μL of total reaction 
volume.  The PCR reaction contains 1.0 μL of 100 ng/ μL each primer (Sigma-
Aldrich/Invitrogen), 5.0 μL of 5x PCR buffer mixture of 5mM Tris-HCL, pH 8.4 
(Sigma-Aldrich/Invitrogen), 50mM KCL, 1.5 mM MgCl2 (I Sigma-
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Aldrich/Invitrogen), 0.5 μL of 100mM dNTP mix (Sigma-Aldrich/Invitrogen), 1.0 
μL (~10 ng) of  DNA template  and 0.2 μL of 5 U/ μL of  Platinum Taq DNA 
Polymerase (Sigma-Aldrich/Invitrogen).  Amplification was performed after a 
denaturation process of  3 minutes at 94°C followed by annealing step with 35 
cycles each of 30 seconds at 94°C, 30 seconds at 55°C, and 30 seconds at 
72°C.  A final extension period of 5 minutes at 72°C completed the PCR (Stott 
1999). 
 
Restriction digestions were carried out overnight at 37°C, using 15 μL  of the 
PCR product, 0.5 μL of 10 U/ μL BbrP1 enzyme (Roche Diagnostics, UK) and 
0.5 μl 10x RE buffer (pre-diluted 20-fold with 4.0 μL nuclease-free sterile water) 
added directly to the PCR product. The restriction fragments were separated by 
gel electrophoresis using 2.5% Hi-Sieve Agarose gels stained in 1 mg/L 
ethidium bromide (Helena Biosciences) for 60-70 minutes at 97 volts.  Products 
were visualized using ABI reader transilluminator at 302 nm and printed on HP 
photographic A4 paper (Stott 1999). 
 
2.2.18 C70R HAMP genotyping 
The detection of C70R gene mutations were determined using polymerase 
chain reaction (PCR) method by Roetto et.al. with minor modifications.  
Restriction endonuclease digestion was carried out using 44.5 μl PCR product 
and 1.0 μL of 10 U/ μL SacII enzyme (Sigma-Aldrich/Invitrogen). The C70R 
primers (Applied Biosytems) Exon1 forward (5’-CAA GCT CAA GAC CCA GCA 
GT-3’), Exon1 reverse (5’-CAG TGC CCT AGG CTG A-3’), Exon2 forward (5’-
CAG TCT CAG AGG TCC ACT-3’), Exon2 reverse (5’-AAT GTG AGC AGG 
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GAA CC-3’), Exon3 forward (5’-CAG TGA TGC CTT TCC TAG C-3’, Exon3 
reverse (5’-AAG GCA GGG TCA GGA CAA-3’) were used in the mutation 
screening. These primers are equally mismatched to both alleles but uniquely 
introduce SacII sites into the products from both the wild-type alleles.  Digestion 
using restriction endonuclease SacII enzyme (Sigma-Aldrich/Invitrogen) yields 
complete digestion of both wild-type products, generating bands of 139 bp, 213 
bp and 352 bp respectively.  The presence of either mutation destroys the 
corresponding restriction site, allowing complete determination of the patient‘s 
genotype in a single reaction (Roetto 2004). 
 
The PCR reactions were carried out using ABI Applied Biosystems Veriti 
Thermal Cycler, a Veriti 96-Well Thermal Cycler with 1.0 μL of 25 pmoL C70R 
primers/exons 1/2/3 (Applied Biosystems) and 2.0 μL of 50 ng template DNA, 
with an average protocol of 32 cycles.  Amplification was performed after a 
denaturation process of  30 seconds at 94°C followed by annealing step with 32 
cycles each of 30 seconds at 94°C, 30 seconds at 56°C, and a final extension 
period of 45 seconds at 72°C  and 0.2 μL of 1 U/ μL AmpliTaq DNA polymerase 
(Sigma-Aldrich/Invitrogen) completed the PCR (Roetto 2004). 
 
Restriction endonuclease digestions were carried out  overnight at 37°C, using 
44.5 μL  of the PCR product, 1.0 μL of 10 U/ μL SacII enzyme (Sigma-
Aldrich/Invitrogen), 0.5 μL of 10x RE buffer (pre-diluted 20-fold with 4.0 μL 
nuclease-free sterile water) added directly to the PCR product with a total 
volume of 50 μL. The restriction fragments were separated by gel 
electrophoresis using 2.5% Hi-Sieve Agarose gels stained in 1 mg/L ethidium 
bromide (Helena Biosciences) for 50-60 minutes at 80-90volts (Roetto 2004). 
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2.2.19 Control samples used to validate genotyping 
DNA samples from known patient diagnosed with hereditary haemochromatosis 
and samples from carrier status genotyped by the National Centre for Medical 
Genetics, Crumlin, Dublin were used as test control samples to verify and 
validate the Cardiomyopathy patients results for HFE genotyping and 
commercially provided positive and negative controls for the HAMP genotyping. 
 
 
 
 
 
 
 
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CHAPTER   3   Results 
 
 
 
 
3.0   Introduction  
The genotypes of C282Y/H63D mutations of the HFE gene and genotype of 
C70R mutation of HAMP gene identified from dilated cardiomyopathy patients 
and family members will be correlated. This will establish the relationship 
between the biochemical markers and the allele frequencies presented in 
percentage appearance of an allele. The genotypes of the studied DCM disease 
group led this study to identify their digenic co-existence and the potential 
development of iron overload cardiomyopathy within the Irish population.  
 
The iron status was evaluated by measuring concentration levels of serum 
ferritin, serum hepcidin and percent transferrin saturation (calculated from total 
iron and total iron binding capacity levels) from samples of diagnosed Irish 
patients with dilated cardiomyopathy and their family members. The cardiac 
markers including serum creatine kinase and troponin-I were assessed 
according to the concentration level and activity of the analytes in relation to 
symptomatic features of the patients and asymptomatic family members. The 
significant asymptomatic features of biochemical markers that may indicate 
relationship of potential progression and development of the disease condition 
is the nature of elevation towards the median assay concentration. 
 
The data for disease and control groups were matched for age and sex. The 
percentage of heterozygous or homozygous occurrences of the HFE and HAMP 
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genotypes will be used to prove indication of their co-existence.  The 
probabilities of the mutations in this study were determined using Balanced 
ANOVA (Minitab v16) incorporating two crossed factors, biochemical markers 
and genotypes of the HFE and HAMP genes.  Results were considered 
significant at p<0.001 to target 0.1% chance of concluding the identification of 
mutations to be more accurate due to moderately smaller samples studied. 
 
3.1 HFE and HAMP Genotyping 
 
3.1.1 Optimizing polymerase chain reaction (PCR) 
The primers and Mg2+ concentration in the PCR buffer and annealing 
temperature of the reaction was optimized for each primer pair for efficient PCR. 
At the initial set-up, several technical issues were encountered where the PCR 
did not generate correct electrophoresis bands as shown in Figure 3.0. 
 
 
 
 
 
 
Figure 3.0 The initial electrophoresis panel set-up.  
Genotyping results following the adapted method with the Mg2+ concentration at 2.5 
mM and agarose gel cast at 3.0%. (Merryweather et.al. 2003) 
 
The issues identified included the initial Mg2+ concentration following the original 
protocol, prepared to 2.5 mM which was too concentrated which resulted in 
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smearing. Also, the strength of the Hi-sieve agarose gel was too concentrated, 
weighed 5 grams more than required of the agarose powder and added 5 μl  
more of ethidium bromide.  We decided to source out a pre-cast and ready to 
use agarose gel and seek further purchasing approval.  Therefore using 2.5 % 
Hi-sieve low melt agarose gel and adjusting the Mg2+ concentration to 2.0 mM 
was optimized.  The protocol has been updated and followed through-out the 
study incorporating random run of positive controls in every batch of gel cast. In 
addition, PCR efficiency has been improved by using high-purity reagents 
resulting in successful PCR shown in our initial repeat genotyping in Figure 3.1. 
 
 
 
 
Figure 3.1 Electrophoresis panel after optimizing Mg2+ concentration.  
Using the new 2.0mM Mg2+ concentration (Sigma-Aldrich/Invitrogen) and commercially 
purchased 2.5% Hi-sieve 10-well pre-cast agarose gel (Helena Biosciences,2004), the 
electrophoresis showed a more clearly defined bands. The marker lane showed a clear 
bands ranging from 100 base pairs to 400 base pairs. In Lanes 1 to 4 showed three 
distinct bands expected isolation of  heterozygous mutations and lanes 5 to 6 expected 
a negative results or no mutation isolated post enzyme digestion. 
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The inclusion of control materials were essential for monitoring the success of 
PCR reactions. In every PCR run, a positive control has been included to check 
that the PCR conditions have successfully amplify the target sequence. As PCR 
is extremely sensitive, requiring only a few copies of target template, a negative 
control containing no template DNA also been included to ensure that the 
solutions used for PCR have not contaminated with the template DNA. PCR 
was setup and performed in a separate area from PCR analysis to ensure that 
reagents used for PCR do not become contaminated with PCR products. 
Similarly, pipettes used for analysis of PCR products were never used for 
setting up PCR. 
 
DNA polymerase requires magnesium for activity usually supplied to a PCR 
amplification in the form of magnesium chloride. Varying the magnesium 
concentration usually has the most profound effect on the quality of the 
reaction. In this study, prior to the final analysis of these cohorts for HFE and 
HAMP genotyping, optimization of PCR reactions were carried by comparing 
two concentrations of magnesium including a negative control run (Figure 3.2 
for HFE and Figure 3.3 for HAMP genotyping). The second preparation using 
2.0mM magnesium concentration showed a more pronounced electrophoresis 
bands.  
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Figure 3.2 Comparison of two optimized magnesium concentration for HFE 
genotyping.     
1) Optimization using the mixture with concentration of 1.5mM MgCl2 and a 2.0% hi-
sieve agarose gel; 2) optimization using  2.0mM MgCl2 and a 2.5% hi-sieve agarose 
gel; 3) a negative control preparation. The lane 2 showed a clear and more pronounced 
separation of the electrophoresis bands. 
 
 
Similar steps were followed for HAMP genotyping, optimizing magnesium 
concentration using the supplied magnesium chloride (MgCl2).  In Figure 3.3 
showed the effect of electrophoresis bands using 2.0mM magnesium 
concentration comparing the two preparations. 
 
 
Figure 3.3 Comparison of two optimized magnesium concentration for HAMP 
genotyping.  
1) Optimization using the mixture with concentration of 1.5mM MgCl2 and a 2.0% hi-
sieve agarose gel; 2) optimization using  2.0mM MgCl2 and a 2.5% hi-sieve agarose 
gel; 3) a negative control preparation. The lane 2 showed and clear separation of the 
electrophoresis bands. 
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3.1.2 Evaluation of sample DNA integrity and purity 
In this study we adapted the technique to determine DNA yield and purity by 
measuring absorbance, a method by Sambrook et.al.  Absorbance readings 
were performed at 260 nm (A260) and values within the instrument's linear range 
of 0.1–1.0. DNA purity was quantified using the Eppendorf spectrophotometer. 
DNA concentration was estimated by measuring the absorbance at 260 nm, 
adjusting the A260 measurement for turbidity (measured by absorbance at 320 
nm), multiplying by the dilution factor, and using the relationship that an A260 of 
1.0 = 50 µg/mL pure dsDNA. 
Concentration (µg/mL) = (A260 reading – A320 reading) × dilution factor × 50µg/mL 
Total yield was obtained by multiplying the DNA concentration by the final total 
purified sample volume. 
DNA yield (µg) = DNA concentration × total sample volume (mL) 
However, DNA usually is not the only molecule that can absorb UV light at 260 
nm. Since RNA also has an absorbance at 260 nm, and the aromatic amino 
acids present in protein absorb at 280 nm, both contaminants, if present in the 
DNA solution, will contribute to the total measurement at 260 nm. Additionally, 
the presence of guanidine will lead to higher 260 nm absorbance. This means 
that if the A260 number is used for calculation of yield, the DNA quantity may be 
overestimated. 
To evaluate DNA purity, we measured absorbance from 230 nm to 320 nm to 
detect other possible contaminants. The most common purity calculation is the 
ratio of the absorbance at 260 nm divided by the reading at 280 nm. Good-
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quality DNA will have an A260/A280 ratio of 1.7–2.0. A reading of 1.6 does not 
render the DNA unsuitable for any application, but lower ratios indicate more 
contaminants are present. The ratio can be calculated after correcting for 
turbidity (absorbance at 320 nm). 
DNA purity (A260/A280) = (A260 reading – A320 reading) ÷ (A280 reading – A320 reading) 
Strong absorbance around 230 nm can indicate that organic compounds or 
chaotropic salts – an agent which is a molecule in water solution that can 
disrupt the hydrogen bonding network between water molecules, are present in 
the purified DNA. A ratio of 260 nm to 230 nm can help evaluate the level of salt 
carryover in the purified DNA. The lower the ratio, the greater the amount of 
thiocyanate salt is present, for example. As a guideline, the A260/A230 is best if 
greater than 1.5. A reading at 320 nm will indicate if there is turbidity in the 
solution, another indication of possible contamination. Therefore, taking a 
spectrum of readings from 230 nm to 320 nm is most informative (Sambrook et 
al. 1989). 
In this study, the 59 DCM group samples, DNA template purity were within 1.7 – 
2.0 ratio.  Among the 58 control group samples, ratios were all within the 
required limits, although at the initial DNA extractions, there were 62 control 
samples collected but 4 samples have poor DNA yield and we were unable to 
re-collect from the subjects as their details have been changed and we failed to 
locate accordingly, and decided to continue with the 58 control samples. 
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3.1.3 HFE (C282Y/H63D)  genotyping of DCM group samples 
The simultaneous genotyping of the mutations C282Y/H63D of the HFE gene 
were carried out in all dilated cardiomyopathy patients and family members 
along with control groups within Irish population. The aim is to identify the 
genotypes of the HFE gene in either heterozygous or homozygous state of 
C282Y and/or H63D mutations, then to assess the incidence of coexistence of 
HFE (C282Y/H63D) and HAMP (C70R) gene mutations. The relationships of 
these mutations will be correlated with the concentration levels of the iron and 
cardiac biochemical markers. The association of these co-existent mutations 
and various degree of activity and  concentration of the biochemical markers will 
be discussed as a potential contributing or underlying factors in the 
development of dilated cardiomyopathy and eventually iron overload 
cardiomyopathy especially among the family members of a diagnosed dilated 
cardiomyopathy patient.  
Multiplex or simultaneous genotyping of C282Y and H63D mutations 
amplification is illustrated in Figure 3.4. The presence of either mutation 
destroys the corresponding restriction site, allowing complete determination of 
the patient‘s genotype in a single reaction. Although mutagenic primers are 
used in this method, it is important to note that they are equally mismatched to 
both the wild-type (negative) and mutant alleles. The specificity is introduced by 
extension of the primers (Table 3.0), which introduces a different base at the 
first step. This is an important feature of the assay design, removing any 
possibility of allele-specific amplification, and produces a robust procedure, 
demonstrating  simultaneous genotyping and gene-expression profiling which 
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can reveal cis-regulatory variation (or regulates the expression of genes located 
on that same molecule of DNA) by screening genes for allele-specific 
expression.  
 
The objective of this work was to develop a simple, single-step assay for the 
simultaneous analysis of the C282Y and H63D mutations that need rapid and 
effective medium to high-throughput genotyping. To this end, multiplex real-time 
PCR and genotype discrimination, attained by melting curve analysis of the 
BbrPI (enzyme) restriction sites. This study managed and successfully 
investigated the suitability of this method and assessed its performance as 
compared with other conventional multiplex PCR. 
 
Figure 3.4 C282Y and H63D digest primers location  
The primers 282mut and 63mut allow simultaneous amplification of the C282Y locus 
(188bp) and the H63D locus (130bp). Digestion using restriction endonuclease BbrPI 
yields complete digestion of both normal products, generating bands of 162bp and 
110bp for C282Y and H63D. 
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Figure 3.5 Schematic diagram of BbrP1 digested PCR products  
The primers 282mut and 63mut allow simultaneous amplification of the C282Y locus 
(188bp) and the H63D locus (130bp). Digestion using restriction endonuclease BbrPI 
yields complete digestion of both normal products, generating bands of 162bp and 
110bp for C282Y and H63D. 
 
 
 
 
Table 3.0 Primer sequence and product size of HFE mutations 
 
HFE gene Primer sequence 
Product 
size 
C282Y 
     282 mutation 5’-GTA CCC CCT GGG GAA GAG CAG AGA TAC A-3 188 
     282 reverse 5’-CCA TCC CCT AAC AAA GAG CAG ATC CAC-3’  
H63D 
     63 forward 5’-CAC ACT CTC TGC ACT ACC TCT T –3’ 130 
     63 mutation 5’ –GGC TCC ACA CGG CGA CTC ACG T- 3’  
 
 
To assess the efficiency of the reaction, known positive and negative control 
samples were included in every PCR reaction. The electrophoresis band 
patterns of the positive genotype control, C282Y/wt;H63D/wt (C282Y 
heterozygous; H63D heterozygous or compound heterozygous) showed similar 
band, read as wt/wt;H63D/wt (H63D heterozygous) and included the C282Y 
heavier fragment at 188bp upon digestion using restriction endonuclease BbrP1 
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which yields further lighter band of 162bp for C282Y In Figure 3.6 the control 
group (N=58), showed genotype pattern of wt/wt;H63D/wt, expected result 
interpretation as H63D heterozygous, showed the 3 bands at 162bp, 130bp and 
110bp.  The band pattern for 130bp and 110bp for H63D, showed in lane 4 of 
Figure 3.6, as both heterozygous for C282Y and H63D (or compound 
heterozygous or genetic compound). It is the presence of two different mutant 
alleles at a particular gene locus, one on each chromosome of a pair when both 
alleles of a gene mutations, but the mutations are different, in this case C282Y 
and H63D.  The lanes 5-10 represent the electrophoresis band pattern with 
fragments at 162bp and 110bp respectively showing 2 bands and no cut after 
enzyme digestion, characteristic of patients with no mutations identified. 
 
The genotyping results among the subjects in DCM group, (N=59) as illustrated 
in Figure 3.7 showed a significant findings and this has been validated by 
incorporating in the panel a marker, negative and positive controls.  The marker 
in lane 1 is a 100-300 base pairs indicated by the various bands. The negative 
control in lane 2 showed no band and also indicating the purity of the panel. The 
positive control in lane 3 showed 3 bands at 162 bp, and post digestion using 
restriction endonuclease BbrPI, at 130 bp and a band at 110 bp.  This was an 
expected result for  H63D heterozygous gene mutation. In lanes 4 and 5 both 
subjects from the same family in DCM group showed 2 clear bands at 162 bp 
and 110 bp but not band generated post digestion using restriction 
endonuclease BbrPI, an expected result for absence or no mutation present. 
The same result and interpretation in lanes 7, 8 and 10. In lanes 6 and 9 are 
two members of the same family that showed 3 bands at 162 bp, post digestion 
  
 
Jereza, Noel                                                                                                         95                                                                                                                
 
using restriction endonuclease BbrPI  band at 130 bp and a band at 110 bp  an 
expected result as H63D heterozygous. Overall, in this representative 
electrophoresis panel showed that any of the parents carrying an HFE mutation 
has been inherited among one of the siblings in the family.  The data of  all 
mutation isolated among all the various families in the DCM group is 
summarized in the Table 3.2 and data control group matched for age and sex  
summarized in Table 3.3. 
 
 
 
 
 
 
Figure 3.6 HFE (C282Y/H63D) genotyping result panel of the Control group 
(N=58) The PCR using  the control group samples as observed in lanes 5 to 10 
showing two clear bands at 162 and 110 base pairs indicate no mutations isolated after 
digestion using restriction endonuclease BbrPI, as compared with the control samples 
in lanes 2 to 4. Lane 1 is 100 base pair loading marker, lane 2 is a negative control 
indicated with no band, using esterase free de-ionized water to validate purity of run; 
lane 3 is a positive control showing 3 bands with an isolated 130bp band after 
digestion illustrates the expected banding patterns of a heterozygous H63D only and 
the lane 4 also a positive control showing 4 bands with isolated 130 and 188 base 
pairs after digestion indicating heterozygous for both C282Y and H63D or so called 
compound heterozygous.  
wt wt wt wt wt wt 
Undigested PCR product 
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Figure 3.7 HFE(C282Y/H63D) genotyping result panel of the DCM group (N=59). 
The PCR results as observed in the sample result panel of the DCM group showed in 
lanes 4, 5 7, 8, 10 with two bands at 162 and 110 base pairs illustrating the expected 
banding for absence of mutations and lanes 6 and 9 showed 3 bands at 130 base 
pairs isolated after digestion using restriction endonuclease BbrPI, with an expected 
band for H63D mutations, therefore these subjects were H63D heterozygous, as 
compared with the control samples in lanes 2 to 3. Lane 1 is 100 base pair loading 
marker, lane 2 is a negative control showing no bands using esterase free de-ionized 
water to validate purity of run; lane 3 is a positive control showing 3 bands with an 
isolated 130bp band after digestion, expected bands for heterozygous H63D only.   
 
 
 
3.1.4 HAMP genotyping of DCM patients  
The C70R mutation of the HAMP gene among DCM group was assessed and 
compared to control group matched for age and sex.  The expected fragment 
sizes include 192bp, 206bp and 352bp and the specificity is introduced by 
extension of the primers is summarized in Table 3.1.  Restriction analysis of 
C70R mutation by SacII enzyme restriction sites were carried out demonstrating 
simultaneous genotyping which eliminates screening hundreds of genes for 
wt wt wt wt 
H63D 
Hetero 
H63D 
Hetero 
Undigested PCR product 
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allele-specific expression. As previously described, this methodology is easy to 
follow and suitable for molecular and clinical studies that involve large sample 
numbers.   
 
The simultaneous analysis of the three exons (a segment of a DNA  molecule 
containing information coding for a protein or peptide sequence) of C70R 
mutation was performed. It is a rapid and effective PCR procedure that can 
generate from medium to high throughput of genotyping results. The multiplex 
real-time PCR and genotype discrimination by melting curve analysis of the 
SacII enzyme restriction sites managed and successfully investigated the 
suitability of this method. The identified nucleotide change causes the 
substitution of the cysteine at position 70 with arginine (C70R). The mutation 
creates a restriction site for SacII enzyme digestion of HAMP, exon3 to 
demonstrate the correct segregation of the mutation within the family and to 
show the absence of the same mutation in 58 subjects as healthy controls. 
Restriction analysis of C70R mutation by SacII restriction site was assessed in 
all 59 control and 58 DCM samples to isolate the specific genotype amplified by 
polymerase chain reaction (PCR). 
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Table 3.1  Primer sequence and product size of C70R gene mutation 
HAMP gene Primer sequence 
PCR 
product  
length, bp 
Exon 1   
     C70R forward 5’-GTA CCC CCT GGG GAA GAG CAG AGA TAC A-3 206 
     C70R reverse 5’-CCA TCC CCT AAC AAA GAG CAG ATC CAC-3’  
Exon 2   
     C70R forward 5’-GTA CCC CCT GGG GAA GAG CAG AGA TAC A-3 192 
     C70R reverse  5’-GTA CCC CCT GGG GAA GAG CAG AGA TAC A-3  
Exon 3   
     C70R forward 5’-CAC ACT CTC TGC ACT ACC TCT T –3’ 352 
     C70R reverse 5’ –GGC TCC ACA CGG CGA CTC ACG T- 3’  
 
The genotyping results in Figure 3.8 of the control group and Figure 3.9 for the 
DCM group showed electrophoresis band pattern which identify the presence or 
absence of the mutations. The electrophoresis band closer to the loading area 
(top of the panel) is the heavier fragment of 352bp C70R in exon3 indicating 
absence of mutation. Upon digestion using restriction SacII enzyme yields 
further lighter band of 139bp C70R an expected positive control result in lane 10 
as illustrated in Figure 3.8, generating a heterozygous C70R. Among 58 
subjects in the control group 3.4% were C70R heterozygous and 96.6% were 
negative or wild type.  
 
The genotyping results among DCM group of 59 subjects showed in Figure 3.9 
follow the same pattern as in the control group panel.  The negative control in 
lane 2, followed by a sample from a subject in DCM group in lane 3 showed a 
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single band at 352 bp and the other subjects of the same family in lanes 6 to 10 
which were all negative. A positive control in lane 4 and a sample from a subject 
from DCM group in lane 6 showed 3 bands at 352 bp, 219 bp and 192 bp in 
exon 3, post digestion using SacII enzyme restriction indicating a C70R 
heterozygous mutation. There were no overwhelming difference among DCM 
group which showed results of 40.7% C70R heterozygous and 59.3% were 
negative or wild type. In the Irish population, reported hereditary 
haemochromatosis patients are homozygous for the C282Y mutation of the 
HFE gene though not affected or asymptomatic with iron overload 
cardiomypathy. Nevertheless, penetrance of the disease is very variable. In 
some patients, penetrance can be mediated by associated mutations in other 
iron master genes. In this study we evaluated the clinical impact of hepcidin 
(HAMP) in 59 Irish cohorts comprising one family member diagnosed with 
dilated cardiomyopathy and asymptomatic family members.  
 
The HAMP mutations were identified in all patients by PCR-Restriction 
Fragment Length Polymorphism (PCR-RFLP) analysis and their genotype 
status either homozygous or heterozygous state were identified. The results 
were correlated and evaluated whoever among the direct family members been 
identified with the mutations and the number of family members affected. A 
heterozygous mutation of the HAMP gene (C70R) was found in at least every 
member of the family whose parents either carrier or heterozygous for C70R.  
All the identified mutations were all summarised in Table 3.2 for DCM group and 
Table 3.3 for the control group. 
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Figure 3.8 HAMP (C70R) genotyping result panel of the Control group (N=58). The 
PCR results as observed in lanes 3 to 9 with one band, only at 352 base pairs 
illustrate as expected of no mutations, compared in the negative control sample at lane 
2 showed no band at 352bp, while lane 10, showed three bands for exons 2 and 3 at 
219 and 192 base pairs isolated after digestion using SacII enzyme restriction sites 
indicating C70R mutations, and expected result as C70R heterozygous. Lane 1 is 500 
base pair loading marker with 206 and 139bp as marker comparison for exons 2 and 3. 
Lane 2 is a negative control using esterase free de-ionized water to validate purity of 
run.  
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Figure 3.9 HAMP (C70R) genotyping result panel of DCM group (N=59). In this 
PCR result panel of the DCM group showed as observed  in lane 5 showed three 
bands for exons 2 and 3 at 219 and 192 base pairs isolated after digestion indicating 
C70R mutations, illustrating the expected banding for  C70R heterozygous and lanes 3 
and 6 to 10 with one band only at 352 base pairs illustrate no mutations, compared in 
the control samples at lane 4, showed  three bands for exon 2 and 3 at 219 and 192 
base pairs isolated after digestion using SacII enzyme restriction sites with expected 
bands for C70R mutations, and classified as C70R heterozygous. Lane 1 is 500 base 
pair loading marker with 206 and 139 bp as marker comparison for exons 2 and 3. 
Lane 2 is a negative control using esterase free de-ionized water to validate purity of 
run.  
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Table 3.2  Disease group data for iron studies, cardiac biomarkers, HFE and HAMP genotype results of all family 
members with one member diagnosed with dilated cardiomyopathy. 
 
 
 
No 
Family Groups 
(One Member Diagnosed 
with DCM) 
 Members of the 
FamilyTested Sex 
Age 
(years) 
Ferritin 
(ng/ml) 
Trans 
Sat 
(%) 
Troponin I 
(ng/ml) 
Creatine  
Kinase 
(IU/L) 
Hepcidin 
(ng/ml) HFE Genotype HAMP Genotype 
1 DCM Patient 1(Father) Parent1(Father) M 68 380 54 0.45 110 37 H63D Heterozygous Wild Type(Normal) 
2 Family Group 1 Son1 M 45 120 38 0.01 145 205 Wild Type(Normal) Wild Type(Normal) 
3 Parent 2 (Mother-Deceased) Son2 M 47 200 20 0.04 109 96 Wild Type(Normal) Wild Type(Normal) 
4   Daughter1 F 33 65 39 0.00 120 54 Wild Type(Normal) Wild Type(Normal) 
5   Grand-daughter1 F 19 109 24 0.00 106 65 Wild Type(Normal) Wild Type(Normal) 
6   Grand-daughter2 F 21 115 26 0.28 100 109 Wild Type(Normal) Wild Type(Normal) 
7 DCM Patient 2 (Father) Parent1 (Father) M 75 164 48 0.25 120 21 C282Y Heterozygous Wild Type(Normal) 
8 Family  Group 2 Parent2 (Mother) F 79 68 45 0.08 174 190 Wild Type(Normal) Wild Type(Normal) 
9   Son1 M 49 92 36 0.00 118 56 Wild Type(Normal) Wild Type(Normal) 
10   Daughter1 F 45 73 28 0.01 101 98 Wild Type(Normal) Wild Type(Normal) 
11   Daughter2 F 43 145 41 0.07 99 20 Wild Type(Normal) C70R Heterozygous 
12   Daughter3 F 42 170 49 0.09 78 22 Wild Type(Normal) C70R Heterozygous 
13   Grandson1 M 19 85 31 0.01 109 34 Wild Type(Normal) Wild Type(Normal) 
14 DCM Patient 3 (Father) Parent1(Father) M 59 64 28 0.02 96 31 Wild Type(Normal) Wild Type(Normal) 
15 Family Group 3 Parent2(Mother) F 61 51 24 0.00 108 39 Wild Type(Normal) Wild Type(Normal) 
16   Daughter1 F 27 45 32 0.00 116 29 Wild Type(Normal) Wild Type(Normal) 
17   Daughter2 F 25 68 31 0.01 88 41 Wild Type(Normal) Wild Type(Normal) 
18 DCM Patient 4 (Mother) Parent2(Mother) F 56 121 48 0.29 135 31 H63D Homozygous C70R Heterozygous 
19 Family Group 4 Parent1(Father) M 58 96 34 0.01 162 48 H63D Heterozygous Wild Type(Normal) 
20   Son1 M 28 99 32 0.00 91 104 Wild Type(Normal) Wild Type(Normal) 
21   Son2 M 27 85 43 0.02 124 35 Wild Type(Normal) Wild Type(Normal) 
22   Son3 M 25 148 44 0.02 88 51 C282Y Heterozygous Wild Type(Normal) 
23   Daughter1 F 24 77 29 0.06 112 34 Wild Type(Normal) Wild Type(Normal) 
24   Daughter2 F 23 89 31 0.00 131 30 Wild Type(Normal) Wild Type(Normal) 
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No 
Family Groups 
(One Member Diagnosed 
with DCM) 
 Members of the 
FamilyTested Sex 
Age 
(years) 
Ferritin 
(ng/ml) 
Trans 
Sat 
(%) 
Troponin I 
(ng/ml) 
Creatine  
Kinase 
(IU/L) 
Hepcidin 
(ng/ml) HFE Genotype HAMP Genotype 
25 DCM Patient 5 (Father) Parent1(Father) M 74 148 47 0.35 206 23 H63D Heterozygous C70R Heterozygous 
26 Family Group 5 Parent2(Mother) F 76 76 25 0.09 113 46 Wild Type(Normal) Wild Type(Normal) 
27   Son1 M 38 109 33 0.05 117 124 Wild Type(Normal) Wild Type(Normal) 
28   Daughter1 F 37 96 31 0.03 56 30 Wild Type(Normal) Wild Type(Normal) 
29   Daughter2 F 34 75 28 0.02 82 41 Wild Type(Normal) Wild Type(Normal) 
30   Grandson1 M 19 130 38 0.07 123 62 Wild Type(Normal) C70R Heterozygous 
31 DCM Patient 6 (Mother) Parent2(Mother) F 51 141 42 0.09 164 35 Wild Type(Normal) Wild Type(Normal) 
32 Family Group 6 Parent1 (Father) M 50 98 32 0.05 115 64 Wild Type(Normal) Wild Type(Normal) 
33   Daughter1 F 26 95 30 0.02 92 41 Wild Type(Normal) Wild Type(Normal) 
34   Daughter2 F 24 101 33 0.02 89 30 Wild Type(Normal) Wild Type(Normal) 
35 DCM Patient 7 (Mother) Parent2(Mother) F 72 148 42 0.38 199 20 Wild Type(Normal) C70R Heterozygous 
36 Family Group 7 Son1 M 51 96 32 0.05 110 33 Wild Type(Normal) Wild Type(Normal) 
37 Parent1(Father-Deceased) Son2 M 48 105 34 0.07 75 42 Wild Type(Normal) Wild Type(Normal) 
38   Daughter1 F 47 65 28 0.04 92 30 Wild Type(Normal) Wild Type(Normal) 
39   Grandson1 M 21 124 36 0.01 114 62 Wild Type(Normal) Wild Type(Normal) 
40   Grand-daughter1 F 19 119 32 0.04 88 56 Wild Type(Normal) Wild Type(Normal) 
41 DCM Patient 8 (Father) Parent1(Father) M 54 201 48 0.42 115 17 H63D Heterozygous C70R Heterozygous 
42 Family Group 8 Parent2(Mother) F 52 74 26 0.05 92 29 Wild Type(Normal) Wild Type(Normal) 
43   Daughter1 F 30 88 31 0.01 68 31 Wild Type(Normal) Wild Type(Normal) 
44   Daughter2 F 29 165 47 0.28 122 20 H63D Heterozygous C70R Heterozygous 
45   Son1 M 27 133 34 0.02 97 33 Wild Type(Normal) Wild Type(Normal) 
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No 
Family Groups 
(One Member Diagnosed 
with DCM) 
 Members of the 
FamilyTested Sex 
Age 
(years) 
Ferritin 
(ng/ml) 
Trans 
Sat 
(%) 
Troponin I 
(ng/ml) 
Creatine  
Kinase 
(IU/L) 
Hepcidin 
(ng/ml) HFE Genotype HAMP Genotype 
46 DCM Patient 9 (Father) Parent1(Father) M 50 346 54 0.29 151 5 C282Y Homozygous C70R Heterozygous 
47 Family  Group 9 Son1 M 25 206 51 0.15 124 17 C282Y Heterozygous C70R Heterozygous 
48 Parent2(Mother-Deceased) Son2 M 24 96 39 0.02 119 32 Wild Type(Normal) Wild Type(Normal) 
49   Son3 M 23 118 40 0.00 96 46 Wild Type(Normal) Wild Type(Normal) 
50   Daughter1 F 21 143 48 0.09 119 21 C282Y Heterozygous Wild Type(Normal) 
51 DCM Patient 10 (Father) Parent1(Father) M 74 218 57 0.28 138 34 C282Y Heterozygous C70R Heterozygous 
52 Family Group 10 Parent2(Mother) F 68 85 36 0.08 107 28 H63D Heterozygous Wild Type(Normal) 
53   Son1 M 45 110 25 0.06 88 45 H63D Heterozygous Wild Type(Normal) 
54   Daughter/inLaw1 F 43 152 31 0.02 75 22 Wild Type(Normal) Wild Type(Normal) 
55   Daughter2 F 42 99 34 0.03 91 36 C282Y Heterozygous C70R Heterozygous 
56   Daughter3 F 40 75 29 0.01 83 41 Wild Type(Normal) Wild Type(Normal) 
57   Grand-daughter1 F 19 110 41 0.11 101 22 Wild Type(Normal) C70R Heterozygous 
58   Grand-daughter2 F 18 104 39 0.05 97 44 Wild Type(Normal) Wild Type(Normal) 
59   Grandson1 M 20 121 40 0.01 86 32 H63D Heterozygous Wild Type(Normal) 
  
 
Jereza, Noel                                                                                                         105                                                                                                                
 
Table 3.3  Control group data for iron studies, cardiac biomarkers, HFE and HAMP genotype. 
 
Control No. Gender 
Age 
(y) 
Ferritin 
(ng/ml) 
TSat 
(%) 
Troponin I 
(ng.ml) 
Creatine  
Kinase 
(IU/L) 
Hepcidin 
(ng/ml) HFE Genotype HAMP Genotype 
C1 M 54 94 36 0.00 105 32 Wild Type(Normal) Wild Type(Normal) 
C2 M 40 86 27 0.00 94 101 Wild Type(Normal) Wild Type(Normal) 
C3 M 38 103 42 0.02 89 41 Wild Type(Normal) Wild Type(Normal) 
C4 F 45 38 22 0.01 146 31 Wild Type(Normal) Wild Type(Normal) 
C5 M 28 74 28 0.00 112 164 Wild Type(Normal) Wild Type(Normal) 
C6 F 29 41 25 0.00 119 121 Wild Type(Normal) Wild Type(Normal) 
C7 F 35 74 31 0.01 119 45 Wild Type(Normal) Wild Type(Normal) 
C8 F 70 25 24 0.03 68 33 Wild Type(Normal) Wild Type(Normal) 
C9 M 64 78 30 0.00 121 76 Wild Type(Normal) Wild Type(Normal) 
C10 M 30 93 35 0.01 84 39 Wild Type(Normal) Wild Type(Normal) 
C11 M 34 34 28 0.05 99 101 Wild Type(Normal) Wild Type(Normal) 
C12 M 25 104 38 0.01 114 134 Wild Type(Normal) Wild Type(Normal) 
C13 M 19 134 46 0.05 63 105 H63D Heterozygous Wild Type(Normal) 
C14 M 40 81 33 0.00 105 34 Wild Type(Normal) Wild Type(Normal) 
C15 F 38 53 28 0.00 96 42 Wild Type(Normal) Wild Type(Normal) 
C16 M 26 95 29 0.02 117 62 Wild Type(Normal) Wild Type(Normal) 
C17 M 43 101 34 0.01 133 56 Wild Type(Normal) Wild Type(Normal) 
C18 F 51 73 29 0.04 88 39 Wild Type(Normal) Wild Type(Normal) 
C19 F 49 84 32 0.00 96 24 Wild Type(Normal) Wild Type(Normal) 
C20 M 55 105 38 0.01 112 33 Wild Type(Normal) Wild Type(Normal) 
C21 M 34 99 30 0.02 119 46 Wild Type(Normal) Wild Type(Normal) 
C22 F 28 63 29 0.02 89 23 Wild Type(Normal) Wild Type(Normal) 
C23 M 26 108 31 0.09 76 101 Wild Type(Normal) Wild Type(Normal) 
C24 F 20 48 29 0.04 110 34 Wild Type(Normal) Wild Type(Normal) 
C25 F 34 136 48 0.08 118 15 Wild Type(Normal) C70R Heterozygous 
  
 
Jereza, Noel                                                                                                         106                                                                                                                
 
Control No. Gender 
Age 
(y) 
Ferritin 
(ng/ml) 
TSat 
(%) 
Troponin I 
(ng.ml) 
Creatine  
Kinase 
(IU/L) 
Hepcidin 
(ng/ml) HFE Genotype HAMP Genotype 
C26 M 70 98 31 0.00 114 31 Wild Type(Normal) Wild Type(Normal) 
C27 F 57 73 29 0.01 98 109 Wild Type(Normal) Wild Type(Normal) 
C28 M 51 119 34 0.00 121 200 Wild Type(Normal) Wild Type(Normal) 
C29 F 48 95 32 0.01 78 36 Wild Type(Normal) Wild Type(Normal) 
C30 M 31 108 36 0.00 119 196 Wild Type(Normal) Wild Type(Normal) 
C31 M 29 124 30 0.00 89 58 Wild Type(Normal) Wild Type(Normal) 
C32 M 64 96 28 0.05 142 43 Wild Type(Normal) Wild Type(Normal) 
C33 F 38 56 29 0.01 74 42 Wild Type(Normal) Wild Type(Normal) 
C34 F 36 91 31 0.04 118 100 Wild Type(Normal) Wild Type(Normal) 
C35  M 42 109 36 0.01 94 97 Wild Type(Normal) Wild Type(Normal) 
C36 M 29 116 38 0.00 79 201 Wild Type(Normal) Wild Type(Normal) 
C37 M 49 82 29 0.00 88 197 Wild Type(Normal) Wild Type(Normal) 
C38 F 50 48 30 0.01 119 38 Wild Type(Normal) Wild Type(Normal) 
C39 M 61 113 42 0.06 136 216 Wild Type(Normal) Wild Type(Normal) 
C40 M 68 115 34 0.09 184 36 Wild Type(Normal) Wild Type(Normal) 
C41 F 50 62 28 0.00 90 34 Wild Type(Normal) Wild Type(Normal) 
C42 M 54 88 31 0.00 114 102 Wild Type(Normal) Wild Type(Normal) 
C43 F 31 65 24 0.00 111 30 Wild Type(Normal) Wild Type(Normal) 
C44 F 29 79 28 0.01 124 60 Wild Type(Normal) Wild Type(Normal) 
C45 M 25 108 36 0.00 109 76 Wild Type(Normal) Wild Type(Normal) 
C46 M 21 79 28 0.00 96 34 Wild Type(Normal) Wild Type(Normal) 
C47 M 34 99 31 0.00 102 199 Wild Type(Normal) Wild Type(Normal) 
C48 F 38 101 32 0.01 78 20 Wild Type(Normal) Wild Type(Normal) 
C49 F 42 54 29 0.00 84 28 Wild Type(Normal) Wild Type(Normal) 
C50 M 54 121 38 0.02 110 114 Wild Type(Normal) Wild Type(Normal) 
C51 F 29 60 26 0.00 93 105 Wild Type(Normal) Wild Type(Normal) 
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Control No. Gender 
Age 
(y) 
Ferritin 
(ng/ml) 
TSat 
(%) 
Troponin I 
(ng.ml) 
Creatine  
Kinase 
(IU/L) 
Hepcidin 
(ng/ml) HFE Genotype HAMP Genotype 
C52 M 48 138 36 0.01 95 24 Wild Type(Normal) C70R Heterozygous 
C53 M 26 114 31 0.00 124 65 Wild Type(Normal) Wild Type(Normal) 
C54 F 29 84 28 0.00 74 30 Wild Type(Normal) Wild Type(Normal) 
C55 F 37 79 24 0.00 92 29 Wild Type(Normal) Wild Type(Normal) 
C56 M 44 105 30 0.00 145 192 Wild Type(Normal) Wild Type(Normal) 
C57 F 36 66 29 0.00 96 131 Wild Type(Normal) Wild Type(Normal) 
C58 F 49 92 28 0.00 69 65 Wild Type(Normal) Wild Type(Normal) 
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3.2 Allele frequencies among control and DCM groups 
Allele frequencies expressed in 95% confidence interval for each of the 
mutations were calculated from 58 unrelated controls that were age and sex 
matched relative to the 59 DCM group subjects comprising of direct family 
members and a diagnosed DCM from each family (Table 3.4). In this analysis 
the allele frequencies were not significantly different between the control and 
DCM group identified as heterozygous for both mutations.   However, the DCM 
group could not be compared directly as there were some samples shared 
between the groups, but removal of these samples from the analysis revealed 
there were significant differences in allele frequencies.  The probabilities were 
derived using the Fisher‘s exact and Levene‘s test (Minitab v16) to determine 
the statistical significance of the findings whether high or low, determining if the 
difference or relationship happened by chance.  The percentage and the 
probabilities using Fisher‘s and Levene‘s test (Minitab V16) tests set at p<0.001 
as significant to target only 0.1% chance of concluding the identification of 
mutations to be more accurate due to moderately smaller samples included in 
this study.  
 
Among subjects in DCM group of 59, 1.7% were C282Y homozygous; 15.2% 
(C282Y heterozygous); 1.7% (H63D homozygous); 18.6% (H63D 
heterozygous) and 62.7% (negative). The homozygous patients have 
significantly high transferrin saturation where 48% were H63D homozygous and 
54% (C282Y homozygous) respectively, a consistent trend reported among 
Irish population who were predisposed to hereditary haemochromatosis 
compared with the various reported allele frequencies from different ethnic 
origins (Table 3.5). The data showed a trend of a lower frequency of 
homozygous to C282Y, H63D and C70R in this study. However, in our 
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population, there were significant enrichment in C282Y, H63D and C70R 
heterozygous in DCM group analysed for molecular diagnosis of hereditary 
haemochromatosis and ruling out the co-existence of the both HFE and HAMP 
gene mutations.  
Table 3.4 Allele frequencies of HFE and HAMP gene mutations among control and 
DCM groups.  
 
Gene 
Mutation/  
Genotype 
Control Group  
(n=58) 
DCM Group  
(n=59) 
Number 
Frequency 
(95% CI) 
Number 
Frequency 
(95% CI) 
HFE 
C282Y Homozygous - 
a 
- 
a 
1 1.7 
C282Y Heterozygous - 
a
 - 
a
 9 15.2 
H63D Homozygous - 
a
 - 
a
 1  1.7 
H63D Heterozygous 1 1.7 11  18.6 
Compound Heterozygous 0 0.0 1 1.7 
HFE Wild Type 57 98.3 37 62.7 
HAMP 
C70R Homozygous - 
a
 - 
a
 - 
a
 - 
a
 
C70R Heterozygous 2  3.4 24  40.7 
HAMP Wild Type 56  96.6 35  59.3 
a   Genotype not identified 
 
 
 
Table 3.5 Geographical comparison of HFE (Hanson et. al. 2001) and HAMP (Pajares 
et.al. 2010) allele frequencies in general population. 
 
Mutation/  
Genotype 
Gene Frequencies (95% CI) in General Population - HFE 
(Hanson et. al 2001) and HAMP (Pajares et.al.2010)  
Ireland Europeans 
The 
Americas 
Asians Blacks 
C282Y Homozygous 0.7 0.4 0.5 0.0 0.0 
C282Y Heterozygous 28.4 9.2 9.0 0.0 0.2 
H63D Homozygous 3.7 2.0 1.9 0.0 0.0 
H63D Heterozygous 24.8 21.6 19.4 4.4 5.4 
Compound Heterozygous 3.7 1.8 1.6 0.0 0.0 
HFE Wild Type 39.4 65.1 63.1 99.7 94.4 
C70R Homozygous (-) 0.014 (-) 0.0 (-) 
C70R Heterozygous (-) 0.218 (-) 0.1 (-) 
HAMP Wild Type (-) 99.8 (-) 99.9 (-) 
(-) No current/previous report/data as to date of this study 
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3.3 The significance of the biochemical marker levels 
The cardiac biochemical markers were troponin-I and creatinine kinase and for 
iron metabolism were serum ferritin, serum hepcidin and transferrin saturation 
were measured to determine the mechanism of their activity on the onset of 
dilated cardiomyopathy. The biochemical marker data was correlated as risk 
markers along with the HFE and HAMP genotype allele frequencies in the 
potential development of dilated cardiomyopathy and iron overload 
cardiomyopathy. 
 
 
The mean concentration levels of these biochemical markers are summarized in 
Table 3.6, where the concentration of serum ferritin and transferrin saturation 
were both significantly higher in the DCM group, compared with the control 
group. The mean serum ferritin level among men in DCM group is 143 ng/mL 
which is 68% higher from the normal mean level for men at 85 ng/mL (normal 
range 20–150 ng/mL), compared in the control group with 102 ng/mL, a 20% 
difference from the normal mean values. The women in DCM group, on the 
other hand showed the same trend in serum ferritin level of 102 ng/mL, 22% 
higher than the normal mean at 83.5 ng/mL (normal range 17-150 ng/mL) 
compared among women in control group with mean serum ferritin level of 70 
ng/mL.  
 
The percent transferrin saturation follow the same trend among men of DCM 
group with 39%,  an 11.4% higher than the normal mean of 35% (normal range 
20-50%) compared with the control group with 34% mean concentration level. 
The women also follow the same trend with 7.7% higher than the median 
percent transferrin saturation at 32.5% (normal range 15-50%).  
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Overall, serum ferritin  and  transferrin saturation  showed with p-value of 
<0.001 which is statistically significant and  both iron markers were clinically 
implicated.  However the serum hepcidin levels among men in DCM group 
showed the reverse trend at the mean concentration level of 52 ng/mL, 63% 
below the normal mean of 141.5 ng/mL (normal range 29-254 ng/mL) compared 
with the control group mean value of 91 ng/mL and the women in DCM group 
follow the same reverse trend at 43 ng/mL, 71% below the normal mean of 
151.5 ng/mL (normal range 17-286 ng/mL), compared with control group mean 
level of 47 ng/mL.   
 
Table 3.6 Summary of the mean concentrations of the various measured 
biochemical markers among DCM and Control groups. 
 
 
Biomarkers 
Assay reference 
values 
DCM Group 
(N = 59) 
Mean conc.  
level 
Control Group 
(N = 58) 
Mean conc. 
level 
Men Women 
Men 
(N=28) 
Women 
(N=31) 
Men 
(N=34) 
Women 
(N=24) 
Mean, Age (years)  
Not 
applicable
 
Not 
applicable 
42 39 41 40 
 
Serum Ferritin, ng/mL 
(Median) 
20-150 
(85) 
17-150 
(83.5) 
143 102 102 70 
Mean, all subjects 84.25  105   p=<0.001 
 
 
Transferrin Sat, (%) 
(Median) 
20-50 
(35) 
15-50 
(32.5) 
39 35 34 29 
Mean, all subjects 33.75  34.5 p= <0.001 
 
 
Serum Hepcidin, ng/mL 
(Median) 
29-254 
(141.5) 
17-286 
(151.5) 
52 43 91 47 
Mean, all subjects 146.5   60  p=<0.001 
 
 
Troponin-I, ng/mL 
(Median) 
0.00-0.30 
(0.15) 
0.00-0.30 
(0.15) 
0.10 0.07 0.02 0.01 
Mean, all subjects 0.15  0.10 P=<0.001 
 
 
Creatine Kinase , IU/L 
(Median) 
30-200 
(85) 
29-168 
(98.5) 
116 107 108 98 
Mean, all subjects 91.75  107.5 p=<0.001 
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3.4 The associated relationship between HFE C282Y/H63D gene mutations 
and iron biochemical marker levels. 
The relationship between the HFE (C282Y/H63D) gene mutations and the iron 
biochemical markers among DCM group (Figure 3.10) among the subjects in 
DCM group identified with HFE mutations showed that subjects identified  as 
heterozygous or homozygous with either C282Y or H63D have significant 
elevation in serum ferritin indicating they were potentially expressing the 
disease with the p value of 0.164.  The serum hepcidin on the other hand 
showed a significant decreased among H63D and C282Y heterozygous (Figure 
3.11) indicating the deficiency in serum hepcidin resulted from mutations in the 
hepcidin gene itself of the the genes encoding HFE with  p value of 0.312, 
where the two markers were both statistically and clinically significant. 
 
The transferrin saturation in hereditary haemochromatosis, high total iron level  
and low or normal TIBC, causing the transferrin  saturation to increase (Figure 
3.12) where both the C282Y and H63D heterozygous showed both elevated 
leves from the median with p value of 0.050 also statistically and clinically 
significant.  Although it may not be a reliable test for iron overload, elevated 
serum transferrin saturation has a sensitivity of 0.92, a specificity of 0.93, and a 
positive predictive value of 86% for the diagnosis of hereditary 
haemochromatosis (Knovich et.al. 2009). The control group showed no 
mutation identified on either heterozygous or homozygous in C282Y and 
homozygous in H63D of the HFE gene (Table 3.4).  
 
 
  
 
Jereza, Noel                                                                                                         113                                                                                                                
 
   A 
W
ild
 T
yp
e
H6
3D
 H
om
oz
yg
ou
s
H6
3D
 H
et
er
oz
yg
ou
s
C2
82
Y
 H
om
oz
yg
ou
s
C2
82
Y 
He
te
ro
zy
go
us
400
300
200
100
0
HFE Genotype
S
e
ru
m
 F
e
rr
it
in
 (
n
g
/m
l)
100
85
121
346
114.5
Relationship between Serum ferritin level and HFE(C282Y/H63D) gene mutations
in DCM group
 
   B 
Wild Type
H63D Homozygous
H63D Heterozygous
C282Y Homozygous
C282Y Heterozygous
18016014012010080604020
H
F
E
 G
e
n
o
ty
p
e
95% Confidence Intervals for Standard Deviations(Bonferroni method)
Test Statistic 1.87
p-value 0.164
Levene's Test
Relationship between Serum Ferritin and HFE(C282Y/H63D) gene mutations
 
Figure 3.10 The associated relationship between serum ferritin level and HFE 
(C282Y/H63D) gene mutations. (A) DCM subjects found to be H63D heterozygous 
showed high level of agreement with the level of serum ferritin at 121 ng/mL, although 
one subject with 346 ng/mL an extremely high level and identified as C282Y 
homozygous consistent as predisposed factor.  (B) The wide 95% confidence intervals 
among H63D heterozygous provide less precise estimates but limited the probability 
that a significant association of serum feritin level among DCM subjects with greater 
risk of developing iron overload, p = 0.164. 
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Figure 3.11 The associated relationship of serum hepcidin level with the HFE 
(C282Y/H63D) gene mutations. (A) DCM subjects found to be H63D heterozygous 
showed high level of agreement with the level of serum hepcidin at 32 ng/mL. (B) The 
95% confidence intervals among DCM subjects identified heterozygous or homozygous 
with either C282Y or H63D gene mutations showed inversely  have significant 
decreased in serum hepcidin, p = 0.312. When hepcidin levels are low, iron-exporting 
cells, including duodenal enterocytes, macrophages, and hepatocytes display 
abundant ferroportin and release iron into plasma. 
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Figure 3.12 The associated relationship of transferrin saturation with the HFE 
(C282Y/H63D) gene mutations (A) DCM subjects found to be H63D  and C282Y 
heterozygous showed consistent agreement with transferrin saturation elevation at 
40% and 37% respectively, and well correlated with one DCM subject who was C282Y 
homozygous with 54% transferrin saturation. (B) The 95% confidence intervals among 
H63D/C282Y heterozygous limited the probability that one or more of the confidence 
intervals does not contain the parameter to a maximum of 5% as indicated in the wild 
type. This was indicative of a predisposition to iron overload and considered a 
phenotypic marker in hereditary haemochromatosis, but by itself does not indicate the 
presence or absence of iron overload, p = 0.050. 
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3.5 The associated relationship between HFE C282Y/H63D gene mutations 
and cardiac biochemical marker levels. 
 
The cardiac biochemical markers among the DCM group illustrated in Figure 
3.13 for the troponin-I showed that among the subjects identified with H63D 
heterozygous showed a significant detectable troponin-I concentration of 0.08 
ng/mL from the overall median reference value of 0.15 ng/mL and subject 
identified with H63D homozygous had a significant elevation of troponin-I 
concentration of 0.29 ng/mL.  The subjects identified with C282Y heterozygous 
also presented a detectable level of 0.05 ng/mL but slightly lower than those 
identified with H63D homozygous showing less troponin activity. The subjects 
identified with H63D heterozygous indicated both clinical and statistical 
significance with the p value of 0.003. The creatine kinase activity in Figure 3.14 
showed a significant concentration elevation compared from the overall median 
reference value of 91.75 IU/L.  The subjects in the DCM group identified with 
C282Y and H63D heterozygous showed both clinically and statistically 
significant with p-value of 0.594. 
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Figure 3.13 The associated relationship of troponin-I level with the HFE 
(C282Y/H63D) gene mutations (A) DCM subjects found to be H63D heterozygous 
showed high level of agreement with the level of serum ferritin at 121 ng/mL median. 
(B) The wider confidence intervals among H63D heterozygous provide less precise 
estimates but limits the probability that one or more of the confidence intervals does not 
contain the parameter to a maximum of 5%. In comparison, the family error rate 
associated with the five regular 95% confidence intervals is 25%. 
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Figure 3.14 The associated relationship of creatine kinase level with the HFE 
(C282Y/H63D) gene mutations (A) DCM subjects found to be H63D heterozygous 
showed high level of agreement with the level of serum ferritin at 121 ng/mL median. 
(B) The wider confidence intervals among H63D heterozygous provide less precise 
estimates but limits the probability that one or more of the confidence intervals does not 
contain the parameter to a maximum of 5%. In comparison, the family error rate 
associated with the five regular 95% confidence intervals is 25%. 
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3.6 The associated relationship between HAMP C70R gene mutation and 
iron biochemical marker levels. 
The association of HAMP C70R gene mutation in our patient cohorts showed 
that hepcidin is an important regulator of iron homeostasis. There is strong 
evidence in support of an important role for hepcidin dysregulation in the 
pathogenesis of iron overload disorders. The DCM group data for C70R 
genotyping of the HAMP gene revealed a very interesting  observation shown in 
Figures 3.15, 3.16 and 3.17, where most subjects who were genotyped with 
C70R showed mutation  have been identified predominantly  as heterozygous  
with C70R of the HAMP gene.  The values presented validated the trend among 
the DCM subjects who showed significant trend of elevated  level of the serum 
ferritin and transferrin saturation, inversely, serum hepcidin  presented a picture 
with more insufficient or inadequate iron regulation. All subjects identified with 
C70R heterozygous gene mutations, showed clinical and statistical significance, 
against serum ferritin with p-value of 0.568, serum hepcidin (p-value = 0.033) 
and transferring saturation (p-value = 0.141) suggesting possible disease 
implication over time.   
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Figure 3.15 The associated relationship of serum ferritin level with the HAMP 
(C70R) gene mutations (A) DCM subjects found to be H63D heterozygous showed 
high level of agreement with the level of serum ferritin at 121 ng/mL median. (B) The 
wider confidence intervals among H63D heterozygous provide less precise estimates 
but limits the probability that one or more of the confidence intervals does not contain 
the parameter to a maximum of 5%. In comparison, the family error rate associated 
with the five regular 95% confidence intervals is 25%. 
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Figure 3.16 The associated relationship of serum hepcidin level with the HAMP 
(C70R) gene mutations (A) DCM subjects found to be H63D heterozygous showed 
high level of agreement with the level of serum ferritin at 121 ng/mL median. (B) The 
wider confidence intervals among H63D heterozygous provide less precise estimates 
but limits the probability that one or more of the confidence intervals does not contain 
the parameter to a maximum of 5%. In comparison, the family error rate associated 
with the five regular 95% confidence intervals is 25%. 
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Figure 3.17 The associated relationship of transferrin saturation with the HAMP 
(C70R) gene mutations. (A) DCM subjects found to be H63D heterozygous showed 
high level of agreement with the level of serum ferritin at 121 ng/mL median. (B) The 
wider confidence intervals among H63D heterozygous provide less precise estimates 
but limits the probability that one or more of the confidence intervals does not contain 
the parameter to a maximum of 5%. In comparison, the family error rate associated 
with the five regular 95% confidence intervals is 25%. 
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3.7 The associated relationship between HAMP C70R gene mutation and 
cardiac biochemical marker levels. 
 
The cardiac biochemical markers among the patients, troponin-I revealed a 
significant detectable level of 0.07 ng/mL in Figure 3.18, with increasing trend 
from the assay reference median level of 0.15 ng/mL for the subjects identified 
as heterozygous with C70R gene mutations. The significant clinical implication 
with p-value of 0.009 indicated detectable increasing troponin activity.  The 
creatinine kinase, on the other hand outlined in the first part of this chapter in 
Tabel 3.6 showed mean concentration level of 116 IU/L for men and 107 IU/L 
for women which showed a trend and sign of increasing levels of creatine 
kinase from the reference median value of 85 IU/L and 98.5 IU/L among men 
and women respectively. It is also consistently showed a significant elevation 
from the overall median reference value of 91.75 IU/L. Thus, subjects identified 
heterozygous with C70R in Figure 3.19 were more apparent when creatine 
kinase was correlated with the HAMP C70R genotype compared with the 
control group matched for age and sex with p-value of 0.449 which is significant 
clinically and statistically, suggesting their association in the disease 
progression. 
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Figure 3.18 The associated relationship of troponin-I level with the HAMP (C70R) 
gene mutations. (A) DCM subjects found to be H63D heterozygous showed high level 
of agreement with the level of serum ferritin at 121 ng/mL median. (B) The wider 
confidence intervals among H63D heterozygous provide less precise estimates but 
limits the probability that one or more of the confidence intervals does not contain the 
parameter to a maximum of 5%. In comparison, the family error rate associated with 
the five regular 95% confidence intervals is 25%. 
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Figure 3.19 The associated relationship of the creatine kinase level with the 
HAMP (C70R) gene mutations. (A) DCM subjects found to be H63D heterozygous 
showed high level of agreement with the level of serum ferritin at 121 ng/mL median. 
(B) The wider confidence intervals among H63D heterozygous provide less precise 
estimates but limits the probability that one or more of the confidence intervals does not 
contain the parameter to a maximum of 5%. In comparison, the family error rate 
associated with the five regular 95% confidence intervals is 25%. 
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3.8  Epidemiological study 
In this study 5 selected family group selected from Table 3.2 and Table 3.3 
were used for epidemiological and family study, tracing  the mutation 
inheritance and succession among family generations. The first example in 
Figure 3.20, from family group number 2 from Table 3.2 and Table 3.3 where 
the siblings of parents, where the father diagnosed with DCM was C282Y 
heterozygous and  the mother was HFE negative. The probands include a son, 
three daughters and one grandson. The second (II.2) daughter had a transferrin 
saturation level of 28% and a serum ferritin level of 73 ng/mL , identified as 
HAMP C70R heterozygous. The third daughter who also identified as C70R 
heterozygous, presented a more significant levels of iron and cardiac markers. 
She had levels of transferrin saturation at 41%, 145 ng/mL serum ferrtin, 
showed low serum hepcidin at 20 ng/mL, with 0.07 ng/mL troponin-I level and 
creatine kinase of 99 IU/L.  The algorithm of this family group 2 of this study, 
when taken together, confirmed that the combination of a genetic alteration in 
any of the HFE and HAMP loci could lead to an adult onset phenotype of either 
of the mutations among the members of the family that is not apparent when an 
individual carries only one or both of these gene alterations (Majore et.al, 2004) 
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                                                                             I.2                                                                I.1 
 
 
 
  Age                                                         75 years/M                                                                           79 years/F 
  HFE                                                        C282Y/wt                                                                                wt/wt 
  HAMP                                                     wt/wt                                                                                wt/wt 
  Ferritin (ng/ml)                                       164                                                                                         68 
  Transferrin saturation (%)                       48                                                                                         45 
  Serum hepcidin (ng/ml)                          21                                                                                          190 
  Troponin-I (ng/ml)          0.25                    0.08  
  Creatine Kinase (IU/L)                           120                                                                                     174 
  
 
 
 
 
                                                    II.1                       II.2                       II.3                         II.4                       II.4a                                               
 
 
 
                                                                                                                                                                                          III.1                        
 
  Age                                            49years/M            45years/F            43years/F           42years/F          41years/M       19years/M               
  HFE                                          wt/wt                     wt/wt          wt//wt                  wt/wt                  not tested        wt/wt           
  HAMP                                       wt/wt                     wt/wt                    C70R/wt               C70R/wt            not tested        wt/wt                 
  Ferritin (ng/ml)                          92                        73                        145                      170                     not tested        85         
  Transferin saturation (%)           36                         28                         41                        49                      not tested        31 
  Serum hepcidin (ng/ml)             56                         98                         20                        22                      not tested        34  
  Troponin-I (ng/ml)       0.00  0.01               0.07            0.09             not tested        0.01 
  Creatine Kinase                              118                       101                       99                         78                      not tested       109 
 Figure 3.20  Epidemiology and Family Study Group 2.  
The parents identified with C282Y heterozygous father (I.2) diagnosed with DCM and negative for both mutations mother (I.1). Among the siblings the 
third (II.3) and fourth (II.4) showed  both heterozygous with HAMP C70R with significant levels of biochemical markers. 
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The next selected family group (group 4, Figure 3.21), data from Table 3.2 and 
Table 3.3 showed  that both parents were identified with HFE H63D and HAMP 
C70R gene mutations. The father was H63D heterozygous, with serum ferritin 
of 96 ng/mL, serum hepcidin of 48 ng/mL, transferrin saturation of 34 % and 
creatine kinase of 162 IU/L and a troponin-I of 0.01 ng/mL. The mother who was 
diagnosed with DCM was heterozygous with H63D of the HFE and C70R of 
HAMP. She presented a significant  values of the biochemical markers, with 
serum ferritin of 121 ng/mL, serum hepcidin of 31 ng/mL, transferrin saturation 
of 48 % and creatine kinase of 135 IU/L and a troponin-I of 0.29 ng/mL. The 
probands include three sons and two daughters. The third son is the only 
member of the family identified with mutation of the HFE as C282Y 
heterozygous, with serum ferritin of 148 ng/mL, serum hepcidin of 51 ng/mL, 
transferrin saturation of 44 % and creatine kinase of 88 IU/L and a troponin-I of 
0.02 ng/mL. The other members of the family were not identified to any of the 
mutations.   The algorithm of this family group 4 of this study, presented a 
different specificity of the genes as only one family affected. This confirmed that 
the combination of a genetic alteration in any of the HFE and HAMP loci is 
considered a more complex genetic situation due to the implication of a third 
mutation that might be located either in non-coding regions of the HFE or HAMP 
genes that possibly be carried down further to the next generation (Majore et.al, 
2004). 
 
 
 
 
  
 
Jereza, Noel                                                                                                         129                                                                                                                
 
 
                                                                             I.2                                                                I.1 
 
 
 
  Age                                                         56 years/M                                                                            58 years/F 
  HFE                                                        H63D/wt                                                                                H63D/wt 
  HAMP                                                    C70R/wt                                                                                wt/wt 
  Ferritin (ng/ml)                                       121                                                                                         96 
  Transferrin saturation (%)                       51                                                                                         34 
  Serum hepcidin (ng/ml)                          31                                                                                          48 
  Troponin-I (ng/ml)          0.29                    0.01  
  Creatine Kinase (IU/L)                           135                                                                                      162 
  
 
 
 
 
                                                    II.1                         II.2                        II.3                       II.4                       II.5 
 
 
 
 
 
  Age                                            28years/M            27years/M            25years/M           24years/F           23years/F 
  HFE                                           wt/wt                    wt/wt         C282Y/wt              wt/wt                  wt/wt 
  HAMP                                       wt/wt                     wt/wt                    wt/wt               wt/wt                  wt/wt    
  Ferritin (ng/ml)                          99                         85                        148                       77                       89 
  Transferin saturation (%)           32                         43                         44                         29                       31 
  Serum hepcidin (ng/ml)             104                       35                         51                         34                       30 
  Troponin-I (ng/ml)       0.00   0.02               0.02            0.06       0.00 
  Creatine Kinase (IU/L)               91                        124                       88                         112                      131 
 
 
Figure 3.21  Epidemiology and Family Study Group 4.  
The parents identified for H63D and C70R gene mutations, (wt) indicates wild-type allele; black vertical lines circle for the third son who is 
HFE(C282Y) heterozygous. 
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The next selected family group 5 (Figure 3.22), data from Table 3.2 and Table 
3.3 showed  that the father was diagnosed with DCM and both heterozygous to 
HFE H63D and HAMP C70R, with significant levels of serum ferritin of 148 
ng/mL, serum hepcidin of 23 ng/mL, transferrin saturation of 47 % and creatine 
kinase of 206 IU/L and a troponin-I of 0.35 ng/mL. The mother has normal 
biochemical markers and no gene mutation isolated. The probands include one 
son, two daughters and one grandson from the unmarried second daughter. 
The only affected subject in this family group is the grandson identified with 
mutation of the HAMP as C70R heterozygous, with serum ferritin of 130 ng/mL, 
serum hepcidin of 62 ng/mL, transferrin saturation of 38 % and creatine kinase 
of 123 IU/L and a troponin-I of 0.07 ng/mL. The other members of the family 
were not identified to any of the mutations and an assumption that the father of 
the grandson has no mutation to both HFE and HAMP genes.  The algorithm of 
this family group 5 of this study, presented a different gene pattern that led us to 
an assumption that the penetrance of the H63D, C282Y of the HFE and C70R 
of the HAMP genotype might, not be complete and probably may not be related 
to the recognition of non-expressing elderly H63D and C70R individual in this 
case, his grandfather (Majore et.al, 2004). 
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                                                                             I.2                                                                I.1 
 
 
 
  Age                                                         74 years/M                                                                           76 years/F 
  HFE                                                        H63D/wt                                                                                wt/wt 
  HAMP                                                     C70R/wt                                                                                wt/wt 
  Ferritin (ng/ml)                                       148                                                                                         76 
  Transferrin saturation (%)                       47                                                                                         25 
  Serum hepcidin (ng/ml)                          23                                                                                          46 
  Troponin-I (ng/ml)          0.35                    0.09  
  Creatine Kinase (IU/L)                           206                                                                                     113 
  
 
 
 
 
                                                    II.1                       II.2                       II.3                       II.3a                                               
 
 
 
                                                                                                                                                                   III.1                        
 
  Age                                            38years/M            37years/F            34years/F           36years/M        19years/M               
  HFE                                          wt/wt                     wt/wt          wt//wt                  not tested         wt/wt           
  HAMP                                       wt/wt                     wt/wt                     wt/wt                   not tested         C70R/wt                  
  Ferritin (ng/ml)                         109                       96                        75                        not tested         130         
  Transferin saturation (%)           33                         31                         28                       not tested          38 
  Serum hepcidin (ng/ml)             124                       30                         41                       not tested          62 
  Troponin-I (ng/ml)       0.05  0.03               0.02              not tested          0.07 
  Creatine Kinase (IU/L)              117                       56                         82                       not tested         123 
 
Figure 3.22 Epidemiology and Family  Study 5.   
The parents identified for H63D and C70R gene mutations (family no. 5 in Table 3.2 and Table 3.3). where the only affected member of the family is 
the grandson who is heterozygous to the HAMP C70R indicated on the diagram as circle with vertical black lines. 
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The next selected family group 8 (Figure 3.23),data from Table 3.2 and Table 
3.3 showed  that the father was diagnosed with DCM and both heterozygous to 
HFE H63D and HAMP C70R, with significant levels of serum ferritin of 201 
ng/mL, serum hepcidin of 17 ng/mL, transferrin saturation of 48 % and creatine 
kinase of 115 IU/L and a troponin-I of 0.42 ng/mL. The mother has normal 
biochemical markers and no gene mutation isolated. The probands include one 
son and two daughters. The only affected subject in this family group is the 
second daughter identified with the both mutations of the HAMP as C70R 
heterozygous and HFE H63D heterozygous, with serum ferritin of 165 ng/mL, 
serum hepcidin of 20 ng/mL, transferrin saturation of 47 % and creatine kinase 
of 122 IU/L and a troponin-I of 0.28 ng/mL. The other members of the family 
were not identified to any of the mutations and an assumption that the father of 
the grandson has no mutation to both HFE and HAMP genes.  The algorithm of 
this family group 8 of this study, presented a pattern similar to family group 2 
that a combination of a genetic alteration in any of the HFE and HAMP loci 
could lead to an adult onset phenotype of either of the mutations among the 
members of the family  that is not apparent when an individual carries only one 
or both of these gene alterations, but  because of the non-genetic factors 
account for part of the iron overload processing, this later subject must be 
considered as carrying mutations that may lead to haemochromatosis but not 
yet having the disease. He needs to be followed clinically. (Majore et.al, 2004). 
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                                                                             I.2                                                                I.1 
 
 
 
  Age                                                         50 years/M                                                                           52 years/F 
  HFE                                                        H63D/wt                                                                                wt/wt 
  HAMP                                                     C70R/wt                                                                                wt/wt 
  Ferritin (ng/ml)                                        201                                                                                                      74                            
  Transferrin saturation (%)                       48                                                                                         26 
  Serum hepcidin (ng/ml)                          17                                                                                          29 
  Troponin-I (ng/ml)          0.42                    0.05  
  Creatine Kinase (IU/L)                            115                                                                                     92 
  
 
 
 
 
                                                  II.1                                                  II.2                                                II.3                                                                  
 
 
                                                                                                                
 
  Age                                            30years/F                                 29years/F                                  27years/M               
  HFE                                          wt/wt                                        C282Y//wt                                 wt/wt           
  HAMP                                       wt/wt                                             C70R/wt                                    wt/wt                  
  Ferritin (ng/ml)                         88                                                 165                                            133         
  Transferin saturation (%)           31                                                  47                                              34 
  Serum hepcidin (ng/ml)             31                                                  20                                              33  
  Troponin-I (ng/ml)       0.01              0.28                                 0.02 
  Creatine Kinase (IU/L)              68                                                 122                                             97 
Figure 3.23 Epidemiology and Family Study Group 8.   
The family with parents identified for H63D and C70R gene mutations (family group no. 8 in Table 3.2 and Table 3.3), showed a 29 year old female 
(daughter 2) identified with as heterozygous of  both gene mutations C282Y heterozygous of the HFE and C70R heterozygous of the HAMP. The 
other members of the family with no mutations isolated. 
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In this last example (Figure 3.24) of selected family group 10 from Table 3.2 
and Table 3.3 for epidemiological study presented a more complex inheritance 
among the siblings of parents who were C282Y, H63D and C70R gene 
mutations carrier. In Figure 3.24, the 74 year old father diagnosed with dilated 
cardiomyopathy who is heterozygous with C282Y and C70R and the 68 year 
old wife, identified as heterozygous to H63D. The probands includes a son, two 
daughters, a daughter-in-law, two grand-daughters and a grandson. The (II.1) 
son who has been identified as H63D heterozygous, had a transferrin saturation 
level of 32 %, serum ferritin level of 99 ng/mL, serum hepcidin of 45 ng/mL, 
creatine kinase of 88 IU/L and a troponin-I of 0.06 ng/mL. His younger sister 
(II.2), who was identified heterozygous for C282Y and C70R gene mutations, 
had a transferrin saturation level of 34 %, serum ferritin level of 99 ng/mL, 
serum hepcidin of 36 ng/mL, creatine kinase of 91 IU/L and a troponin-I of 0.03 
ng/mL. 
 
In this family group, it also shows that two among third generation family 
members inherited both heterozygous HFE and HAMP gene mutations.  The 
first grand-daughter (III.1) who was identified heterozygous with C70R gene 
mutation, had a transferrin saturation level of 41 %, serum ferritin level of 110 
ng/mL, serum hepcidin of 22 ng/mL, creatine kinase of 101 IU/L and a troponin-I 
of 0.11 ng/mL. The grandson (III.3) who was identified heterozygous with H63D 
gene mutation, had a transferrin saturation level of 40 %, serum ferritin level of 
121 ng/mL, serum hepcidin of 32 ng/mL, creatine kinase of 86 IU/L and a 
troponin-I of 0.01 ng/mL. 
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The algorithm of this particular group collated together, the data confirmed that 
the combination of a genetic alteration at both the HFE and HAMP loci can 
present an adult-onset phenotype iron overload to potential cardiomyopathy that 
is not apparent when an individual carries more than one of these gene 
alterations. A similar situation recently been reported by Merryweather-Clarke 
et.al. in 2004 who have partially described the proband heterozygous for the 
C282Y HFE mutation and for a HAMP deletion that removes the last 3 
nucleotides of exon 2. Among the example of several other genetic disorders, at 
least we could propose that, in some cases, a digenic model of inheritance 
might be responsible for an adult-onset iron overload phenotype (Majore et.al, 
2004). 
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                                                                                  I.2                                                                                         I.1 
 
 
 
  Age                                                         74 years/M                                                                             68 years/F 
  HFE                                                        C282Y/wt                                                                               H63D/wt 
  HAMP                                                     C70R/wt                                                                                 wt/wt 
  Ferritin (ng/ml)                                        218                                                                                         85 
  Transferin saturation (%)                        57                                                                                          36 
  Serum hepcidin (ng/ml)                          34                                                                                           28 
  Troponin-I (ng/ml)          0.28                      0.08  
  Creatine Kinase (IU/L)                           138                                                                                        107 
  
 
 
   II.1        II.1a        II.2         II.3 
 
                                                                          
  Age                                           45years/M                       43years/F                           42years/F            40years/F 
  HFE                                          H63D/wt                       wt/wt                                   C282Y/wt                 wt/wt 
  HAMP                                       wt/wt                                        wt/wt                                  C70R/wt                  wt/wt    
  Ferritin (ng/ml)                          110                                    152                                    99                        75 
  Transferin saturation (%)          25                                     31                                      34                         29 
  Serum hepcidin (ng/ml)            45                                  22                                      36                        41 
  Troponin-I (ng/ml)         0.06               0.02                         0.03                     0.01 
  Creatine Kinase (IU/L)              88                                   75                                       91                     83 
 
 
                                                               III.1                                          III.2                                  III.3 
                                                           
                                                                                                                                      
Age                                                                19years/F                                18years/F                        20years/M 
HFE                                                               wt/wt                                        wt/wt                                 H63D/wt 
HAMP                                                           C70R/wt                                   wt/wt                                 wt/wt    
Ferritin (ng/ml)                                              110                                           104                                   121 
Transferrin saturation (%)                              41                                             39                                     40              
Serum hepcidin (ng/ml)                                 22                                             44                                     32 
Troponin-I (ng/ml)                         0.11                                    0.05                                  0.01 
 Creatine Kinase (IU/L)                                 101                                           97                                      86 
 
Figure 3.24    Epidemiology and Family Study Group 10.   
The family with parents identified for C282Y/H63D/C70R gene mutations (Family group 10 in Table 3.3 and Table 3.5) showed  the son (II.1) identified with H63D heterozygous, who have 
a daughter (III.1) who is C70R heterozygous and son (III.3) who is H63D heterozygous, as  shown in the algorithm with marker of vertical black lines. 
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3.9 Result summary 
In summary, the data presented in this study showed a significant estimated 
prevalence of dilated cardiomyopathy as compared to the report by Nemeth in 
2001 of 1:2500, where a potential difference between the number of 
haemochromatosis patients and number of C282Y/H63D homozygous and 
heterozygous in Irish population is higher considering moderately smaller 
sample size population studied. These results suggest that a large proportion of 
the many undetected C282Y homozygous in Irish population and in similar 
populations could be in the preclinical stages of haemochromatosis, and 
warrant investigation for cardiomyopathy. However, there may be a wide 
variation in the expression of the condition, and a more extensive study of the 
level of disease penetrance encompassing a large number of undetected 
C282Y/H63D homozygotes is therefore imperative to carry on this study in a 
larger scale. 
 
This study described a heterozygous C70R (HAMP gene) which in association 
with C282Y/H63D heterozygous (HFE gene) appeared to lead a trend of iron 
overload in the cardiomyopathy patients and family members. This 
demonstrated in vitro that the HAMP (C70R) mutation decreases transcriptional 
activity of the hepcidin promoter, HFE genotypes other than the homozygous 
C282Y or the compound heterozygous state for the C282Y and H63D 
mutations, are considered responsible for causing symptomatic forms of iron 
overload.  The C70R mutation was thus present at a high allele frequency at 
40.7%, or 24 out of 59 subjects (p = <0.001) among DCM group in this series. 
This study also found in the control group, with a low allele frequency of  3.4% 
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or 2 out of 58 subjects with p-value of <0.001 (identified mostly as 
heterozygous, and no homozygous) due to moderately small sample size. 
However, the data presented in this thesis, indicate that in a selected samples 
of the control group individuals, especially those with non-HFE genotypes, the 
search for this mutation could be of interest, as it can possibly explain iron 
overload in certain patients with dilated cardiomyopathy. Indeed, we found that 
2 out of 10 diagnosed cardiomyopathy over 59 overall subjects in the dilated 
cardiomyopathy group who is C282Y/H63D homozygous, though had the wild 
type to heterozygous HAMP genotype as a potential genetic factor toward 
developing iron overload cardiomyopathy as also indicated in the significant 
elevation trend of the biochemical markers from their respective overall median 
reference values. 
 
In this study, among the 58 control group samples showed only two 
heterozygous mutations of HAMP C70R and only one (1)  mutation identified in 
the HFE gene whom heterozygous to H63D which less likely to progress or 
cause iron overload. There was no significant elevation trend in the biochemical 
markers among the control group samples with the exception of those have 
been identified heterozygous to any of the gene mutations. 
 
The extended analysis to all family members, aimed to rule-out the disease 
progression and to identify any family member that could potentially inherit the 
disease which could eventually develop both the disease and iron overload 
revealed d a significant observations and trend. Overall, with the correlation 
emphasis on these results, the potential linkage within the family members were 
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becoming more apparent and clear.  The mutations identified among family 
members showed disposition and varied asymptomatic activity of the 
biochemical marker concentrations. Therefore this thesis, the digenic 
coexistence of HFE(C282Y/H63D) and HAMP(C70R) present a significant  and 
considerable direct findings but could potentially be expanded to a larger scale 
study that could eventually lead to clinical application in medical practice. 
 
 
 
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CHAPTER   4   Discussion 
 
 
 
 
4.0 Introduction  
The main objective of this study was to investigate the potential digenic co-
existence of haemochromatosis gene mutations C282Y/H63D (HFE gene) and 
C70R (HAMP gene), the association of iron and cardiac biomarkers 
concentration in Irish patients diagnosed with dilated cardiomyopathy and their 
family members. The method using the simultaneous genotyping identifies if the 
patients and family members are homozygous or heterozygous with the HFE 
(C282Y/H63D) and HAMP (C70R) gene mutations. The measurements of the 
biochemical markers were analyzed using the Abbott Architect C8200 to 
determined any significant degree of concentration difference from the overall 
reference median value. 
 
 
It has been documented also in this study the coexistence of HFE and HAMP 
gene mutations as potential contributing and predisposing factors in the 
development of dilated cardiomyopathy and to iron overload cardiomyopathy 
among family members of the affected patients. The results revealed that 
heterozygous genotypes of both the C282Y/H63D of the HFE genes and C70R 
of the HAMP gene influenced the association on the degree of concentration 
elevation or to the extent of reduction of serum hepcidin in iron and cardiac 
biomarkers. This study determined the concentration effects of reduced serum 
hepcidin, elevated transferrin saturation, serum ferrtin, troponin-I and creatine 
kinase as potential predictor iron and cardiac biomarkers in the potential 
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development of dilated cardiomyopathy and probability to progress to iron 
overload cardiomyopathy. The clinical significance revealed in this study by the 
degree of elevation or reduction of the biochemical markers associated with the 
heterozyogous genotypes of the HFE and HAMP genes, where in some aspect  
agreed with  the report by Valenti et.al. in  2009 published in Clinical Journal in 
American Society of Nephrology that serum hepcidin is increased in 
haemodialysis patients, regulated by iron stores and inflammation, and 
relatively reduced in subjects carrying HFE mutations. Hepcidin-25 may 
contribute to the pathogenesis of anaemia by decreasing iron availability. 
(Valenti et.al  2009). 
 
 
The significant allele frequency among the DCM group where 18.6% (11 out of 
59 subjects) were H63D heterozygous of the HFE and 40.7% (24 out of 59 
subjects) were C70R heterozygous of the HAMP revealed the co-existent gene 
mutations in Irish population. This clearly supported the mechanism that in Irish 
population a preclinical stage of two or more alterations was more apparent that 
could potentially contributed in the development of iron overload 
cardiomyopathy. The digenic inheritance as seen in this study explained the 
heterogenous character of the haemochromatosis phenotype, in which 
heterozygous for HFE C282Y/H63D and HAMP C70R mutations were 
necessary but not sufficient in many cases for development of the disease 
phenotype. The degree of iron overload varies with different genetic 
backgrounds which could also be explained by such mechanisms (Kamisago 
2000). The natural mutations and phenotypes observed in our patients are proof 
of predictions to progress to iron overload and potentially iron overload 
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cardiomyopathy.  Furthermore, this study clarified important issue reported by 
Vatenti et.al in 2009, that the effect of HFE mutations on serum hepcidin 
concentration found that the presence of either the H63D or the C282Y 
mutations was associated with reduced induction of serum hepcidin by iron 
stores, and was an independent predictor in most analysis. These results 
clearly suggested that in iron overload cardiomyopathy, the simple 
heterozygous HFE and HAMP mutations altered iron metabolism by decreasing 
serum hepcidin concentration. The subtle effect of these molecular variants 
were likely magnified in DCM patients due to exposure of high amounts of iron. 
 
 
There are several reasons an individual or family may be referred for 
biochemical markers, HFE and HAMP testing to rule out dilated 
cardiomyopathy.  Testing the clinically affected patient can clarify the diagnosis, 
assist in treatment decisions and stratify risk management (Imanishi et.al. 
2001). Diagnostic genetic testing may be considered for patients who clinically 
manifest with symptoms of DCM and for asymptomatic family members of 
patients who were carrier of either one or more HFE and HAMP gene 
mutations. Identification of a mutation in the family can lead to genetic 
identification of at risk family members who were clinically asymptomatic and 
moreover potential progression to iron overload cardiomypathy. 
 
4.1 The association of HFE C282Y/H63D and HAMP C70R gene 
mutations in iron overload dilated cardiomyopathy. 
Data were analyzed using the Balanced ANOVA (Minitab v16) and allele 
frequencies were calculated on genotypes of both H63D and C282Y mutations 
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determined from 59 subjects of the DCM disease group and 58 control subjects 
from random healthy Irish population. There is a trend association of iron 
overload cardiomyopathy (IOC) in any of the HFE gene mutations wherein the 
diagnosis of IOC is made when evidence of heart disease, coexists with iron 
overload as indicated in the elevated concentration pattern of serum ferritin and 
transferrin saturation. The iron studies correlation in this study confirmed with 
the report by Adams et.al. in 2000, that despite the poor correlation of serum 
ferritin with cardiac iron or the presence of IOC, an increased concentration of 
serum ferritin still indicated the presence of significant total body iron content 
with a high risk of heart disease.  
 
The allele frequencies within the control group revealed no significant findings. 
There were less than 2% identified either as HFE C282Y/H63D homozygous 
and/or C282Y/H63D heterozygous. The allele frequencies among the control 
group showed 1.7% H63D heterozygous (p=<0.001) and 98.3% negative for 
both HFE mutations (p=<0.001). Similar low frequencies in the HAMP gene 
mutations where 3.4% identified as C70R heterozygous, 96.6% negative for 
C70R and none among the control subjects identified as C70R homozygous. 
Whereas, the DCM group showed interesting allele frequency distribution where  
1.7% C282Y homozygous (p=<0.001); 15.2% C282Y heterozygous (p=<0.001); 
1.7% H63D homozygous (p=<0.001); 18.6% H63D heterozygous (p=<0.001) 
and 62.7% HFE negative. The genotyping result among the DCM group 
subjects, showed significant association of the HFE and HAMP genotypes and 
the potential development of iron overload dilated cardiomyopathy among family 
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members confirmed by the results of the iron biochemical markers with 
significant concentration difference from the overall median reference values. 
 
Since cardiomyopathy is known to be one of the most severe complications of 
hereditary haemochromatosis, a study of the prevalence of HFE mutations in 
patients with DCM by Mahon et.al. in 2000 showed a reported increased 
frequency of H63D gene mutation. This study also showed a similar H63D 
heterozygous state with frequency of 18.6% in DCM patients compared to 
control group (1.7%), which also replicated the results reported by Hetet et.al. in 
2001, and Pereira et.al. in 2001 where they reported increased proportion at 
36%. The other study by Pereira et.al. in 2000, reported an increased frequency 
of C282Y heterozygous among patients with cardiomyopathy of ischaemic 
etiology (10.4%, 6 of 58) compared to another group of patients with non-
ischaemic etiology (2.3%, 6 of 261). In this study, ischaemia has been excluded 
and assessed as general category of the C282Y gene mutation, however, 
despite of a moderately small sample size, identified 15.2% (9 of 59) C282Y 
heterozygous and 1.7% (1 of 59) C282Y homozygous.  
 
As previously mentioned at the beginning of this discussion, this study explored 
the association of co-existent HFE and HAMP gene mutations in dilated 
cardiomyopathy. The results in this study although moderately small sample 
size, but  well characterized population confirming the implication of these two 
common mutations in the HFE gene as genetically predisposing factors in DCM 
which overtime could potentially lead to iron overload cardiomyopathy. These 
data may result from different factors including sample size, different genetic 
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background, selection criteria including degree of cardiac dilatation or bias in 
the recruitment of the control population. Although this study, was able to 
correlate the hypothetical question of association of HFE gene mutations and 
iron overload dilated cardiomyopathy, future studies to further validate these 
results are still therefore be recommended with clearly defined subgroups in 
order to determine the modulating influence of HFE mutations in dilated 
cardiomyopathy in Irish population. 
 
In this study, the identified  HAMP gene C70R mutation presented in 
heterozygous state among Irish patients diagnosed with dilated cardiomyopathy 
although no DCM subjects identified for homozygous HAMP C70R. The allele 
frequency showed C70R heterozygous at 40.7% (p=<0.001); C70R wild type 
(negative) at 59.3% (p=<0.001) among the DCM group. There were 3.4% 
(p=<0.001) as C70R heterozygous; 96.6% (p=<0.001) were C70R wild type 
(negative) among the control group. The data followed the principle that the two 
predominant secreted forms of the peptide containing 20 and 25 amino acids 
are respectively present (Andriopoulos 2006). The recent report of 
Merryweather-Clarke et.al. in 2003 suggested the presence of a simultaneous 
effect between HAMP(C70R)  and HFE (C282Y) gene mutations, can result in 
hereditary haemochromatosis. On the hand, undetectable HAMP variants only 
act as modifier mutations in presence of the HFE C282Y homozygous condition 
leading to a more serious degree of iron overload (Merryweather-Clarke et.al. 
2003).   
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Illustrated in the results of this study showed an agreement with the recent 
various reported data. Furthermore, we have outlined the epidemiology study in 
the result chapter selecting five families of the DCM group. The first example 
revealed that the third son (II.3) was HAMP and HFE heterozygous who could 
potentially developed an iron overload due to the fact that degree of elevation of 
the iron concentration difference was significant from the overall reference 
median value. The father (I.2) in the selected family epidemiological study was 
carrying the same genotype. The elevated iron studies also confirmed the trend 
towards potential development of iron overload. The second selected family 
study (group 4), the mother who was diagnosed with DCM were H63D 
homozygous and C70R heterozygous while the father was H63D heterozygous. 
The third son was  C282Y heterozygous. The selected family group consistently 
showed the trend of genetic inheritance down to one family member with 
elevated serum ferritin at 148 ng/mL and transferrin saturation of 44 % which 
showed a significant elevation from the overall reference media value of 84.25 
ng/mL for serum ferritin and 33.75% for transferrin saturation.  This study was 
consistent with mechanism of a potential development of iron overload and 
higher chanced to progress as iron overload dilated cardiomyopathy as 
indicated in the trend of progression as described by the report  of McCullen in 
2002. 
 
4.2 The relationship of cardiac biochemical markers and HFE 
(C282Y/H63D)/HAMP(C70R) gene mutations in iron overload dilated 
cardiomyopathy. 
The cardiac biomarkers analysed were troponin-I and creatine kinase. In this 
study the cardiomyopathy group identified heterozygous with HFE C282Y and 
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H63D mutations showed a trend of elevation from the mean concentration 
which correlated that the creatine kinase (CK) activity was abundant in striated 
muscle and heart tissue (Schmitt 2003). Our data showed the CK level among 
subjects identified heterozygous with C282Y and H63D both showed an 
elevation trend towards the upper limit, 99 IU/L and 107 IU/L respectively. There 
was no dramatic difference in cardiovascular function for the altered HAMP 
C70R mutation with low or high CK activity. Even a small increased in the 
contractility of vascular smooth muscle could have a profound effect that could 
cause potential abnormal heart activity (Taylor et.al. 2004).  The present results 
supported that the increased CK activity in muscle tissue might led to 
hyperdynamic activity of the heart (Somjen et.al. 1998). It cannot be excluded 
the possibility that subclinical cardiovascular damage contributed to the results; 
however, this option has been considered unlikely.  
The Troponin-I values among the DCM group subjects in this study may be not 
significantly high in concentration but considerably detectable at 0.12 ng/mL, 
indicating values showed a significant increasing trend of detectable 
concentration towards the overall reference median at 0.15ng/mL, for both men 
and women suggesting increase risk factors. As revealed in this study that 
among subjects identified with the H63D of the HFE and C70R of the HAMP, 
mean troponin-I levels at 0.12 ng/mL potentially a good predictor. At present, 
the role of cardiac troponin (cTn) concentration in blood serum for diagnostics 
and risk assessment in patients with DCM has been highly regarded 
assessment tool (Wilde 2005). The cardiac troponins were part of the 
troponin/tropomyosin complex in thin filaments of heart muscle myofibrils. This 
complex consists of troponin C(TnC), troponin I(TnI), troponin T(TnT) and 
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tropomyosin. Troponins do not occur outside cells; therefore, their occurrence in 
blood is a sensitive and abnormal indicator of heart muscle cell defects (Wiviott 
2004). 
 
The elevation of the troponin-I levels in this study, correlated the study by 
James et.al. in 2000 published in the Circulation Research  which described the 
effects of the cTnI (troponin-I) mutation in mice a consistent presentation of 
many of the pathological features of typical DCM, the mice exhibited myofibrillar 
disarray, and interstitial fibrosis; some of the molecular markers of 
cardiomyopathy (Maron 2009). The initial elevation of troponin-I was attributed 
to the measurement of the Ca2+ affinity of troponin-I reconstituted with DCM 
troponin-I mutants, which maked this study more significant possibly leading to 
some questions and importance of the probable presence of troponin-I 
mutations, that possibly been masked together with the HFE and HAMP 
mutations (Gomes 2004).  
 
Overall, the association of the cardiac markers (troponin-I and creatine kinase) 
against the HAMP gene mutations, where the double heterozygous mutations, 
at single disease caused mutations in 2 different genes exist as reported in this 
study among several DCM families. Analogous to families with homozygous 
mutations, double heterozygous DCM patients also collectively display more 
symptoms of the clinical disease  where the troponin-I level between 0.09 to 
0.29 ng/mL and creatine kinase levels between 120 – 151 IU/L  with a 
significant elevation  trend  out from the median value compared with the control 
group.  Among the 22 subjects with the HFE C282Y and  H63D mutations and 
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24 subjects with HAMP C70R gene mutations coexisted in affected family 
members who carried both mutations potentially suggesting an additive effect 
leading to iron overload cardiomyopathy. 
 
4.3 The relationship of iron studies and HFE 
(C282Y/H63D)/HAMP(C70R) gene mutations in iron overload dilated 
cardiomyopathy. 
In this study there was no significant increased in the frequency of C282Y in 
Irish patients with dilated cardiomyopathy, with the frequency of 1.7%, similar to 
frequency among the control group in this study, similar to the reported 
frequency of 2.1% by Worwood in 1999. In contrast, H63D was found with 
increased frequency in dilated cardiomyopathy, suggesting that it may 
predispose to this disease. However, these data and data from large population 
studies suggest that H63D appeared to have moderate effect on iron 
metabolism compared with C282Y. The levels of iron studies which included 
ferritin, transferrin saturation and serum hepcidin, where there was evidence 
from a number of studies that abnormalities of hepcidin production and 
regulation are involved in the pathogenesis of hereditary haemochromatosis.  
When hepcidin levels are low, iron-exporting cells, including duodenal 
enterocytes, macrophages, and hepatocytes displayed abundant ferroportin and 
released iron into plasma. When hepcidin concentrations increased, hepcidin 
binds to ferroportin, ferroportin is degraded, and iron is retained within cells in 
cytoplasmic ferritin as illustrated in Figure 4.0 showing  the mechanism when 
the serum/plasma hepcidin concentration levels becomes low or high. 
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Figure 4.0 The mechanism when the serum/plasma hepcidin concentration 
becomes low or high.  
“Images adapted with permission from the author. [Nemeth E, Preza GC, Jung CL, Kaplan J, Waring 
AJ, Ganz T., 2006. The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-
function study. Blood, 107, pp.328-333.]”  
Hepcidin levels are low, iron-exporting cells, including duodenal enterocytes, 
macrophages, and hepatocytes display abundant ferroportin  and release iron into 
plasma. (Nemeth et.al 2004).  
 
 
There were reports that genetic haemochromatosis was linked to an 
inappropriate low level of hepcidin regarding iron status. The molecular 
mechanisms linking the C282Y mutation and low hepcidin levels are not fully 
characterized, although mutations of HAMP (C70R) are known to induced 
phenotypic presentations similar to HFE genetic haemochromatosis (Island 
2009). In individuals with heterozygous and homozygous HFE C282Y 
mutations, the iron overload was more severe if there was a co-existent 
heterozygous HAMP mutation. The severity of the HAMP (C70R) mutation, 
which disrupted the normal function of hepcidin, corresponded to the severity of 
the iron overload (Merryweather-Clarke et.al. 2003).  
  
 
Jereza, Noel                                                                                                   151                                                                                                                 
 
 
4.4 The hereditary digenic existence of HAMP(C70R) and 
HFE(C282Y/H63D) gene mutations in the development of iron overload 
dilated cardiomyopathy. 
The 4th and 10th family of the DCM group data has been selected as example 
epidemiological algorithm, showing a clear simultaneous effect observed 
between the HAMP C70R mutation and the HFE H63D, but not the C282Y 
mutation. This was consistent where hepcidin deficiency caused by HFE 
deficiency seemed to be the primary pathogenic factor mediating iron overload 
in HFE-related haemochromatosis, as reported in mice studies by Mahon et.al. 
in 2000. 
 
The iron loading seen in the proband of the 4th and 10th  family group (from the 
study data) where both severe and of early onset, which correlates with the fact 
that heterozygous for a similar frameshift mutation against a wild-type HFE 
background also leads to hereditary haemochromatosis. The phenotype in 
family group 4 was more milder compared with the family group 10, the double 
heterozygous having been identified through family screening. Hepcidin 
carrying the C70R mutation is likely to have reduced activity and in conjunction 
with heterozygous C282Y lead to less severe disease than that of patients who 
have the hepcidin mutation C70R (Pereira et.al. 2001). 
 
Our data suggested that mechanisms including digenic inheritance as seen in 
severe haemochromatosis would explained the heterogeneity of the 
haemochromatosis phenotype, in which homozygous for HFE H63D mutation is 
necessary but not sufficient in many cases for development of the disease 
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phenotype (Sampietro et.al. 1998; Pereira et.al. 2001).  Analysis of clinical 
outcomes in relation to the presence of mutations yielded an unexpected 
finding. Although we did not observed an effect of the C282Y allele on the 
clinical course of disease, carriers of the C282Y and H63D alleles had milder 
disease with significantly less cardiac enlargement. The significance of this 
finding can still be validated further, as these DCM patients were not younger in 
age and they would not be expected to have earlier disease as no test data 
prior to diagnosis. It is possible that the C282Y and H63D alleles were protected 
by mechanisms as yet unidentified, or it is equally possible that it predisposed 
to the development of dilated cardiomyopathy in individuals who would 
otherwise have been disease free.  
 
The allele gene frequencies were compared from both HFE and HAMP 
mutations between the Irish patients to the various race/ethnicity groups 
collated by Hanson et. al. published in American Journal of Epidemiology in 
2001, as summarised in Table 3.7 in result chapter. In this study the Irish 
patients had allele frequencies that were comparable with the reported data by 
Hanson et.al. especially among the Europeans.  Among the other ethnicity 
including The Americas, Asians and Blacks, the Irish patients showed higher 
allele HFE gene frequencies among those ethnic groups, but no data  for allele 
frequencies for the HAMP gene mutations, although just for the Irish patients 
alone showed a significant reportable  frequency of 40.7% C70R heterozygous 
in the HAMP gene. The effect of the gene mutations on the hepcidin levels in 
vivo would be likely negligible, showed a frequency high enough to be 
considered when a genetic analysis is done in iron overload patients. 
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However, these findings needed to be interpreted with caution and  required a 
validation in future studies due to moderately smaller group of samples. The 
observation of milder disease may be a chance finding related to the multiplicity 
of clinical variables measured, and the study was underpowered to detect a 
survival advantage of the magnitude observed.  The data in this study were 
incorporated to association these results to the various reports on iron 
transporting gene mutations. Systemic iron balance is basically maintained 
through the control of dietary iron absorption by duodenal enterocytes. After 
entering the enterocytes, iron is transferred to plasma transferrin through 
ferroportin.  Iron absorbed through the gut, however, accounted for only a part 
of circulating iron, most of which originated from the macrophages that recycled 
iron from senescent or old erythrocytes. In common with the process in 
enterocytes, iron is exported from macrophages to plasma through ferroportin. 
Hepcidin, a small peptide produced in the liver, blocked cellular iron flowing out 
by binding to and inducing the degradation via internalization of ferroportin. 
Hepcidin synthesis is regulated by iron, being increased by iron loading and 
suppressed by iron deficiency. 
 
The type 2 hereditary haemochromatosis characterized with severe cardiac and 
endocrine dysfunction, due to increased iron overload leading to mortality 
before the age of 30, and is also known as juvenile haemochromatosis. 
Mutations in hepcidin (HAMP) and or haemojuvelin (HJV, also known as HFE2) 
genes are implicated in the disease process. As HJV acted as a co-receptor for 
BMP, and through this regulatory mechanism increased hepcidin synthesis 
leading to iron overloading (Papanikolaou, 2004). Haemojuvelin plays an 
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essential role in the regulation of hepcidin expression, specifically in the iron-
sensing pathway. Dietary iron sensing and inflammatory pathways converged in 
the regulation of the key regulator hepcidin. Hepcidin is a small defensin-like 
peptide whose production by hepatocytes is modulated in response to anaemia, 
hypoxia, or inflammation. It is expressed in liver, heart and skeletal muscle and 
expression linked to hepcidin.  Mutations in this gene are linked to pathogenesis 
similar to hepcidin. 
 
A recent study demonstrated that a membrane-bound serine protease encoded 
by the TMPRSS6 gene is a physiological suppressor of hepcidin TMPRSS6 or 
matriptase-2 is a member of a family of cell surface proteolytic enzymes defined 
as type II transmembrane serine proteases. The available evidence suggested 
that in the absence of TMPRSS6, increased hepcidin concentrations degraded 
intestinal ferroportin and interfered with normal iron absorption. Patients with the 
TMPRSS6 mutation is a hybrid between classical iron-deficiency anaemia (low 
body iron, inadequate iron supply for erythropoiesis) and anaemia of 
inflammation, reticuloendothelial iron block, inadequate iron supply for 
erythropoiesis (Finberg, 2008). By contrast, in adult patients with anaemia of 
inflammation and overproduction of hepcidin, body iron content is normal but 
the iron is partially redistributed to reticuloendothelial cells. 
 
Hepcidin acted as the main regulator of iron homeostasis through regulation of 
intestinal absorption and macrophage release. Hepcidin deficiency causes iron 
overload whereas its overproduction was associated with anaemia of chronic 
diseases. The genetic variants in the hepcidin gene (HAMP) promoter assesed 
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the association of iron status parameters, and to functionally study the role on 
HAMP expression. The c-.582A > G variant in the human HAMP promoter 
would have no effect on the hepcidin transcription in normal situations but it 
might have some effect in physiopathological situations where more hepcidin 
was needed. No significant association between the c.-582A > G genotype and 
serum iron, serum transferrin, transferrin saturation or ferritin levels were found, 
which reflected no differences in liver iron concentration (Nemeth 2006). Due to 
the role of hepcidin as a key modulator of systemic iron levels, it was seemingly 
reasonable that differences in the level of its expression may partly account for 
the phenotypic variant in iron metabolism between individuals. This result was 
supported by the functional in-vitro studies, which showed only a 10-20% 
reduction of the promoter transactivation by allele c.-582G compared to the c.-
582A allele. 
 
In the past decade significant advances have been made in our understanding 
of iron uptake, storage and homeostasis mechanisms. The efforts to understand 
the uneasiness in iron metabolism in certain inherited disorders have largely 
contributed to this success. The investigations carried out in numerous animal 
models that mimic these diseases either due to spontaneous mutations or 
experimental gene deletion led to identification of a number of key molecules 
involved in iron metabolism and homeostasis. Identification and characterization 
of one such molecule, a 25-mer peptide, hepcidin, contributed to the 
comprehensive understanding of intricate connections among the molecular 
networks that are involved in maintaining both systemic and cellular 
homeostasis mechanisms (Rutherford, 2004). The various hypothetical 
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regulators, storage, erythropoeitic, and inflammation/hypoxic regulators, 
regulated iron homeostasis with hepcidin in the centre of this network. 
Transcriptional regulation of hepcidin appears to be controlled by soluble HJV 
and this process seems to be under the control of circulating iron. How these 
signals are sensed and communicated to the regulation of hepcidin synthesis 
and downstream signaling cascades is still not known. 
 
4.5 Discussion summary 
 
Overall, the deposition of iron in the heart is a gradual process and depends on 
the increasing levels of serum iron. Under normal iron homeostasis, cardiac iron 
is regulated through transferrin mediated uptake mechanisms. During iron 
overload, transferrin becomes saturated, and non transferrin bound iron is 
released into the circulation and enters cardiac myocytes in the ferrous form 
through L-type calcium channels (LTCC) as described by Tsushima et.al. in 
1999. Conversely, when gene mutations occur in the haemochromatosis iron 
protein (HFE) or hepcidin (HAMP); hepcidin production is knocked out or 
reduced. Hepcidin then is not available to block iron transport through the 
ferroportin channel into the bloodstream (Nemeth 2004).  As the body does not 
have an effective mechanism to dispose of excess iron, the iron is deposited 
throughout the body. The iron-overload syndrome known as haemochromatosis 
then develops, leading to complications such as liver failure with cirrhosis, 
dilated cardiomyopathy, gray discoloration of the skin, and diabetes from 
pancreatic dysfunction (Jacolot 2004). 
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Despite the genetic complexity of this disease, the rapid development of the 
knowledge of the molecular mechanisms of DCM appears promising. This 
included early and specific diagnosis of patients at risk, detection of carriers, 
and early management of subjects at risk in order to prevent the progression of 
the disease (Mearryweather-Clarke 2006, Roetto 2006).  Based on these 
findings, the objective of our study was to determine if HFE and HAMP 
mutations could both contributed to the expression of an iron overload 
phenotype in  Irish group of iron overload dilated cardiomyopathy patients and 
potentially their family members with at least one chromosome lacking an HFE 
mutation, and this has been achieved.  These patients were identified in a 
screening study on the basis of an elevated serum ferritin, transferin saturation 
in the absence of other known causes of iron disorder. Among the 59 subjects 
of the DCM group and  their family members, this study identified 40.7% novel 
C70R and 18.6%% H63D  missense gene mutations in the heterozygous state. 
 
The findings in this study,  demonstrated that HAMP mutation was very frequent 
among Irish cardiomyopathy patients who were heterozygous for the C282Y 
and H63D mutations of the HFE genes. The reported number of mutations 
excluded the projected statistical comparisons of groups described in this study. 
The report has been limited to a description of the dilated cardiomyopathy 
patients with mutated genes and family members. Only one mutation of each 
gene was detected from among the 10 subjects diagnosed with DCM, and there 
was no clear impact on iron burden or clinical behaviour of disease in either 
case. In the family carrying a C70R mutation in the HAMP gene, 50% of the 
family member showed elevated iron levels, a trend toward potential iron 
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overload, although one DCM subject do not have a mutation in the HAMP gene, 
though he was H63D heterozygous which will potentially direct to more iron 
loading. 
 
Moreover, one subject in this study had a double heterozygous for C282Y and 
C70R mutations in the HFE and HAMP genes, and had a trend towards high 
transferrin saturation and serum ferritin. Previous studies have shown that 
HAMP mutations act as genetic modifiers in haemochromatosis. Nevertheless, 
the calculated frequency of these alterations in our patient cohorts indicated a 
significant impact of these mutations in the penetrance of hereditary 
haemochromatosis in Irish patients with dilated cardiomyopathy and family 
members.  
 
The significant association trend  of heterozygous C70R of the HAMP gene and 
transferrin saturation, serum ferritin or serum hepcidin levels were found. These 
results were no agreement with Bruno et.al. in 2000, that did not find 
association among South Americans. The difference clearly a geographical and 
descent locations, where this study focused among Irish patients with higher 
prevalence among other descents. In addition, one has to bear in mind that the 
in-vitro model used may not completely reflected what happened in-vivo. This 
data together with the fact that HAMP was regulated by many different signals 
suggested that the effect of the C70R mutation on hepcidin levels, and therefore 
on the iron status in-vivo is most likely negligible. We hypothesize that C70R in 
the human HAMP gene would have no effect on the hepcidin transcription in 
normal situations but it might have some effect in physiopathological situations 
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where more hepcidin was needed. However, further studies would be 
necessary to confirm this hypothesis. 
 
In this study, mutations in HAMP (C70R) and HFE (C282Y/H63D), genes have 
been demonstrated to favour the development of iron overload in C282Y and 
C70R heterozygous in DCM patients and family members showed a trend to 
increase iron burden.  In HFE and HAMP, it can be hypothesized that every 
genetic factor tend to lower serum hepcidin level as outlined in this study in 
dilated cardiomyopathy patients and family members. The effect of HFE and 
HAMP mutations on serum hepcidin levels found that the presence of either the 
H63D/C282Y and C70R mutations were associated with reduced induction of 
serum hepcidin by iron stores, and was an independent predictor of serum 
hepcidin levels. These results clearly suggested that in dilated cardiomyopathy, 
simple heterozygous HFE and HAMP mutations altered iron metabolism by 
decreased hepcidin levels. 
 
4.6 Conclusion 
This thesis shown that the allele frequency of HFE H63D and HAMP C70R 
were increased in Irish patients with dilated cardiomyopathy and their family 
members although further larger studies with clearly defined subgroups are 
useful to determine the modulating influence of HFE mutations in dilated 
cardiomyopathy and iron overload cardiomyopathy. The role of hepcidin as a 
key modulator of systemic iron levels, it is reasonable that differences in the 
level of its expression may partly account for the phenotypic variant in iron 
metabolism between individuals. In this study, association was found between 
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levels of transferrin saturation, serum ferritin, serum hepcidin and heterozygous 
with C70R in HAMP gene and C282Y/H63D in HFE gene. The results 
presented in this thesis have advanced our understanding of the variable 
penetrance in HFE and HAMP associated haemochromatosis as a multifactorial 
phenomenon and the digenic occurrence contributing to the development of iron 
overload dilated cardiomyopathy. The association of HFE and HAMP mutations 
indicated that the disease severity was partially modulated by HFE genotype 
thus supported the hypothesis that HFE and HAMP interacted in causing iron 
overload. Further studies are needed to define optimal medical care for 
increasing survival and improving quality of life for affected individuals. In the 
interim, it is important to use the techniques presently available for early 
diagnosis.  
 
4.7 Future directions 
The results presented in this study provide some quite unexpected findings and 
an interesting basis for future experiments. An increased sample size will help 
address a measure of uncertainty in some of the results (particularly for the 
heterozygous C70R). Measuring the expression of an increased number of 
genes involved in the iron metabolic pathway could also be important in 
identifying potential modifier genes in hereditary haemochromatosis. If tests 
confirmed that C70R, C282Y and H63D are detected and therefore HAMP is 
unable to influence iron regulation, insights into the control of HAMP expression 
may still be achieved through the study of genes that are involved in the 
regulation of HAMP expression. The possibility of exploring analysis of allele-
specific transcription of the HFE gene should also be explored. Preliminary 
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experiments to do this were unsuccessful and discontinued, but technical 
advances in the future may enable this experiment. 
 
Iron overload cardiomyopathy is a potentially lethal, but treatable disease when 
diagnosed and treated early in its course. Newer insights into iron homeostasis 
and the complicated mechanism of iron entry into the heart are now emerging. 
Improved cardiac imaging techniques are being developed and perfected for the 
early identification of iron overload and its treatment. New therapeutic options 
with better chelating agents with increased safety, efficacy, and absorption, with 
therefore better compliance, are being evaluated. The role of hepcidin, and 
genetic and stem cell therapy are being investigated and may play a role in 
future disease management. Further studies are needed to define optimal 
medical care for increasing survival and improving quality of life for these 
patients. In the interim, it is important to use the techniques presently available 
for early diagnosis and to utilize the existing therapeutic interventions in a safe 
manner. 






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CHAPTER   5   Appendix 
 
 
 
 
 
Appendix 5.0  Schematic outline for HFE  C282 Y and H63D genotyping 
 
  
 
 
INTERPRETATION OF RESULTS 
Genotype Interpretation 
1. N/N; N/N Normal/Wild type 
2. C282Y/C282Y; N/N C282Y Homozygous 
3. C282Y/N; N/N C282Y Heterozygous 
4. N/N; H63D/H63D H63D Homozygous 
5. N/N; H63D/N H63D Heterozygous 
6. C282Y/N; H63D/N Compound heterozygous for C282Y and 
H63D 
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Appendix 5.1 Schematic outline for HAMP C70R  genotyping 
 
 
 
 
 
 
 
 
 
 
 
 
Interpretation of Results 
 
Genotype 
Interpretation 
DNA Change Protein Change 
 
1. [c.=]/[c.=] 
 
[p.=]/[p.=] 
 
Normal/Wild type 
 
 
2. [c.208T>C]/[c.=] 
 
C70R/[p.=] 
 
C70R Heterozygous 
 
 
3. [c.208T>C/[c.208T>C] 
 
C70R/C70R 
 
C70R Homozygous 
 
 
HAMP: GenBank reference sequence NM_021175.1, considering nucleotide +1 
the A of ATG translation initiation codon: c.208
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Appendix 5.2  PCR WORKSHEET: C70R/Ex1/Ex2/Ex3  
 
DATE: 2.0%Agarose Gel (Hi-Sieve)      Catalogue no. 
REAGENTS SINGLE REACTION X 14 Aliquot no. Date prepared Comments 
DNA TEMPLATE 1.0 ul -----    
WATER 17.3 ul 242.2 ul    
5XBUFFER (1.5 MgCl2) 5.0 ul 70.0 ul    
DNTPs                             10mM 0.5 ul 7.0ul     
PRIMERS                          C70R/HAMP 1.0 ul 14.0 ul    
TAQ POLYMERASE        AmpliTaq 0.2 ul 2.8ul    
TOTAL 
25.0 ul Aliquot 24.0ul   Machine 
C1 (Check when taking/thawing out DNA templates):C2(Checks against the worklist); C3 (Tube label checks when loading DNA templates into strips) 
      HAMP GENOTYPE 
TUBE NO. C1 C2 C3 
PROJECT 
No. 
DESCRIPTION LANE C70R(Ex1) C70R(Ex2) C70R(Ex3) Interpretation 
1           
2           
3           
4           
5           
6           
7           
8           
9           
10    Ladder Marker 100Bp      
PROTOCOL PROFILE: 
Thermocyling;  94
O
C/3min : 32cycles  94
O
C/30sec,  56
O
C/30sec,  72
O
C/45sec : 72
O
C/5min ;Cycle completed : Digestion: Electrophorese: Photo 
Date: Sign Date: Sign 
DIGESTION:  15 ul  +  5 ul Digest  Mix 
PCR CHECK 1 (W/S)  DIGEST CHECK (W/S)  REAGENTS LOT#:DATE VOL(ul)X14     TEMP 37
O
C 
PCR CHECK 2 (DNA)  DIGEST CHECK (DNA  
WATER 4.0 
 56.0  ul Incubator Incubator 
PCR CHECK (MIX)  DIGEST CHECK (MIX)  REB        0.5  7.0  ul On: Time  
GEL LOAD CHECK 3  GEL LOAD CHECK 3  SacII       0.5  7.0  ul Off: Time  
100 bp DNA Ladder/Marker:               Lot No.:                                               Date opened: 
Date reported:                                                                            Date data compiled: 
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Appendix 5.3   PCR WORKSHEET: C282Y / H63D  
 
DATE: 2.5%Agarose Gel (Hi-Sieve) 
     Catalogue no. 
REAGENTS SINGLE REACTION X 14 Aliquot no. Date prepared Comments 
DNA TEMPLATE 1.0 ul -----    
WATER 17.3 ul 242.2 ul    
5XBUFFER (1.5 MgCl2) 5.0 ul 70.0 ul    
DNTPs                             10mM 0.5 ul 7.0ul     
PRIMERS                        Stott 1.0 ul 14.0 ul    
TAQ POLYMERASE        Platinum 0.2 ul 2.8ul    
TOTAL 
25.0 ul Aliquot 24.0ul   Machine 
C1 (Check when taking/thawing out DNA templates):C2(Checks against the worklist); C3 (Tube label checks when loading DNA templates into strips) 
      HFE GENOTYPE 
TUBE NO. C1 C2 C3 
PROJECT 
No. 
DESCRIPTION LANE C282Y H63D Interpretation 
1          
2          
3          
4          
5          
6          
7          
8          
9          
10    Ladder Marker 100Bp     
PROTOCOL PROFILE: 
Thermocyling;  94
O
C/3min : 35cycles  94
O
C/30sec,  55
O
C/30sec,  72
O
C/30sec : 72
O
C/5min ;Cycle completed : Digestion: Electrophorese: Photo 
Date: Sign Date: Sign 
DIGESTION:  15 ul  +  5 ul Digest  Mix 
PCR CHECK 1 (W/S)  DIGEST CHECK (W/S)  REAGENTS LOT#:DATE VOL(ul)X14     TEMP 37
O
C 
PCR CHECK 2 (DNA)  DIGEST CHECK (DNA  
WATER 4.0 
 56.0  ul Incubator Incubator 
PCR CHECK (MIX)  DIGEST CHECK (MIX)  
REB        0.5 
 7.0  ul On: Time  
GEL LOAD CHECK 3  GEL LOAD CHECK 3  
Bbrp1     0.5 
 7.0  ul Off: Time  
100 bp DNA Ladder/Marker:               Lot No.:                                               Date opened: 
Date reported:                                                                            Date data compiled: 
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Appendix 5.4   PREPARATION WORKSHEET FOR PCR BUFFER AND dNTPs 
 
10 mM dNTPs PREPARATION Date prepared:  
STOCK = 100mM each dNTP 
0.5ul gives 0.2mM per simplex reaction 
 
Stored at: -20
O
C 
dNTPs 100 Reactions 500 Reactions Conc. Lot number Expiry date  
A 10 50     
C 10 50     
G 10 50     
T 10 50     
Sterile H2O 60 300     
Total vol 100 500 10mM / / 
No. of aliquot = 2 tubes in 
250 ml 
     5X PCR BUFFER PREPARATION  : Date prepared:  
Prep# Final conc 10X Buffer supplied 50mM MgCl2 supplied Water Total Volume 
 Lot number=>     
 Expiry date=> / /   
1 1.0mM 250 (500)* 50 (100)* 200 (400)* 500(1000)* 
2** 1.5mM 250 (500)* 75 (150)* 175 (350)* 500(1000)* 
3 2.0mM 250 (500)* 100 (200)* 150 (300)* 500(1000)* 
4 2.5mM 250  125 125 500 
5 3.0mM 250 (500)* 150 (300)* 100 (200)* 500(1000)* 
6 3.5mM 250 175 75 500 
7 4.0mM 250 (500)* 200 (400)* 50 (100)* 500(1000)* 
8 4.5mM 250 225 25 500 
9 5.0mM 250 250 0 500 
 
dNTP  50 ul/vial (Stock)    **Prep/Conc in use                  *5X Buffer  for 1.5mM, If final volume of 1000 = 200ul/vial 
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Appendix 5.5  Poster Presentation 1 
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Appendix 5.6  Poster Presentation 2 
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